



Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW[®] 2019

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)
www.gastro.org

*** Information contained in this report
is current as of April 22, 2019.**



AGA Oral Presentations

1. . . . HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL... (2*)
2. . . . STEM CELL-DERIVED 3D ORGANOID RECAPITULATE FEATURES... (2*)
3. . . . A NEW FORM OF HUMAN ROTAVIRUS... (2*)
4. . . . FIRST LARGE SCALE STUDY DEFINING THE... (4*)
5. . . . MICROBIOTA-DEPENDENT BEHAVIORAL ABNORMALITIES IN THE ZONULIN... (2*)
6. . . . INTESTINAL MICROBIAL FUNCTIONAL CONTENT BETTER DEFINES... (4*)(2)
7. . . . THE ICON STUDY: INFLAMMATORY BOWEL DISEASE... (6*)(2)
8. . . . POPULATION-SCALE MICROBIOME ANALYSIS DEFINES A NEW... (2*)
9. . . . PREVALENCE AND PREDICTORS OF GERD AND... (3*)(Ironwood Pharmaceuticals)
10. . . . EFFECT OF RECENTLY DESCRIBED ADVERSE EVENTS... (5*)
11. . . . THE EFFECT OF REBAMIPIDE IN PATIENTS... (3*)(Korea Otsuka Pharmaceutical Co., Ltd.)
12. . . . IMPACT OF IW-3718, A NOVEL GASTRIC-RETENTIVE... (3*)(Ironwood Pharmaceuticals)
13. . . . ANTIREFLUX SURGERY WITHIN SIX MONTHS AFTER... (5*)
14. . . . PANCREATIC AND HEMATOPOIETIC CALCINEURIN INDEPENDENTLY MEDIATE... (2*)
15. . . . SOLUTE TRANSPORTER SLC26A9 LOCALIZES TO THE... (2*)
16. . . . IMMUNE PROFILING OF THE HUMAN PANCREAS... (2*)
17. . . . DYNAMIC ASSOCIATION OF SYSTEMIC INFLAMMATION, GUT... (2*)
18. . . . ROLE OF SONIC HEDGEHOG PATHWAY IN... (2*)(5)
19. . . . KRÜPPEL-LIKE FACTOR 5 PLAYS AN IMPORTANT... (4*)
20. . . . TRANSCRIPTOME ANALYSIS DURING PROGRESSION OF CHRONIC... (4*)(Nil)
21. . . . EFFICACY AND SAFETY OF URSODEOXYCHOLIC ACID... (3*)(Daewoong Pharmaceutical Co., Ltd.)
22. . . . CAN CHOLECYSTITIS BE AN ADVERSE EVENT... (5*)
23. . . . BILIARY DILATION IN PATIENTS WITH NORMAL... (2*)(4)
24. . . . TIMING OF CHOLECYSTECTOMY AFTER ACUTE BILIARY... (5*)
25. . . . UNDERLYING EATING DISORDER PATHOLOGY IN CHRONIC... (5*)
26. . . . THE EFFECT OF RECREATIONAL MARIJUANA USE... (7*)(2)
27. . . . TRANSLUMBOSACRAL NEUROMODULATION THERAPY FOR FECAL INCONTINENCE... (2*)
28. . . . DEFECATORY FUNCTION TESTING IN FI PATIENTS... (2*)
29. . . . RESTORATION OF FECAL CONTINENCE IN A... (6*)
30. . . . NORMAL VALUES FOR ANORECTAL PRESSURES MEASURED... (2*)(3)(Medspira Inc)
31. . . . ENDOSOMAL SNX17 SETS THE PLASMA MEMBRANE... (2*)
32. . . . UNIQUE REGULATION OF INTESTINAL EPITHELIAL CELL... (2*)
33. . . . GLP-2 INCREASES ELECTROGENIC ANION SECRETION AND... (2*)(3)(Shire Pharmaceuticals)
34. . . . E.COLI HEAT STABLE ENTEROTOXIN (ST) INHIBITION... (2*)(6)
35. . . . SHIGELLA GASTROENTERITIS TARGETS INTESTINAL URATE TRANSPORTER... (2*)
36. . . . GLUCOCORTICOID AND SGK1-POTENT REGULATORS OF... (2*)
37. . . . METHYLATION CHANGES AT THE GNAS IMPRINTED... (7*)
38. . . . ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE BIOPSY HAS... (5*)
39. . . . AGE, OBESITY, DIABETES AND INITIAL CYST... (5*)
40. . . . TRIACYLGLYCEROLS AS A MARKER FOR CHARACTERIZATION... (2*)
41. . . . THE DUTCH AMERICAN RISK STRATIFICATION TOOL... (5*)
42. . . . THIOPURINE METABOLITE LEVELS IN PREGNANT IBD... (4*)(6)
43. . . . PREGNANCY OUTCOMES IN INFLAMMATORY BOWEL DISEASE... (5*)
44. . . . INFLIXIMAB CLEARANCE IS DECREASED DURING 2ND... (1*)
45. . . . LONG-TERM OUTCOMES OF IN-UTERO EXPOSURE TO... (6*)
46. . . . SAFETY OF FLEXIBLE SIGMOIDOSCOPY IN PREGNANT... (5*)
47. . . . SIRT2 REGULATES INTESTINAL CELL PROLIFERATION AND... (2*)
48. . . . HEAT SHOCK PROTEIN GP96 IS ESSENTIAL... (4*)
49. . . . MIR-181A-5P CONTRIBUTES TO INTESTINAL CELL DIFFERENTIATION... (2*)
50. . . . MULTITARGET STOOL DNA TESTING AS ALTERNATIVE... (6*)
51. . . . POST-COLONOSCOPY MORTALITY IN A FIT-BASED COLORECTAL... (2*)
52. . . . INTERVAL CANCERS AFTER A NEGATIVE FAECAL... (2*)
53. . . . COMPARING THE COST-EFFECTIVENESS OF NEW COLORECTAL... (2*)
54. . . . FACTORS ASSOCIATED WITH THE PROGRESSION OF... (7*)(4)
55. . . . SYSTEMATIC SCREENING PROTOCOL FOR THE STOMACH... (2*)
56. . . . SERUM PROTEOMIC PROFILING IN ULCERATIVE COLITIS... (4*)
57. . . . INCREASED INTESTINAL PERMEABILITY IS A PREDICTOR... (6*)(2)
58. . . . INCREASED RISK OF ULCERATIVE COLITIS IN... (5*)
59. . . . HORMONE THERAPY FOR CANCER IS A... (6*)(The Chemotherapy Foundation, philanthropic organization)
60. . . . INFLAMMATORY BOWEL DISEASE IN UK PRIMARY... (6*)
61. . . . LONGITUDINAL CHANGES IN THE DIRECT COSTS... (6*)(Crohn's and Colitis Cada)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

101. . . . INCREASED EXPRESSION OF MELATONIN IN THE... (2*)
102. . . . PHYSIOLOGICAL AND PROTEOMIC CHARACTERIZATION OF CAMPYLOBACTER... (2*)|(NIH K23 DK103911)
103. . . . BENEFICIAL EFFECTS OF A LOCALLY ADMINISTERED... (2*)|(4)
104. . . . ASSOCIATIONS BETWEEN FECAL SHORT CHAIN FATTY... (4*)
105. . . . SACCHAROMYCES BOULARDII, A YEAST PROBIOTIC, REGULATES... (5*)
106. . . . ALTERED GENDER DIFFERENCE IN BRAIN HISTAMINE... (2*)
107. . . . DISCONTINUITY OF CARE AMONG INFLAMMATORY BOWEL... (5*)
108. . . . THE PREVALENCE AND USE OF CANNABIS... (5*)
109. . . . ORAL VANCOMYCIN INDUCES AND MAINTAINS REMISSION... (5*)
110. . . . STOPPING 5-AMINOSALICYLATES IN CROHN'S DISEASE PATIENTS... (6*)
111. . . . INCREASING VACCINATION RATES WITH A PATIENT... (5*)
112. . . . TELEPHONE STRAIGHT-TO-TEST (TSTT) IMPROVES EARLY DIAGNOSIS... (5*)
113. . . . HIGHER RESILIENCE IS ASSOCIATED WITH DECREASED... (5*)
114. . . . TISSUE-ENGINEERED INTESTINES CAN NEO-INNervATE EXPERIMENTALLY DENERVATED... (2*)
115. . . . TRANSCUTANEOUS AURICULAR VAGAL NERVE STIMULATION IMPROVES... (5*)
116. . . . ELECTROGASTROGRAPHY AT BASELINE AND RESPONSE TO... (5*)
117. . . . SYNDAPIN 2 IS REQUIRED FOR MICROVILLUS... (2*)
118. . . . ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE... (2*)
119. . . . RNA-BINDING PROTEIN HUR REGULATES AUTOPHAGY ACTIVITY... (2*)
120. . . . MITOCHONDRIAL IMPAIRMENT IN CROHN'S DISEASE-LIKE INFLAMMATION... (2*)
121. . . . HIGH CONTENT MORPHOLOGICAL ANALYSES OF ESOPHAGEAL... (2*)|(4)
122. . . . CALPONIN-HOMOLOGY AND MICROTUBULE-ASSOCIATED PROTEIN INTERACTS WITH... (2*)
144. . . . POSTOPERATIVE ENDOSCOPIC AND CLINICAL RECURRENCE AFTER... (6*)|(7)
145. . . . INFLAMMATORY POTENTIAL OF DIET IS NOT... (2*)
146. . . . GUT MICROBIAL DYSBIOSIS CONTRIBUTES TO FATIGUE... (6*)|(3)
147. . . . PEPT1 ENHANCED BACTERIAL PEPTIDE TRANSPORT INTO... (2*)
148. . . . SLC7A5 IS CRUCIAL FOR MAINTENANCE OF... (2*)
149. . . . IN-DEPTH CHARACTERIZATION OF HOST-GENETICS AND GUT... (4*)|(2)
150. . . . SINGLE-CELL ANALYSIS OF T CELL PATHOGENESIS... (4*)
151. . . . USING DEEPLARNING AND GENETIC BIGDATA TO... (2*)|(6)
152. . . . PENTOXIFYLLINE TREATMENT IN ACUTE PANCREATITIS: FEASIBILITY... (2*)
153. . . . CORONIN 1 IS NECESSARY FOR M... (2*)
154. . . . GUT MICROBE-PRODUCED SHORT CHAIN FATTY ACIDS... (2*)|(4)
155. . . . PRIMARY AND PLURIPOTENT STEM CELL DERIVED... (2*)|(4)
156. . . . H. PYLORI INDUCES GASTRIC EPITHELIAL CELL... (2*)
157. . . . THE INTESTINAL MICROENVIRONMENT INDUCES A TRANSCRIPTION... (4*)
158. . . . LEVERAGING HUMAN INTESTINAL ORGANOIDS TO ADVANCE... (3*)|(AbbVie)
159. . . . ALDH1A3 PROMOTES METASTATIC COLONISATION OF PANCREATIC... (2*)
160. . . . DELETION OF NRF2 IN PANCREATIC STELLATE... (5*)
161. . . . PANCREATIC ACINAR CELL REPROGRAMMING INDUCED BY... (2*)
162. . . . GLYCEMIC PROFILE OF SUBJECTS WITH FAMILIAL... (5*)
163. . . . METFORMIN AND BET INHIBITORS REDUCE PROLIFERATION... (2*)
164. . . . ESTABLISHMENT OF A NOMOGRAM COMPRISING OF... (2*)|(4)
165. . . . DEVELOPMENT OF THE EOSINOPHILIC GASTRITIS MOLECULAR... (2*)|(CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy grou)
166. . . . L-TYPE CALCIUM CHANNEL INHIBITORS (VERAPAMIL AND... (4*)
167. . . . EOE ESOPHAGEAL EPITHELIAL CELLS INDUCE TH2... (4*)|(2)
168. . . . EPIGENETIC ANALYSIS INDICATES ACCELERATED MOLECULAR AGEING... (5*)
169. . . . INTERLEUKIN-13-MEDIATED RELEASE OF MITOCHONDRIAL DNA FROM... (2*)|(3)|(Shire)
202. . . . THE MICROBIAL METABOLITE BUTYRATE PROMOTES GOBLET... (2*)
203. . . . COLONIC MESENCHYMAL STROMAL CELL MYD88-MEDIATED SIGNALING... (2*)
204. . . . SURGERY IN VERY EARLY ONSET INFLAMMATORY... (6*)
205. . . . COLLEGE ADJUSTMENT IN IBD STUDENTS: AGE... (3*)|(AbbVie Inc.)
206. . . . INCREASED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS... (2*)|(6)
207. . . . INCREASED INCIDENCE OF MALIGNANCY IN PATIENTS... (2*)|(6)
208. . . . SAFETY AND EFFICACY OF ANTI-TNF THERAPY... (5*)
209. . . . EARLY COMBINED IMMUNOSUPPRESSION IS EFFECTIVE AND... (2*)
235. . . . EARLY INFLIXIMAB PHARMACOKINETICS AND WEEK ONE... (6*)|(2)|(Prometheus Laboratories, Inc.provided study assay.)
236. . . . ADOLESCENTS' AND YOUNG ADULTS' SATISFACTION WITH... (5*)
237. . . . GEOGRAPHIC ANALYSIS OF PEDIATRIC INFLAMMATORY BOWEL... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

238. . . . NUCLEIC ACID AMPLIFICATION FOLLOWED BY ENZYME... (2*)
251. . . . ENDOSCOPIST-RELATED FACTORS INFLUENCING POLYP DETECTION RATE... (5*)|(The first author completed this research during a Newman Fellowship programme, sponsored by Boston Scientific)
252. . . . A PROSPECTIVE RANDOMIZED TANDEM COLONOSCOPY STUDY... (4*)|(Nil)
253. . . . THE POLYP-BASED RESECT-AND-DISCARD STRATEGY: A PROSPECTIVE... (5*)
254. . . . VALIDATION OF BLUE LIGHT IMAGING (BLI)... (5*)
255. . . . ARTIFICIAL INTELLIGENCE IMAGE CLASSIFIER BASED ON... (4*)
256. . . . ARTIFICIAL INTELLIGENCE FOR REAL-TIME MULTIPLE POLYP... (5*)
257. . . . HIGHER ABUNDANCE OF BILE ACID-METABOLIZING MICROBIOTA... (5*)
258. . . . INTEGRATED METABOLOMIC AND MICROBIOME APPROACH REVEALED... (6*)
259. . . . INCREASED BACTERIOPHAGE ABUNDANCE AND LOSS OF... (2*)|(4)
260. . . . IDENTIFICATION OF PATHOGENIC BACTERIA IN SEVERE... (2*)
261. . . . PROTEUS IS A KEY CANDIDATE IN... (6*)
262. . . . DIETARY SERINE REGULATE THE INTEGRITY OF... (2*)
263. . . . GUT MICROBIOTA PROFILING IN A PROSPECTIVE... (4*)
264. . . . DIETARY EMULSIFIERS REDUCE THERMOGENESIS IN BROWN... (2*)
265. . . . NEUROTENSIN (NT)- α -DEFENSINS AXIS MEDIATES THE INFLUENCE... (2*)
266. . . . DIETARY INTERVENTIONS AMELIORATE INFECTIOUS COLITIS THROUGH... (2*)
267. . . . EXCLUSIVE ENTERAL NUTRITION (EEN) AND CROHN'S... (2*)|(3)
268. . . . GUT MICROBIOTA MATURATION DURING EARLY LIFE... (2*)|(4)
269. . . . COLONIC EOSINOPHILIA IS ASSOCIATED WITH CURRENT... (4*)
270. . . . ESOPHAGEAL HYPERVIGILANCE AND SYMPTOM ANXIETY ARE... (2*)
271. . . . MANAGEMENT OF SUPRA-GASTRIC BELCHING WITH COGNITIVE... (1*)
272. . . . AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER AMONG ADULT... (5*)
273. . . . A MULTIDISCIPLINARY INTEGRATED TREATMENT APPROACH IS... (2*)
274. . . . VARIATION IN ADENOMA DETECTION RATE AND... (2*)
275. . . . DETERMINATION OF BENCHMARKS FOR SERRATED POLYP... (5*)
276. . . . EFFICACY AND SAFETY OF HOT AND... (5*)
277. . . . RAPID DEVELOPMENT OF FELLOWS' COGNITIVE AND... (5*)
278. . . . SIMULATION BASED TRAINING IMPROVES CONFIDENCE LEVELS... (5*)
279. . . . VALIDATION OF A NATURAL LANGUAGE PROCESSING... (2*)
280. . . . INHIBITORY SMAD6 REDUCES SOX9 EXPRESSION IN... (2*)
281. . . . ROLE OF ENDOGENOUS AND EXOGENOUS CARBON... (4*)|(Jagiellonian University Medical College, Faculty of Medicine, statutory grant No. 007716)
282. . . . EXPOSURE OF BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA... (2*)|(4)
283. . . . THE ROLE OF ST6GAL-I, A GLYCOSYLTRANSFERASE... (4*)|(2)
284. . . . TRANSGENIC MOUSE MODEL BASED ON VSIG10L... (2*)
297. . . . DEEP LEARNING ALGORITHM FOR CHARACTERIZATION OF... (5*)
298. . . . ARTIFICIAL INTELLIGENCE FOR DETECTING GASTRIC CANCER... (5*)
299. . . . VIDEO VALIDATION OF SMALL BOWEL CONVOLUTIONAL... (5*)
300. . . . DIFFERENTIATION BETWEEN PANCREATIC CANCER AND NORMAL... (2*)
301. . . . CROHN'S DISEASE EXCLUSION DIET IS EQUALLY... (2*)|(3)|(Nestlé Health Sciences)
302. . . . EARLY CHANGE IN FECAL CALPROTECTIN PREDICTS... (2*)|(4)
303. . . . EFFECT OF A PRACTICE-WIDE ANTI-TNF THERAPEUTIC... (2*)|(4)
304. . . . NEW KEY PLAYERS IN IMPAIRED ANGIOGENESIS... (2*)
305. . . . GENERATION OF STRATIFIED ESOPHAGEAL EPITHELIUM FROM... (6*)
306. . . . CELLS LINEAGE TRACED FROM LGR5+ CELLS... (2*)
307. . . . PROTEOMIC ANALYSIS OF INTESTINAL BRUSH BORDER... (2*)
308. . . . TEDUGLUTIDE IN A REAL WORLD SETTING... (5*)
309. . . . A NOVEL R-SPONDIN 1/POMC NEUROCIRCUIT IN... (2*)
322. . . . PREVENTION OF RECURRENT IDIOPATHIC GASTRODUODENAL ULCER... (2*)
323. . . . RISK OF GASTROINTESTINAL BLEEDING AFTER TREATMENT... (5*)
324. . . . OPTIMAL TIMING OF WARFARIN RESUMPTION AFTER... (5*)
325. . . . DEVELOPMENT AND VALIDATION OF MACHINE LEARNING... (2*)
326. . . . RIVAROXABAN IS ASSOCIATED WITH HIGHER RATES... (1*)
327. . . . FAK ACTIVATORS PROMOTE INTESTINAL MUCOSAL HEALING... (5*)
328. . . . PRECLINICAL DRUG EVALUATION REVEALS INHIBITION OF... (2*)
329. . . . TNFAIP8 IS A CRITICAL REGULATOR OF... (2*)
330. . . . PHARMACOLOGICAL INHIBITION OF THE APICAL SODIUM-DEPENDENT... (2*)
331. . . . THE LONG NON-CODING RNA, IFNG-AS1/NEST, IS... (6*)|(4)
332. . . . TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES... (2*)|(6)
333. . . . TREM1, THE FIRST ANTI-TNF SPECIFIC BIOMARKER... (4*)
334. . . . DEVELOPMENT AND VALIDATION OF A CLINICAL... (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

335. . . . VEDOLIZUMAB TARGETS LYMPHOID AGGREGATES IN THE... (2*)|(3)|(Takeda Pharmaceuticals)
336. . . . USING DEEP LEARNING FOR AUTOMATED GRADING... (2*)
337. . . . COMPLETE HISTOLOGIC NORMALIZATION IS ASSOCIATED WITH... (5*)
338. . . . LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS... (5*)
347. . . . IS SUCROSE THE SIXTH FODMAP IN... (4*)
348. . . . BMI RATHER THAN SYMPTOMS IS ASSOCIATED... (5*)
349. . . . BASELINE GLP-1 LEVEL CORRELATES WITH DEGREE... (5*)
350. . . . GWAS-IDENTIFIED METABOLIC SYNDROME GENES ARE TIGHTLY... (2*)|(3)|(Pathway Genomics)
357. . . . PROSPECTIVE EVALUATION OF A NOVEL, ENDOSCOPIC... (2*)|(6)
358. . . . CLOSE FOLLOW-UP IS ASSOCIATED WITH FEWER... (2*)
359. . . . EOSINOPHILIC ESOPHAGITIS-LIKE DISEASE WITH LACK OF... (2*)
360. . . . ORAL VISCOUS BUDESONIDE VERSUS SWALLOWED FLUTICASONE... (2*)
361. . . . FUNCTIONAL LUMINAL IMAGING PROBE PROVIDES AN... (6*)|(2)
362. . . . IBD EPIDEMIOLOGY: WHAT IS GOING ON... (5*)
363. . . . DOES RIFAXIMIN OFFER ANY PROMISE IN... (5*)
364. . . . EARLY USE OF AZATHIOPRINE ASSOCIATED WITH... (5*)
365. . . . EFFICACY AND SAFETY OF INFlixIMAB RETREATMENT... (5*)
366. . . . SURVEILLANCE COLONOSCOPIES IN ULCERATIVE COLITIS: DOES... (4*)
367. . . . VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY... (3*)|(SetPoint Medical)
369. . . . TARGETED DELETION OF THE ATP-BINDING CASSETTE... (2*)
370. . . . PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
371. . . . USING A MACHINE LEARNING PROGRAM -... (2*)
372. . . . ELMO1, A MICROBIAL SENSOR, REGULATES BACTERIAL... (2*)
373. . . . ROLE OF SURFACE POLYSACCHARIDES OF ADHERENT-INVASIVE... (6*)
374. . . . MICRORNA-125A PROTECTS INTESTINAL MUCOSAL INFLAMMATION THROUGH... (2*)|(the tiol tural Science Foundation of Chi (81630017))
375. . . . HELMINTH EXPOSURE ALTERS TH17 SUBPOPULATION PLASTICITY... (2*)
377. . . . PROTECTIVE AND POTENTIALLY AGGRESSIVE BACTERIAL SPECIES... (2*)
401. . . . EFFICACY AND SAFETY OF COMBINED CPP-1X/SULINDAC... (3*)|(Cancer Prevention Pharmaceuticals, Inc.)
414. . . . A ROLE FOR THE STOMACH IN... (4*)
415. . . . COMBINED BLOCKADE OF $\alpha 4\beta 7$ AND $\alpha E\beta 7$... (3*)|(Genentech Inc., South San Francisco, CA)
416. . . . THE ORAL $\alpha 4\beta 7$ INTEGRIN SPECIFIC ANTAGONIST... (3*)|(Protagonist Therapeutics, Inc.)
417. . . . FUNCTIONAL CHARACTERIZATION OF ENTEROCHROMAFFIN CELLS USING... (2*)
418. . . . DEFECTIVE CFTR FUNCTION IN PANCREATIC DUCTAL... (4*)|(2)
419. . . . LACTOBACILLUS REUTERI SECRETES γ -GLUTAMYL CYSTEINE TO SUPPRESS... (2*)
421. . . . PATHOLOGICAL ACTIVATION OF PIEZO1 IS THE... (2*)
422. . . . EPITHELIAL IDO1 MODULATES AHR AND NOTCH... (2*)|(6)
423. . . . IDENTIFYING THE MOST COST-EFFECTIVE TREATMENT ALGORITHM... (5*)
424. . . . A PROSPECTIVE, LONGITUDINAL STUDY OF METABOLOMIC... (2*)
425. . . . DURABLE TRANSFER OF CANDIDATE PROCARCINOGENIC BACTERIA... (2*)
426. . . . MARKED ALTERATIONS IN THE FECAL VIROME... (4*)
427. . . . FECAL MICROBIOTA TRANSPLANTATION REGULATES CIRCULATING MICRORNA... (4*)
428. . . . SOLUTE CARRIER FAMILY 26 MEMBER 3... (3*)|(2)|(Funding: Merck & Company sponsored this study. HWK was supported by NIH R03 DK103964 grant. CP was supported by NIH U01 DK110003-01 and P30 DK 41301-26.)
429. . . . AUTOIMMUNE ANTIBODIES AND SYMPTOMS OF AUTOIMMUNE... (2*)
430. . . . A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF... (3*)|(Lyric Pharmaceuticals, South San Francisco, CA, USA)
431. . . . ACTIVATION OF NRF2 ATTENUATES DELAYED GASTRIC... (2*)
432. . . . PROTEOMICS IN GASTROPARESIS: UNIQUE AND OVERLAPPING... (2*)|(Study funded by NIDDK grants: U01DK112193, U01DK112194, U01DK073983, U01DK073975, U01DK074035, U01DK074007, U01DK073974, U24DK074008)
433. . . . LOSS OF CX3CR1-POSITIVE GASTRIC MUSCULARIS MACROPHAGES... (2*)
434. . . . CHARACTERIZATION OF PYLORIC TONIC AND PHASIC... (5*)
435. . . . DUAL THERAPY WITH ESOMEPRAZOLE AND AMOXICILLIN... (2*)|(3)|(This study was funded by '12th Five-Year' tiol Science and Technology Support Plan project (2012BAI06B02) and AstraZeneca Investment (Chi) Co., Ltd.)
436. . . . THE EFFICACY OF FOURTEEN-DAYS ESOMEPRAZOLE AND... (4*)
437. . . . AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, SUPERIORITY TRIAL... (5*)
438. . . . HISTOLOGICAL GASTRITIS IN A COMMUNITY POPULATION... (3*)|(The study was supported by Olympus Sverige AB (Box 1816, 171 23 Sol, Sweden), who supplied study equipment.)
439. . . . RESIDUAL RISK OF GASTRIC CANCER FOLLOWING... (5*)
440. . . . ROBUSTNESS OF ELUXADOLINE FOR THE TREATMENT... (3*)|(This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.)

441. . . . PSYCHOLOGICAL FACTORS HAVE A VARYING EFFECT... (6*)

442. . . . SAFETY PROFILE OF ELUXADOLINE IN PATIENTS... (3*)|(This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.)

443. . . . INTESTINAL BIOFILMS ARE AN ENDOSCOPIC FEATURE... (2*)

444. . . . RIFAXIMIN FOR IMPROVING ABDOMINAL PAIN AND... (3*)|(Funded by Salix Pharmaceuticals.)

445. . . . NT-NTR1 SIGNALING POSITIVELY REGULATES INTESTINAL FATTY... (2*)

446. . . . MODULATION OF BILE ACIDS PATHWAY IN... (2*)|(3)| (Funds and product provided by Satiogen Pharmaceuticals)

447. . . . DIFFERENCES IN PREVALENCE OF METABOLIC CONDITIONS... (5*)

448. . . . CHOLECYSTECTOMY ALTERS GASTROINTESTINAL HEALTH INDICES AND... (4*)

449. . . . HIGH FAT KETOGENIC DIET DECREASES SERUM... (4*)

450. . . . EFFECT OF FARNESOID X RECEPTOR ACTIVATION... (2*)

451. . . . FUNCTIONAL GENOMIC SCREENING USING CRISPR/CAS9 IDENTIFIES... (4*)

452. . . . TRIM67 PREVENTS COLORECTAL TUMORIGENESIS IN MICE BY... (2*)

453. . . . THERAPEUTIC DOSE OF PELVIC RADIATION SLOWS... (2*)

454. . . . PD-L1 EXPRESSION REGULATES TUMOR CELL APOPTOSIS... (2*)|(4)

455. . . . DIFFERENTIAL POST-TRANSLATIONAL MODIFICATION OF POLYMORPHIC MSH3... (2*)|(4)

456. . . . DCLK1 MONOCLONAL ANTIBODY-BASED CAR-T CELLS AS... (2*)

457. . . . ON DEMAND VS CONTINUOUS USE OF... (4*)

458. . . . SUCCESSFUL REDUCTION OF OVERALL AND INAPPROPRIATE... (5*)

459. . . . TRENDS IN PRESCRIBING OF ACID-REDUCING THERAPIES... (1*)

460. . . . EFFECTS OF PROTON-PUMP INHIBITORS IN PATIENTS... (5*)

461. . . . ANOTHER FALSE ALARM: NO GOOD EVIDENCE... (5*)

462. . . . CIRCULATING EXTRACELLULAR VESICLES AND SPHINGOLIPIDS CARGO... (2*)

463. . . . SIGNIFICANTLY WORSE FUNCTIONAL STATUS AT TIME... (5*)

464. . . . SIGNIFICANT INCREASES IN ALCOHOL CIRRHOSIS RELATED... (5*)

490. . . . INFLAMMATION-INDUCED LOSS OF SPROUTY2 IN THE... (2*)|(6)| (NIH R01DK095004 (MRF) Crohn's & Colitis Foundation Career Development Award (MAS))

509. . . . WOMEN GASTROENTEROLOGISTS ARE UNDERREPRESENTED IN RECOGNITION... (5*)

510. . . . STRATEGIES TO ACCOUNT FOR COLONOSCOPY VOLUME... (6*)

511. . . . ENDOSCOPIC HISTORY POTENTIALLY EXPLAINS SURVIVAL DIFFERENCES... (4*)

512. . . . DONOR HEALTH SCREENING FOR FECAL MICROBIOTA... (5*)

513. . . . MORTALITY IN MICROSCOPIC COLITIS - RESULTS... (5*)

514. . . . BEVERAGE INTAKE AND THE INCIDENCE OF... (2*)

515. . . . COLONOSCOPY AFTER HOLIDAYS IS AN INDEPENDENT... (5*)

516. . . . RACIAL DISPARITIES IN THE CARE OF... (4*)

517. . . . RACIAL AND ETHNIC TRENDS IN ESOPHAGEAL... (5*)

518. . . . RACIAL DISPARITIES IN RATES OF SURGERY... (5*)

519. . . . THE AGE TO STOP ENDOSCOPIC SURVEILLANCE... (2*)

520. . . . OVERUSE OF SURVEILLANCE ENDOSCOPY FOR BARRETT'S... (2*)

521. . . . NUMBER OF SESSIONS TO ACHIEVE COMPLETE... (7*)

522. . . . SEROTONIN MODULATES ARYL HYDROCARBON RECEPTOR (AHR)... (2*)|(6)

523. . . . KSR1 AND EXO70 INTERACT WITH ERK1/2... (2*)

524. . . . EPIDERMAL GROWTH FACTOR IMPROVES GLUCAGON-LIKE PEPTIDE-2-MEDIATED... (2*)

525. . . . ENDOCRINE PROGENITOR CELLS ORCHESTRATE THE INTESTINAL... (2*)

527. . . . LYSOPHOSPHATIDIC ACID TREATMENT AMELIORATES THE FUNCTION... (7*)

528. . . . IN BARRETT'S EPITHELIAL CELLS, NUCLEOPHOSMIN 1... (2*)

529. . . . 3D ORGANOID REVEAL THE EXPANSION OF... (2*)

530. . . . ESOPHAGEAL SQUAMOUS CANCER CELLS CONDITION LYMPHATIC... (2*)

531. . . . TARGETING NERVE-CANCER METABOLISM IMPROVED OVERALL SURVIVAL... (2*)|(4)

532. . . . RSP03 FUNCTIONS AS TUMOUR-SUPPRESSOR AND INHIBITS... (2*)|(The project was supported by NSFC81472727, NSFC81272403, NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100).)

533. . . . GENERATION OF NOVEL PIK3CA-INDUCED GASTRIC CANCER... (2*)

534. . . . MRI IS HIGHLY PREDICTIVE OF THE... (5*)

535. . . . ILEAL BIOPSY EPITHELIAL CELL PYROPTOSIS PREDICTS... (3*)|(Takeda Pharma: grant support)

536. . . . PREDICTING VEDOLIZUMAB INDUCED ENDOSCOPIC REMISSION IN... (4*)|(2)

537. . . . FECAL CALPROTECTIN IS AN EARLY PREDICTOR... (3*)|(Truvion Healthcare (Preventis))

538. . . . A BLOOD BASED PRE-SURGICAL TRANSCRIPTOMIC SIGNATURE... (6*)|(4)

539. . . . WEARABLE DEVICES CAN PREDICT DISEASE ACTIVITY... (3*)|(Takeda Pharmaceuticals)

567. . . . ADEQUATE INFLIXIMAB EXPOSURE DURING THE INDUCTION... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

568. . . . HIGHER INFILXIMAB AND ADALIMUMAB TROUGH LEVELS... (5*)
569. . . . ADALIMUMAB FOR PATIENTS WITH CROHN'S DISEASE... (3*)|(Abbvie)
570. . . . EARLY ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY WITH BILIARY... (2*)|(4)
571. . . . THE PREDICTIVE EFFECT OF A HIGH-QUALITY... (5*)
584. . . . EFFICACY AND SAFETY OF RIFAXIMIN TREATMENT... (3*)|(Funded by Salix Pharmaceuticals.)
585. . . . EFFECT OF THROMBOPOIETIN RECEPTOR AGONIST IS... (5*)
586. . . . BALLOON-OCCLUDED RETROGRADE TRANSVENOUS OBLITERATION (BRTO) VERSUS... (5*)
587. . . . PENTADECAPETIDE BPC 157 THERAPY IN BILE... (4*)
588. . . . COMPLICATIONS ASSOCIATED WITH ANESTHESIA SERVICES IN... (2*)
589. . . . QUALITATIVE DERIVATION AND QUANTITATIVE PREDICTION OF... (7*)
590. . . . HIGH DIAGNOSTIC YIELD USING ADVANCED ARTIFICIAL... (5*)
591. . . . DERIVATION AND VALIDATION OF QUANTITATIVE PARAMETERS... (7*)
592. . . . SEQUENTIAL DIAGNOSIS OF LIVER METASTASIS FROM... (5*)
593. . . . DEVELOPMENT, VALIDATION OF A POST-ERCP PANCREATITIS... (5*)
594. . . . ENDOSCOPIC ULTRASOUND-GUIDED TREATMENT OF GASTRIC VARICES... (5*)
595. . . . UTILITY OF SYMPTOM SEVERITY, FREQUENCY, AND... (3*)|(The origil study was funded by Alvine Pharmaceuticals. The data was then acquired by ImmunogenX. This is a post hoc alysis of the lead in data from that trial and shared with us from ImmunogenX. No funding for this current post hoc alysis was used from t)
596. . . . REAL LIFE PATTERNS OF GLUTEN-FREE DIET... (5*)
597. . . . A THEORY-BASED, BEHAVIORALLY FOCUSED COOKING INTERVENTION... (4*)
598. . . . IDENTIFICATION OF IMMUNOTOXIC PEPTIDES FROM DIETARY... (2*)|(4)
599. . . . EFFECT OF BIFIDOBACTERIUM INFANTIS NSL SUPER... (5*)
600. . . . CONCORDANCE OF BULB AND DISTAL DUODENAL... (5*)
601. . . . THE EFFECT OF ESOMEPRAZOLE ON THE... (2*)|(tural Science Fund of Chi (U1702281 and 81670551))
602. . . . THROMBOEMBOLIC EVENTS IN ACUTE PANCREATITIS... (5*)
603. . . . NATURAL HISTORY OF LOW OUTPUT EXTERNAL... (5*)
604. . . . IMPACT OF STATIN USE ON CLINICAL... (5*)
605. . . . THE CLINICAL COURSE AND DIAGNOSTIC WORK-UP... (5*)
606. . . . CLINICAL FEATURES OF HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS... (5*)
607. . . . DYNAMIC ANALYSIS OF PATIENTS WITH ACUTE... (3*)|(This was not a funded study but it was performed in part by Ariel Precision Medicine, a commercial entity. We performed a cohort alysis that was agreed upon a priori by the investigators as a collaboration.)
608. . . . PAIN MODULATORY PHENOTYPES DIFFERENTIATE CHRONIC PANCREATITIS... (7*)
609. . . . RESULTS FROM A MULTICENTER, PHASE II,... (3*)
610. . . . CHRONIC PANCREATITIS IS ASSOCIATED WITH INCREASED... (5*)
611. . . . A NOVEL METHOD FOR ASSESSMENT AND... (7*)
612. . . . PANCREATIC ATROPHY DOES NOT CORRELATE WITH... (5*)
613. . . . PANCREATIC CANCER INCIDENCE IN A LARGE... (7*)
614. . . . PAIN "BURN-OUT" DURING THE NATURAL COURSE... (2*)
615. . . . ACCELERATED ONSET OF SPONTANEOUS PROXIMAL COLONIC... (2*)
616. . . . LOSS OF GLUTATHIONE PEROXIDASE 1 PROTECTS... (2*)
617. . . . SIMULTANEOUS LOSS OF BOTH ATYPICAL PROTEIN... (2*)|(7)
618. . . . ROLE OF LGR5 IN DCLK1+ CELL-DERIVED... (7*)|(4)
619. . . . MYELOID CALCINEURIN IN THE CONTROL OF... (4*)
620. . . . NEUTROPHILS RESTRICT TUMOR-ASSOCIATED MICROBIOTA TO DAMPEN... (2*)
621. . . . FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT... (3*)|(4)|(This study was an Investigator Initiated Study funded by Finch Therapeutics.)
622. . . . DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF WEEKLY... (3*)|(2)|(SERES THERAPEUTICS NIH Grant P30 DK40561 Massachusetts General Hospital Claflin Distinguished Scholar Award)
623. . . . SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES... (3*)|(Seres Therapeutics)
624. . . . COMPARISON OF TWO OPEN-LABEL TRIALS DEMONSTRATES... (3*)|(This alysis was funded by Rebiotix Inc., Roseville, MN, USA.)
625. . . . DONOR FUNGI AND BACTERIA ENGRAFTMENT AFTER... (4*)
626. . . . GUT MICROBIOTA FROM COLORECTAL CANCER PATIENTS... (2*)
627. . . . DYSREGULATION OF EPITHELIAL TLR4 SELECTS FOR... (2*)|(6)
628. . . . IDENTIFICATION OF CROSSTALK BETWEEN GUT MICROBIOTA,... (2*)
629. . . . COLORECTAL CANCER-ASSOCIATED BACTERIA INDUCE TH1 AND... (6*)
630. . . . GUT MICROBIOTA MODULATES THE CHEMOPREVENTIVE EFFICACY... (2*)
631. . . . DIETARY INTAKE, H2S-PRODUCING MICROBES, AND RISK... (2*)|(6)
632. . . . DEVELOPMENT OF A NOVEL MIRNA-BASED SIGNATURE... (5*)
633. . . . GA-68 DOTATATE PET IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE... (5*)
635. . . . THE UTILITY OF COMPUTED TOMOGRAPHY (CT)... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- 636. . . . DUODENAL NEUROENDOCRINE TUMORS EXHIBIT DISTINCT SOMATIC... (2*)**
- 637. . . . DELINEATION OF THE PATHOGENESIS OF MESENTERIC... (4*)**
- 649. . . . ECONOMIC BURDEN OF CELIAC DISEASE IN... (3*)|(Takeda Pharmaceuticals Intertiol Co.)**
- 650. . . . PREVALENCE OF CELIAC DISEASE AUTOIMMUNITY AND... (5*)**
- 651. . . . INTERNATIONAL STUDY GROUP OF PEDIATRIC PANCREATITIS:... (2*)**
- 652. . . . CLINICAL OUTCOMES IN AUSTRALIAN CHILDREN WITH... (5*)**
- 653. . . . EXTENSIVE GENE TESTING AND GENETIC INVOLVEMENT... (2*)|(Conflicts of Interests: Dr. C. Alexander Valencia worked at Cincinnati Children's when the study was conducted, he currently works at PerkinElmer genomics, Pittsburgh, PA, and this company has not provided any financial support for the study. Dr. Abu-El-Hai)**
- 654. . . . THE STOOL MICROBIOME MAY PREDICT OUTCOMES... (6*)|(4)**
- 655. . . . STANDARDIZING THE CARE OF ACUTE SEVERE... (POSTER PRESENTATION)... (5*)**
- 656. . . . MULTI-SYSTEM APPROACH TO DECREASING PROTON PUMP... (POSTER PRESENTATION)... (5*)**
- 657. . . . FENTANYL WASTE WAS REDUCED BY CONSERVATION... (POSTER PRESENTATION)... (5*)**
- 658. . . . IMPROVING FIRST-CASE START DELAYS IN A... (POSTER PRESENTATION)... (5*)**
- 659. . . . NEW PATIENT ACCESS IN A GASTROENTEROLOGY... (POSTER PRESENTATION)... (5*)**
- 660. . . . IMPROVING VACCINATION ADHERENCE IN INFLAMMATORY BOWEL... (POSTER PRESENTATION)... (2*)|(7)**
- 661. . . . USE OF A SIMPLE 6-ITEM QUESTIONNAIRE... (POSTER PRESENTATION)... (5*)**
- 662. . . . QUALITY GAPS IN PREVENTATIVE CARE PROVIDED... (POSTER PRESENTATION)... (5*)**
- 663. . . . LET'S MAKE YOUR CLINIC VISIT A LITTLE SIMPLER - DEVELOPMENT OF A QUESTION... (POSTER PRESENTATION)... (5*)**
- 664. . . . HEPATOCELLULAR CARCINOMA SCREENING RATES IN A... (POSTER PRESENTATION)... (5*)**
- 665. . . . EVALUATING THE IMPACT OF A NOVEL,... (POSTER PRESENTATION)... (5*)**
- 666. . . . THE IMPACT OF DELAY BETWEEN BIOLOGIC... (POSTER PRESENTATION)... (5*)**
- 667. . . . OPTIMIZING OUTPATIENT COLORECTAL CANCER SCREENING AND...(POSTER PRESENTATION)... (5*)**
- 668. . . . RATE OF INAPPROPRIATE FIT TESTING AT... (POSTER PRESENTATION)... (5*)**
- 669. . . . PROACTIVE MANAGEMENT OF IRON DEFICIENCY AND... (POSTER PRESENTATION)... (5*)**
- 670. . . . UTILIZING A TIME SERIES STUDY TO... (POSTER PRESENTATION)...(5*)**
- 671. . . . IMPLEMENTATION OF AN ACUTE CARE CLINICAL... (POSTER PRESENTATION)... (5*)**
- 672. . . . HEMATOCHEDIA DECREASES USE OF VENOUS THROMBOEMBOLISM... (POSTER PRESENTATION)... (5*)**
- 673. . . . STANDARDIZING INPATIENT BOWEL PREPARATION ORDERS IMPROVES... (POSTER PRESENTATION)... (5*)**
- 674. . . . PATIENTS' SELF-IDENTIFIED STOOL COLOR IS COMPARABLE... (POSTER PRESENTATION)... (5*)**
- 675. . . . REDUCING INAPPROPRIATE FECAL IMMUNOHISTOCHEMICAL TEST (FIT)... (POSTER PRESENTATION)... (5*)**
- 676. . . . ENDOSCOPIC MANAGEMENT OF ACHALASIA: TIME FOR... (POSTER PRESENTATION)... (5*)**
- 677. . . . ESOPHAGEAL MANOMETRY STANDARDIZATION - A COMMUNITY... (POSTER PRESENTATION)... (5*)**
- 678. . . . IMPACT OF GUIDED RELAXATION AND MUSIC... (POSTER PRESENTATION)... (5*)**
- 679. . . . DISCREPANCY BETWEEN SELF-REPORTED PREFERENCES ON POLYPECTOMY... (POSTER PRESENTATION)... (5*)**
- 686. . . . RISK OF METACHRONOUS COLORECTAL CANCER AMONG... (4*)**
- 687. . . . LONG-TERM RISK OF COLORECTAL CANCER AFTER... (2*)**
- 688. . . . BASELINE FINDINGS ON SCREENING COLONOSCOPY IN... (2*)**
- 689. . . . RISK OF COLORECTAL CANCER AND RELATED-MORTALITY... (2*)|(7)**
- 690. . . . COMPLICATIONS OF SCREENING COLONOSCOPY IN A... (2*)**
- 691. . . . INCREASING PHYSICIAN ADENOMA DETECTION RATE IS... (2*)**
- 692. . . . ESCHERICHIA COLI HEAT-STABLE TOXIN IMPAIRS COLONIC... (2*)**
- 693. . . . ATYPICAL PKC ζ ACTIVITY AND RECRUITMENT TO... (2*)**
- 694. . . . THE IBD CANDIDATE GENE, PTPN2, REGULATES... (2*)|(6)**
- 695. . . . TTC7A-DEFICIENT HUMAN COLONIC ENTEROIDS EXHIBIT ALTERED... (4*)**
- 696. . . . TEDUGLUTIDE INCREASES ADAPTATION IN A MURINE... (3*)|(4)|(Shire, Lexington, USA - Investigator Initiated Research Grant)**
- 697. . . . INTESTINAL PERMEABILITY IS AN IMPORTANT FACTOR... (2*)**
- 698. . . . DISTINCTIVE SUBPOPULATION OF INNATE LYMPHOID CELLS... (5*)**
- 699. . . . HUMAN MONOCYTES ENHANCE INTESTINAL STEM CELL... (2*)**
- 700. . . . SEMAPHORIN-3E REGULATES APOPTOSIS DURING THE DEVELOPMENT... (7*)**
- 701. . . . DIETARY INTAKE OF WALNUT TO MITIGATE... (4*)**
- 702. . . . MOLECULAR CHARACTERIZATION OF MOUSE MODELS OF... (5*)**
- 703. . . . TYPE 2 CYTOKINES PROMOTE HYPERPLASIA AND... (2*)**
- 704. . . . PREOPERATIVE SERUM VEDOLIZUMAB LEVELS DO NOT... (5*)**
- 705. . . . PRE-OPERATIVE BIOLOGICS SIGNIFICANTLY REDUCE POST-OPERATIVE LEAKS... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

706. . . . A PROMINENT ROLE FOR CHEMOKINES, IN... (2*)
707. . . . RISK OF VENOUS THROMBOEMBOLISM ACCORDING TO... (5*)
708. . . . A SIGNIFICANT DECREASE IN THE RATE... (6*)
709. . . . COLECTOMY RATES ARE SIGNIFICANTLY HIGHER AMONG... (4*)
756. . . . FUNCTIONAL LUMINAL IMAGING PROBE (FLIP) ASSESSMENT... (2*)
757. . . . FUNCTIONAL GASTROINTESTINAL DISORDERS AND BEHAVIORAL PROBLEMS... (5*)
758. . . . LONG-TERM OUTCOMES OF GASTRIC ELECTRICAL STIMULATION... (5*)
759. . . . SIGNIFICANT VARIANTS IN MONOGENIC INFLAMMATORY BOWEL... (6*)
760. . . . MUTATIONS IN X-LINKED INHIBITOR OF APOPTOSIS... (2*)|(4)
773. . . . CYSTINE/GLUTAMATE ANTIPORTER (XCT) IS REQUIRED FOR... (2*)
774. . . . ROLE OF CELL CYCLE INHIBITOR P21WAF1/CIP1,... (2*)
775. . . . EXOGENOUS STIFFNESS RESULTS IN NUCLEAR TRANSLOCATION... (4*)|(7)
777. . . . LOSS OF TGF- β SIGNALING PROMOTES PROLIFERATION... (2*)|(4)
778. . . . NCX1/CA SIGNAL PATHWAY CONTRIBUTES TO THE... (2*)
779. . . . USE OF NON-ASPIRIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS... (5*)
780. . . . INNOVATIVE SYSTEM FOR SELECTIVE ERADICATION OF... (5*)
781. . . . QUANTIFYING EVOLUTION OF EARLY DYSPLASTIC LESIONS... (2*)|(6)
782. . . . PATIENT-MATCHED STEM CELLS OF THE BARRETT'S-DYSPLASIA-ADENOCARCINOMA... (2*)
783. . . . LONG-TERM PROTON PUMP INHIBITOR USE AND... (3*)|(Investigator initiated research grant from Pfizer)
784. . . . VELUSETRAG IMPROVES GASTROPARESIS BOTH IN SYMPTOMS... (3*)|(Theravance Biopharma R&D, Inc. AlfaSigma S.p.A.)
785. . . . SEXUAL DIMORPHIC EPIGENETIC REGULATION OF CHRONIC... (2*)
786. . . . HOME BIOFEEDBACK THERAPY WITH NOVEL DEVICE... (7*)|(3)|(InControl Medical.)
787. . . . GUT DYSBIOSIS CONTRIBUTES TO VISCERAL HYPERSENSITIVITY... (2*)
788. . . . MICRORNA LET-7F IS OVEREXPRESSED IN COLONIC... (2*)
789. . . . FEAR OF PAIN AND SEROTONERGIC GENE... (4*)
790. . . . IMPACT OF PERSONALIZED COUNSELING ON DEPRESSION... (4*)|(5)
791. . . . A NOVEL HUMANIZED ANIMAL MODEL OF... (2*)
792. . . . EXOME SEQUENCING TO IDENTIFY RISK FACTORS... (2*)
793. . . . PATHWAYS OF PROGRESSION FROM INTRADUCTAL PAPILLARY... (2*)
794. . . . MUTATIONS IN REGULATORY ELEMENTS OF THE... (2*)
795. . . . VALIDATION OF PANCREATITIS ACTIVITY SCORING SYSTEM... (5*)
796. . . . REAL-WORLD EFFECTIVENESS OF TOFACITINIB IN ULCERATIVE... (5*)
797. . . . REAL-WORLD SAFETY OF TOFACITINIB IN INFLAMMATORY... (4*)
798. . . . EFFICACY AND SAFETY OF OPEN-LABEL TREATMENT... (3*)|(Pfizer Inc)
799. . . . EFFICACY OF UPADACITINIB AS AN INDUCTION... (3*)|(AbbVie-sponsored)
800. . . . IMPROVED ENDOSCOPIC OUTCOMES AND MUCOSAL HEALING... (3*)|(The authors and AbbVie scientists designed the study, and analysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the)
801. . . . CLINICAL, ENDOSCOPIC, HISTOLOGIC AND BIOMARKER ACTIVITY... (3*)|(Theravance Biopharma US, Inc)
813. . . . CURCUMA LONGA LINN VERSUS OMEPRAZOLE IN... (7*)
814. . . . HELICOBACTER PYLORI INDUCES ABERRANT LRIG1 STEM... (2*)
815. . . . LONG-TERM CHANGES OF GUT MICROBIOTA, ANTIBIOTIC... (2*)|(4)
816. . . . EFFECTS OF ANTI-HELICOBACTER PYLORI THERAPY ON... (2*)|(4)
817. . . . EFFICACY OF 1-FOOD AND 4-FOOD ELIMINATION... (2*)|(4)
818. . . . CYTOKINE EXPRESSION ILLUSTRATES HETEROGENEITY OF ACTIVE... (2*)|(6)
819. . . . METABOLISM OF WHEAT AMYLASE TRYPSIN INHIBITORS... (2*)
820. . . . PROSPECTIVE LONGITUDINAL GUT METAGENOMIC ANALYSIS SUGGESTS... (2*)
821. . . . A RANDOMIZED, PLACEBO-CONTROLLED EVALUATION OF THE... (3*)|(ImmusanT, Inc.)
822. . . . FURTHER DEVELOPMENT OF A NOVEL IN... (4*)
823. . . . BENEFITS AND BARRIERS OF A HANDHELD... (2*)|(Nima Labs supplied 30 Nima devices (the capsules were purchased separately by the above-acknowledged grant support). Nima labs was not privy to the study design, results, or composition of the abstract.)
824. . . . ACUTE GLUTEN-INDUCED SYMPTOMS IN CELIAC DISEASE... (3*)|(ImmusanT, Inc.)
825. . . . AN ACUTE RISE IN SERUM IL-2... (6*)|(4)|(Nestle Research Center/Society for the Study of Celiac Disease)
826. . . . POLYGENIC RISK SCORE, FAMILY HISTORY, AND... (2*)
827. . . . OPTIMAL TIMING OF TOTAL GASTRECTOMY TO... (5*)
828. . . . WHAT'S MY RISK OF CANCER DOCTOR?... (5*)
829. . . . THE IDENTIFICATION OF DNA MISMATCH REPAIR... (2*)|(4)
830. . . . SCREENING UPPER ENDOSCOPY IS USEFUL FOR... (5*)
831. . . . AN EVALUATION OF THE RISKS AND... (5*)
832. . . . DASHBOARD DRIVEN DOSING OF INFlixIMAB IS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- 833. . . . EFFICACY AND SAFETY OF USTEKINUMAB AS...** (3*)|(This study was funded by Janssen Research & Development, LLC)
- 834. . . . WITHDRAWAL OF THIOPURINES IN CROHN'S DISEASE...** (2*)|(Grant from the Ministry of Health, Labour and Welfare of Japan ("Investigation and research for intractable inflammatory bowel disease"))
- 835. . . . LONG-TERM SAFETY OF VEDOLIZUMAB IN ULCERATIVE...** (3*)|(Takeda)
- 836. . . . IMMUNOLOGIC PREDICTORS OF RESPONSE TO VEDOLIZUMAB...** (3*)|(The study was supported by Takeda (HSR-2014-100922))
- 837. . . . PILOT STUDY OF EARLY SCREENING IN...** (4*)
- 838. . . . IS 45 THE NEW 50? ADENOMA...** (5*)
- 839. . . . DISPARITIES IN COLORECTAL CANCER SCREENING: THE...** (5*)
- 840. . . . COLORECTAL CANCER SCREENING AMONG HISPANICS IN...** (4*)
- 841. . . . PATIENT-DIRECTED MESSAGING TO INCREASE COLORECTAL CANCER...** (5*)
- 842. . . . SEQUENTIAL OR ACTIVE CHOICE FOR COLORECTAL...** (2*)
- 843. . . . IMPACT OF MAILED OUTREACH AND INREACH...** (2*)
- 844. . . . IDENTIFICATION OF PUTATIVE CANCER STEM CELLS...** (5*)
- 845. . . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL...** (4*)
- 847. . . . MIR130B EXPRESSED BY SLFN4+ MDSCS STIMULATES EPITHELIAL...** (2*)
- 848. . . . LOSS OF HUMAN EPIDIDYMIS PROTEIN (HE4)...** (2*)|(3)
- 849. . . . LOSS OF SLC26A9 RESULTS IN THE...** (2*)
- 850. . . . INDUCEMENT OF DOUBLE STRAND BREAKS (DSB)...** (2*)|(4)
- 851. . . . ZINC FINGER PROTEIN 545 SUPPRESSES COLORECTAL...** (2*)
- 852. . . . OVEREXPRESSION OF RAGE AND ITS LIGANDS...** (2*)|(4)
- 853. . . . CHOLANGIOCARCINOMA (CCA) DERIVED EXTRACELLULAR VESICLES REPROGRAM...** (7*)|(4)
- 855. . . . SLC25A22 DRIVES ONCOMETABOLITE SUCCINATE TO PROMOTE...** (2*)
- 856. . . . ASSESSMENT OF THE IMPACT OF INTRODUCING...** (5*)
- 857. . . . MEDICATION UTILIZATION AND SATISFACTION IN IRRITABLE...** (5*)
- 858. . . . THERAPEUTIC RESPONSE TO SMALL INTESTINAL BACTERIAL...** (5*)
- 859. . . . IDENTIFICATION OF BILE ACID DIARRHEA IN...** (4*)
- 860. . . . LOW FODMAP DIET IN THE LONG...** (5*)
- 861. . . . EFFECT OF KETOTIFEN ON ABDOMINAL SYMPTOMS,...** (2*)
- 862. . . . INTESTINAL ACIDIFICATION SENSED BY PH-SENSING RECEPTOR...** (4*)
- 863. . . . INDUCTION OF AUTOPHAGY IN CX3CR1+ MONONUCLEAR...** (2*)|(4)
- 864. . . . PLATELETS AND THEIR INTERACTION WITH PRIMARY...** (4*)
- 865. . . . CIRCULATING FIBROCYTES ARE INCREASED IN PATIENTS...** (2*)
- 866. . . . ORALLY ACTIVE ELAFIN-EUDRAGIT INHIBITS COLITIS-ASSOCIATED INTESTINAL...** (2*)|(6)
- 867. . . . THE BCL-2 INHIBITOR ABT-263 ATTENUATES INTESTINAL...** (3*)|(Abbvie)
- 868. . . . THE ROLE OF NUCLEAR FACTOR NFIB-MEDIATED...** (5*)
- 869. . . . SOX12 PROMOTES COLORECTAL CANCER PROLIFERATION AND...** (2*)|(This study was supported by combined grants from the tiol tural Science Foundation of Chi (No.81522031, No. 81772623, No. 81627807, No.81430072 and No. 81421003), tiol Key Research and Development Program of Chi (2018YFC1312103) and tiol Center for Clinic)
- 870. . . . PLASMA BIOMARKERS OF INSULIN AND THE...** (2*)
- 871. . . . TRANSCRIPTIONAL SIGNATURES OF WESTERN-STYLE AND PRUDENT...** (4*)
- 872. . . . YOGURT CONSUMPTION AND RISK OF CONVENTIONAL...** (2*)
- 873. . . . COGNITIVE BEHAVIORAL THERAPY-INDUCED CHANGES IN RESTING...** (2*)
- 874. . . . GUT DYSBIOSIS CHARACTERIZED BY OVERABUNDANCE OF...** (2*)
- 875. . . . FECAL MICROBIOTA FROM IBS PATIENT INDUCES...** (4*)
- 876. . . . STRESS-INDUCED DISRUPTION OF INTESTINAL BARRIER AND...** (7*)|(This study proposal received AGA Student Research Fellowship award.)
- 877. . . . MICROBIOTA PLAYS A KEY ROLE IN...** (4*)
- 878. . . . GUT MICROBIOME BIOMARKERS BEFORE AND DURING...** (2*)
- 879. . . . SWITCHING FROM INFLIXIMAB ORIGINATOR TO A...** (5*)
- 880. . . . DELINEATING THE PHENOTYPE OF PEDIATRIC PSC-IBD...** (5*)
- 881. . . . PILOT STUDY OF EOSINOPHILIC BIOMARKER MEASURED...** (5*)
- 882. . . . NORMALIZATION OF FECAL CALPROTECTIN REQUIRES HIGHER...** (5*)
- 883. . . . INTEGRATION OF CLINICAL, IMMUNOLOGIC AND GENOMIC...** (2*)
- 884. . . . PROSPECTIVE COMPARISON OF SACRAL NERVE STIMULATION...** (5*)
- 945. . . . GLUTEN AVOIDANCE AND SELF-REPORTED NON-CELIAC WHEAT...** (3*)|(This study was supported by a grant from Prometheus laboratories.)
- 946. . . . A HIGH RATE OF IGE-NEGATIVE FOOD...** (6*)|(2)
- 947. . . . PRIMING AND MATURATION OF THE HUMAN...** (4*)
- 948. . . . NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOG-1 PROMOTES...** (2*)|(6)
- 949. . . . DEVELOPMENT OF COORDINATED ELECTRICAL ACTIVITY IN...** (6*)
- 950. . . . MATERNAL MILK ENHANCES INTESTINAL MUCOSAL BARRIER...** (2*)|(6)
- 969. . . . PRIMARY CILIA TRANSDUCE INFLAMMATORY AND HEDGEHOG...** (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

970. . . . REGULATION OF ONCOGENIC STRESS RESPONSE PATHWAY... (2*)
971. . . . THE INNATE IMMUNE MOLECULE NLRC5 PROTECTS... (2*)|(4)
972. . . . NLRP3 INFLAMMASOME-DERIVED INTERLEUKIN-1 β ATTENUATES STRESS-INDUCED GASTRIC... (5*)
973. . . . FEASIBILITY OF ADIPOSE MESENCHYMAL STEM CELL... (4*)|(81770561 CXTDA2017033 BRA2014332 BE2015716)
974. . . . AURORA KINASE A ACTIVATES UNFOLDED PROTEIN... (2*)
975. . . . PROTON-PUMP INHIBITORS MAY ENHANCE INTESTINAL PERMEABILITY... (3*)|(DAIICHI SANKYO COMPANY, LIMITED EA Pharma Co., Ltd)
976. . . . A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER, MULTIPLE-DOSE... (3*)|(Novartis was the Sponsor of this study)
977. . . . INTESTINE MICROBIOME ASPIRATION (IMBA) CAPSULE: A... (4*)
978. . . . IMPACT OF GASTROINTESTINAL PATHOGEN PANEL IMPLEMENTATION... (5*)
979. . . . A LARGE SCALE EVALUATION OF THE... (4*)
980. . . . CHARACTERISTICS OF GASTRIC MUCOSA AND FECAL... (2*)
982. . . . RISK FACTORS FOR EARLY-ONSET COLORECTAL CANCER... (2*)
983. . . . COMPREHENSIVE ASSESSMENT OF DIET QUALITY AND... (2*)
984. . . . U.S. SEER COLORECTAL CANCER INCIDENCE RATE... (5*)
985. . . . COST-EFFECTIVENESS AND NATIONAL IMPACT OF INITIATING... (4*)
986. . . . ALPHA-TOCOPHERYLQUINONE ENHANCES INTESTINAL EPITHELIAL TIGHT JUNCTION... (5*)
987. . . . VITAMIN D RECEPTOR REGULATES EPITHELIAL TIGHT... (2*)
988. . . . TCPTP REGULATES INTESTINAL EPITHELIAL AND MACROPHAGE... (2*)
989. . . . LOSS OF CLAUDIN-3 EXPRESSION INDUCES GUT... (2*)
990. . . . LONG NONCODING RNA H19 REGULATES AUTOPHAGY... (2*)
991. . . . MATRIX METALLOPROTEINASE 7 CONTRIBUTES TO INTESTINAL... (2*)|(4)
992. . . . HYPOXIA-INDUCIBLE FACTOR 1 ALPHA (HIF1A) COOPERATES... (2*)|(4)
993. . . . MYELOID TRANSLOCATION GENE ON CHROMOSOME 16... (2*)
994. . . . MIR-148A REGULATES CHIEF CELL PLASTICITY IN... (2*)
995. . . . TRANSGENIC EXPRESSION OF MIR-195 DISRUPTS INTESTINAL... (2*)
996. . . . THE EPIGENETIC PROTEIN SP140 DIRECTS INFLAMMATORY... (2*)|(3)|(Marie Skłodowska-Curie Actions and GlaxoSmithKline (Stevege, UK))
997. . . . DIETARY AND PHENOTYPIC INSIGHTS INTO THE... (2*)
998. . . . VITAMIN, MINERAL, AND PROTEIN DEFICIENCIES IN... (5*)
999. . . . IMPAIRED DUODENAL EPITHELIAL BARRIER AND SECRETORY... (2*)
1000. . . . SYMPTOMATIC CONTROL OF CYCLIC VOMITING SYNDROME... (4*)
1001. . . . IMPACT OF RECREATIONAL CANNABIS LEGALIZATION ON... (5*)
1002. . . . CYCLIC VOMITING SYNDROME PRACTICE GUIDELINES COMMITTEE... (6*)|(This article received exteri funding support from the Cyclic Vomiting Syndrome Association (CVSA).)
1004. . . . MAINTENENCE TREATMENT WITH MIRIKIZUMAB, A P19-DIRECTED... (3*)|(Eli Lilly and Company)
1005. . . . A CONTROLLED TRIAL OF AMISELIMOD, A... (3*)|(MITSUBISHI TABE PHARMA)
1006. . . . HISTOLOGIC REMISSION AND MUCOSAL HEALING IN... (3*)|(Are Pharmaceuticals, Inc.)
1007. . . . ABX464 IS SAFE AND EFFICACIOUS IN... (3*)|(ABIVAX)
1008. . . . ESTROGENS MODULATE THE EFFECT OF STRESS... (2*)
1009. . . . SENSORY NEUROPLASTICITY IN THE DORSAL ROOT... (2*)|(NIH/NIDDK)
1010. . . . CASPASE-11 IS CRITICAL FOR ENTERIC NITRERGIC... (2*)
1011. . . . THE VOLTAGE-GATED SODIUM CHANNEL NAV1.7 CONTRIBUTES... (2*)
1012. . . . GENOME-WIDE ASSOCIATION ANALYSIS OF DIVERTICULAR DISEASE... (2*)|(4)
1013. . . . EXPLORING THE ROLES OF VOLTAGE-GATED CALCIUM... (2*)|(7)
1014. . . . SEEKING DIETARY FIBERS TO AMELIORATE INFLAMMATORY... (2*)
1015. . . . PROBIOTICS DIFFERENTIALLY AFFECT THE GUT MICROBIAL... (2*)
1016. . . . PROBIOTICS FOR THE PREVENTION OF PEDIATRIC... (5*)
1017. . . . EFFECTS OF A FLATULOGENIC DIET COMBINED... (3*)|(Da Nutricia Research)
1018. . . . TRANSLATIONAL STUDIES OF LACTOBACILLUS GASSERI EFFECTS... (3*)|(4)|(Funded by Biogaia Probiotics, Stockholm, and ALF funding, Uppsala, Sweden.)
1019. . . . DISRUPTED CIRCADIAN OSCILLATION OF GUT-DERIVED SHORT... (2*)|(4)
1067. . . . A MACHINE LEARNING-BASED MODEL TO PREDICT... (6*)|(7)
1068. . . . INDEPENDENT VALIDATION OF A TISSUE SYSTEMS... (2*)|(3)|(This study was funded in part by Cernostics, Inc.)
1069. . . . A MULTICENTER STUDY OF THE ADEQUACY... (3*)|(Study was funded by Covidien/Medtronic.)
1070. . . . WHEN SHOULD WE LOOK FOR RECURRENCE... (7*)
1071. . . . MUCOSAL INTEGRITY TESTING CAN DETECT CHANGES... (4*)
1072. . . . DIAGNOSTIC UTILITY OF CONTRACTILE SEGMENT IMPEDANCE... (5*)
1073. . . . THE AVERAGE RECOVERY TIME OF THE... (5*)
1074. . . . PROLONGED WIRELESS PH MONITORING OFF PPI... (2*)
1075. . . . RUMINATION SYNDROME AND SUPRA-GASTRIC BELCHING CAN... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- 1076. . . FORKHEAD BOX K2 (FO XK2) PROMOTES HUMAN... (2*)** (This study was supported by combined grants from the tional Science Foundation of Chi (No.81522031, No. 81772623, No. 81627807, No.81430072 and No. 81421003), tial Key Research and Development Program of Chi (2018YFC1312103) and tial Center for Clinic)
- 1077. . . A NOVEL GENE EXPRESSION SIGNATURE FOR... (4*)**
- 1078. . . METHYLATED DNA MARKERS DETECT ESOPHAGEAL SQUAMOUS... (3*)**(2)|(Exact Sciences, Madison, WI.)
- 1079. . . A NOVEL GENE EXPRESSION SIGNATURE FOR... (5*)**
- 1080. . . CHARACTERIZATION OF SONIC HEDGEHOG IN ESOPHAGEAL... (2*)**
- 1081. . . GENOME-WIDE TRANSCRIPTOMIC PROFILING FOR THE IDENTIFICATION... (4*)**
- 1082. . . 'TURNING-OFF' STRESS-INDUCED VISCERAL PAIN VIA OPTOGENIC... (2*)**(6)
- 1083. . . GUT SENSING OF NUTRIENT CALORIC CONTENT... (2*)**(4)
- 1084. . . ENTERIC ALPHA-SYNUCLEIN INCLUSIONS, COLONIC INFLAMMATION, INCREASED... (5*)**
- 1085. . . NEURONAL SEROTONIN AS A LINK BETWEEN... (2*)**(6)
- 1086. . . BILATERAL BRAIN-GUT INTERACTIONS AND ANORECTAL SENSATION... (7*)**
- 1087. . . ENTERIC INFLAMMATION AND ALTERED COLONIC CHOLINERGIC... (4*)**
- 1088. . . META-ANALYSIS: THE RISK OF DEVELOPING NEW... (5*)**
- 1090. . . GASTROINTESTINAL SYMPTOMS OBSERVED AFTER CHIMERIC ANTIGEN... (5*)**
- 1091. . . EARLY INTRODUCTION OF NON-STEROIDAL IMMUNOSUPPRESSIVE THERAPY... (5*)**
- 1092. . . IMPORTANCE OF ENDOSCOPIC AND HISTOLOGICAL EVALUATION... (5*)**
- 1093. . . A NOVEL ROLE OF S-ACYLATION IN... (2*)**
- 1094. . . ROLE OF HISTONE ACETYLATION IN UPREGULATION... (2*)**
- 1095. . . TRANSMEMBRANE PROTEIN 237 (TMEM237) INTERACTS WITH... (2*)**
- 1096. . . REGULATION OF NA-GLUTAMINE CO-TRANSPORT BOAT1 IN... (2*)**
- 1097. . . LINACLOTIDE STIMULATES DUODENAL BICARBONATE SECRETION VIA... (4*)**
- 1098. . . INCREASED DIVALENT METAL TRANSPORTER 1 (DMT1)... (2*)**
- 1099. . . THE MICROBIOME IN IRRITABLE BOWEL SYNDROME... (2*)**
- 1100. . . REDUCED BACTERIA-DERIVED BILE SALT HYDROLASE ENZYMIC... (3*)**(The study was sponsored by Nestle Institute of Health (NIHS).)
- 1101. . . FMT WITH OR WITHOUT ANTIBIOTIC PRETREATMENT... (3*)**((FMT capsules provided by OpenBiome)
- 1102. . . EFFICACY OF HUMAN MILK OLIGOSACCHARIDES ON... (3*)**
- 1103. . . DAILY INTAKE OF SULFORAPHANE-RICH BROCCOLI SPROUTS... (3*)**(Murakami Nohen Co. Ltd.)
- 1104. . . INTEGRATED MULTI-OMICS ANALYSIS OF THE FAECAL... (2*)**
- 1105. . . IMPACT OF CONCURRENT PHARMACOTHERAPY WITH INTRAGASTRIC... (5*)**
- 1106. . . AN ANALYSIS OF LEPTIN AND INSULIN-GLUCOSE... (5*)**
- 1107. . . OBESITY IS AN INDEPENDENT RISK FACTOR... (5*)**
- 1108. . . TRANSPYLORIC SHUTTLE TREATMENT IMPROVES CARDIOMETABOLIC RISK... (3*)**(BaroNova)
- 1109. . . ENDOSCOPIC MANAGEMENT OF LATE DUMPING SYNDROME... (5*)**
- 1110. . . OUTCOMES OF A NOVEL BARIATRIC STENT... (5*)**
- 1129. . . LONG-TERM MULTIDONOR FECAL MICROBIOTA TRANSFER (FMT)... (5*)**
- 1130. . . TRANSFERABLE IGA-REACTIVE MICROBIOTA STRATIFY CLINICAL RESPONSE... (3*)**(2)|(Boehringer Ingelheim Pharmaceuticals provided the ficial support to conduct the study)
- 1131. . . SPERMINE OXIDASE DELETION CONFERS PROTECTION FROM... (2*)**(4)
- 1132. . . THE MACROPHAGE REVERSE TRANSULFURATION PATHWAY MEDIATES... (2*)**(4)
- 1133. . . α INDUCTION OF GASTRIC DYSBIOSIS BY CARCINOGENIC... (2*)**
- 1134. . . POSTTRANSCRIPTIONAL CONTROL OF VDR EXPRESSION BY... (2*)**
- 1135. . . 5-HT3 RECEPTOR ACTIVATION INCREASES ANION SECRETION... (2*)**
- 1136. . . FUSOBACTERIUM NUCLEATUM INITIATES COLORECTAL CANCER BY... (2*)**
- 1137. . . FORWARD GENETICS IDENTIFIES HOST LOCUS RESPONSIBLE... (2*)**
- 1138. . . SHORT-CHAIN FATTY ACIDS POSTPONE THE PROGRESSION... (2*)**
- 1139. . . THE INTESTINAL VIROME IN CHILDREN WITH... (7*)**(2)
- 1140. . . SYN-007, AN ORAL BETA-LACTAMASE PREVENTS GUT... (3*)**(Synthetic Biologics, Inc.)
- 1141. . . TOWARDS HEALTH: RECURRENT CLOSTRIDIUM DIFFICILE INFECTION... (3*)**(This alysis was funded by Rebiotix Inc., Roseville, MN, USA.)
- 1142. . . THE EFFECTS OF HUMAN MILK OLIGOSACCHARIDES... (4*)**(3)|(Supported by an unrestricted grant from Glycom A/S)
- 1143. . . FUNCTIONAL LUMEN IMAGING PROBE DEMONSTRATES REDUCED... (5*)**
- 1144. . . ABNORMALITIES OF ESOPHAGEAL DISTENSION-CONTRACTION PROFILE DURING... (2*)**
- 1145. . . DISTENSION-INDUCED CONTRACTILITY IS FREQUENTLY PRESENT, BUT... (2*)**
- 1146. . . ESOPHAGEAL HYPERCONTRACTILITY IS ABOLISHED BY CHOLINERGIC... (4*)**
- 1147. . . PROSPECTIVE EVALUATION OF RISK FACTORS FOR... (5*)**
- 1148. . . CHARACTERIZATION AND MECHANISM OF THE ESOPHAGO-ESOPHAGEAL... (2*)**
- 1149. . . MICROBIAL SEQUENCING OF THE APPENDICEAL MICROBIOME... (4*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

1150. . . . INTRA-PERSONAL GUT
MICROBIAL VARIATIONS IN PATIENTS...
(6*)

1151. . . . CD8+ T CELL-SPECIFIC TUMOR
NECROSIS FACTOR... (2*)|(6)

1152. . . . A HEALTHY HUMAN FECAL
SPECIMEN INCLUDES... (3*)|(6)|(Janssen
Research Development)

1153. . . . CRITICAL ROLE OF TOLL-LIKE
RECEPTOR 2... (2*)

1154. . . . LACK OF VITAMIN D RECEPTOR
IN... (2*)

1155. . . . COMPARATIVE IN-VIVO
DIAGNOSTIC PERFORMANCE OF
CURRENT... (5*)

1156. . . . INTELLIGENT REAL-TIME IMAGE
SEGMENTATION (IRIS) IMPROVES...
(3*)|(NinePoint Medical, Inc.)

1157. . . . GOBLET CELL METAPLASIA
VARIATIONS IN TARGETED... (3*)

1158. . . . RISK STRATIFICATION OF
BARRETT'S ESOPHAGUS WITH... (5*)

1159. . . . RELIABILITY OF
VIDEOCONFERENCING PATHOLOGY IN
THE... (5*)

0. . . . INTERLEUKIN-33 PROMOTES REG3G
EXPRESSION IN INTESTINAL... (2*)

0. . . . CATHARTOCYTOSIS, A NOVEL
CELLULAR PROCESS ESSENTIAL... (4*)|(2)

0. . . . THE ROLE OF TUFT CELL
SPECIFICATION... (2*)

0. . . . GENOME ANALYSIS OF DUODENAL
GASTRINOMAS AND... (2*)

0. . . . EFFICACY IN BIOLOGIC-FAILURE AND
NONBIOLOGIC-FAILURE POPULATIONS...
(3*)|(This study was funded by Janssen
Research & Development, LLC)

0. . . . INTERLEUKIN-27-PRODUCING
IMMUNE CELLS IN THE GASTRIC... (2*)

0. . . . RNA BINDING PROTEIN IMP1
PROMOTES EXOSOME... (2*)|(7)

0. . . . A NOVEL ROLE FOR $\gamma\delta$
INTRAEPITHELIAL... (2*)|(4)

0. . . . TRENDS IN YOUNG-ONSET
COLORECTAL CANCER INCIDENCE... (2*)

0. . . . DELETION OF CLAUDIN-7 LEADS TO
THE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)



AGA Poster Presentations

BSQS12|Sa1117. . . TNKS2 PROMOTES WNT/ β -CATENIN SIGNALING THROUGH DEGREDAATION... (2*)

BSQS17|Su1879. . . NOVEL ROLE FOR DEATH RECEPTOR 3... (2*)

BSQS9|Su1033. . . CONTRASTING EFFECTS OF GLOBAL VERSUS TISSUE-SPECIFIC... (2*)

Sa1000. . . A NATIONAL SURVEY OF INTERNISTS' PERCEPTIONS... (4*)

Sa1001. . . STRONG RECOMMENDATIONS BASED ON LOWER QUALITY... (5*)

Sa1002. . . UNDERUTILIZATION OF ASPIRIN IN PATIENTS WITH... (1*)(5)

Sa1003. . . POOR KNOWLEDGE OF PERSONAL AND FAMILIAL... (5*)

Sa1004. . . UNDISCLOSED PAYMENTS BY PHARMACEUTICAL AND MEDICAL... (5*)

Sa1005. . . UTILITY OF AND COMPLIANCE WITH RECOMMENDED... (5*)

Sa1006. . . ADHERENCE TO GUIDELINES AND BEST PRACTICES... (4*)

Sa1007. . . INTERNATIONAL GUIDELINES ON THE MANAGEMENT OF... (5*)

Sa1008. . . INTERNATIONAL GUIDELINES ON THE MANAGEMENT OF... (5*)

Sa1009. . . IS COLONOSCOPY NECESSARY AFTER AN ACUTE... (5*)

Sa1010. . . LACK OF RECOMMENDED PNEUMOCOCCAL CONJUGATE VACCINE... (3*)(This study was sponsored by Pfizer Inc. All authors are employees of Pfizer Inc.)

Sa1011. . . A COMPARISON OF CHARACTERISTICS IN LEFT... (5*)

Sa1012. . . TARGETED SCREENING FOR HEPATITIS C AND... (5*)

Sa1013. . . A MULTICENTER STUDY ON GUIDELINE ADHERENCE... (4*)

Sa1014. . . PREVALENCE AND RELEVANCE OF FINANCIAL CONFLICTS... (5*)

Sa1015. . . HIGH SMOKING CESSATION RATES IN A... (5*)

Sa1016. . . CHARACTERIZING INAPPROPRIATE PROPHYLACTIC TRANSFUSION OF BLOOD... (5*)

Sa1017. . . COLONIC BIOPSY PRACTICE IN PATIENTS WITH... (5*)

Sa1018. . . WOMEN WITH HEPATITIS C VIRUS (HCV)... (3*)(Abbvie - investigator initiated research grant support)

Sa1019. . . IS ETHNICITY ASSOCIATED WITH RATES OF... (5*)

Sa1020. . . RACIAL DISPARITIES IN TIME FROM ADMISSION... (5*)

Sa1021. . . HISPANICS UNDER-UTILIZE BARIATRIC SURGERY... (5*)

Sa1022. . . RACIAL DISPARITIES IN COLORECTAL CANCER MORTALITY:... (2*)

Sa1023. . . PATIENT AND PROVIDER REPORTED BARRIERS TO... (4*)

Sa1024. . . RACIAL DISPARITIES IN THE EVALUATION AND... (5*)

Sa1025. . . A QUESTIONNAIRE STUDY TO ASSESS THE... (3*)(Takeda (Chi) Intertiol Trade Co., Ltd.)

Sa1026. . . DEVELOPING A STUDY OF COLORECTAL CANCER... (2*)

Sa1027. . . BEYOND AVAILABILITY: EVALUATING ACCEPTABILITY OF HIGH... (2*)

Sa1028. . . COST SAVINGS FROM GENERIC PROTON PUMP... (5*)

Sa1029. . . COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE... (4*)

Sa1030. . . PATIENT OUTCOMES BASED ON REFERRAL PATTERNS... (5*)

Sa1031. . . WHAT IS THE NATURAL HISTORY OF... (3*)(Janssen Cada)

Sa1032. . . SUBSTANTIAL INCREASE IN ANESTHESIA ASSISTANCE FOR... (5*)

Sa1033. . . HEALTHCARE RESOURCE USE AND DIRECT MEDICAL... (3*)(The funding for this study was provided by Allergan plc. Writing assistance by Complete HealthVizion, funded by Allergan plc.)

Sa1034. . . CAN ALBUMIN-BILIRUBIN GRADE (ALBI) PREDICT PRESENCE... (5*)(Non)

Sa1035. . . IN-HOSPITAL MORTALITY OF TOXIC MEGACOLON HAS... (5*)

Sa1036. . . VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL PREDICTS... (3*)(Takeda Pharmaceuticals U.S.A., Inc.)

Sa1037. . . TRENDS AND HEALTHCARE DISPARITIES IN CIRRHOTICS... (5*)

Sa1082. . . DEVELOPMENT AND VALIDATION OF A MACHINE-LEARNING... (2*)

Sa1083. . . AUTOMATED TIME-RELEASED REMINDERS IMPROVES PATIENT ACCESS... (4*)

Sa1084. . . MOBILE APPLICATION USE IMPROVES NO-SHOW RATES... (5*)(Mobile app (MageMySurgery) is a product of Higgs Boson Health and use of app was doted. No direct study funding was provided.)

Sa1085. . . COLONOSCOPY VOLUME OF COLONIC IRRIGATION (VOCI)... (5*)

Sa1086. . . DIGITAL RECTAL EXAMS ARE RARELY PERFORMED... (5*)

Sa1087. . . A NOVEL ELECTRONIC MEDICAL RECORD-BASED WORKFLOW... (5*)

Sa1088. . . CORRELATION BETWEEN SURROGATE QUALITY INDICATORS FOR... (5*)

Sa1089. . . A RETROSPECTIVE REVIEW OF INTRAVENOUS IRON... (5*)

Sa1090. . . ANEMIA IN PEDIATRIC INFLAMMATORY BOWEL DISEASE:... (5*)

Sa1091. . . APPLICATION OF BAYESIAN MODELING WITH INFlixIMAB... (5*)(1)

Sa1092. . . LUMINAL NITRIC OXIDE AND PLASMA NITRITE/NITRATE... (1*)

Sa1093. . . HEALTH CARE COSTS OF ENDOSCOPY AND... (5*)

Sa1094. . . FACTORS INFLUENCING TIMING OF PARACENTESIS AFTER... (5*)

Sa1095. . . UNDERSTANDING THE ROLE OF PHYSICIAN ATTIRE... (5*)

Sa1096. . . A PERSONALIZED MODEL TO ASSESS INTESTINAL... (4*)

Sa1097. . . HUMAN COLON ORGANOID MODEL OF SESSILE... (4*)

Sa1098. . . MOLECULAR RESPONSE OF CANINE INTESTINAL ORGANIDS... (4*)

Sa1099. . . ESTABLISHMENT OF LONG-TERM NORMAL HUMAN INTESTINAL... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1100. . . KRÜPPEL-LIKE FACTOR 4 REGULATES BMI1+ INTESTINAL... (2*)
- Sa1101. . . KRÜPPEL-LIKE FACTOR 5 IS CRITICAL FOR... (2*)
- Sa1102. . . PROTEIN KINASE D PROMOTES INTESTINAL STEM... (2*)
- Sa1103. . . STEM CELL EXPANSION AND INCREASED MESENCHYMAL... (2*)
- Sa1104. . . DEFICIENCY OF NT-NTR1 SIGNALING PREVENTS THE... (2*)
- Sa1105. . . CONDITIONAL KNOCKOUT OF CDC42/RAC NUCLEOTIDE EXCHANGE... (2*)
- Sa1106. . . INTERACTION BETWEEN PANCREATIC CANCER CELLS AND... (2*)|(5)
- Sa1107. . . ADENYLATE CYCLASE 6 AND CYSTIC FIBROSIS... (2*)
- Sa1108. . . ANALYSING INTESTINAL ORGANOIDS IN A MULTI-OMICS,... (2*)
- Sa1109. . . ROTAVIRUS-MEDIATED DEGRADATION OF DGAT1: A PREVIOUSLY... (2*)
- Sa1110. . . CROSS PRESENTATION OF MICROBIAL TRANSGLUTAMINASE BY... (1*)
- Sa1111. . . REGULATION OF THE BMP SIGNALING INHIBITOR... (2*)
- Sa1112. . . THE ROLE OF NADPH OXIDASE 2... (2*)|(Brain Korea 21 PLUS Project for medical science)
- Sa1113. . . GUT DYSBIOSIS WITH DECREASED AKKERMANSIA MUCINIPHILA.AND... (2*)
- Sa1114. . . RUBICON INHIBITS AUTOPHAGY AND ACCELERATES THE... (5*)
- Sa1115. . . THE POTENTIAL FUNCTION OF CIRCULAR RNA... (2*)
- Sa1116. . . MYPT1 LEVEL MAY BE REGULATED THROUGH... (2*)
- Sa1118. . . DEVELOPMENT OF A NOVEL GALLBLADDER CANCER... (2*)
- Sa1119. . . DEOXYCHOLIC ACID ENHANCES LYMPHOCYTE MIGRATION TO... (4*)
- Sa1120. . . SUPPRESSION OF PLASMACYTOID DENDRITIC CELL MIGRATING... (5*)
- Sa1121. . . A BUTYRATE-TARGETING SYNBIOTIC ATTENUATES CHRONIC-BINGE ETHANOL... (2*)
- Sa1122. . . THE ELECTROGENIC NA⁺/HCO₃⁻ CO-TRANSPORTER (NBCE1/SLC4A4) IS... (2*)
- Sa1123. . . ACTIVATION OF KV7 CHANNELS IN ENTERIC... (2*)
- Sa1124. . . CHRONIC RETARDATION OF GASTROINTESTINAL TRANSIT TIME... (3*)|(YUYANG Dnu Co., Ltd)
- Sa1125. . . INDUCIBLE GENETIC LINEAGE TRACING REVEALS UNEXPECTED... (2*)
- Sa1126. . . PROBENICID IS EFFICIENT IN THE RECOVERY... (4*)
- Sa1127. . . INTESTINAL GUANYLATE CYCLASE C MRNA EXPRESSION... (3*)|(This study was sponsored by Allergan plc and Ironwood Pharmaceuticals.)
- Sa1128. . . ALTERED GASTROINTESTINAL IMMUNOGLOBULINS, MICROBIAL COMMUNITIES AND... (2*)|
- Sa1129. . . EFFECTS OF BUTYRATE SUPPLEMENTATION ON NHE8KO... (2*)
- Sa1130. . . LOSS OF NHE8 IMPAIRS GOBLET CELL... (2*)
- Sa1131. . . LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN EARLY... (2*)
- Sa1132. . . EARLY LIFE LACTOBACILLUS RHAMNOSUS GG COLONIZATION... (2*)|(tiol tural Science Foundation of Chi (NO.81741075))
- Sa1133. . . LACTOBACILLUS REUTERI DSM 17938 FEEDING OF... (2*)
- Sa1135. . . GENOMIC BIOMARKERS FOR CANCER RISK IN... (7*)
- Sa1136. . . DETECTION OF BARRETT'S ESOPHAGUS THROUGH EXHALED... (3*)|(The Aeonose™ was provided by the eNose company for free.)
- Sa1137. . . LIQUID NITROGEN SPRAY CRYOTHERAPY ERADICATES DYSPLASIA... (3*)|(CSA Medical)
- Sa1138. . . ASSESSING THE AMERICAN COLLEGE OF GASTROENTEROLOGY... (2*)
- Sa1139. . . RISK OF DYSPLASTIC PROGRESSION IN PATIENTS... (5*)
- Sa1140. . . HISTOPATHOLOGIST FEATURES PREDICTIVE OF DIAGNOSTIC CONCORDANCE... (6*)
- Sa1141. . . VALIDATION AND COMPARISON OF TOOLS FOR... (2*)
- Sa1142. . . HISTOLOGIC CHANGES IN THE NEOSQUAMOUS EPITHELIUM... (6*)
- Sa1143. . . SURFACE KI-67 EXPRESSION ON HISTOPATHOLOGY PREDICTS... (5*)
- Sa1144. . . WIDE AREA TRANSEPIHELIAL SAMPLING IMPROVES DETECTION... (3*)|(CDx Diagnostics)
- Sa1145. . . NEOSQUAMOUS EPITHELIUM FOLLOWING ENDOSCOPIC ABLATION OF... (2*)
- Sa1146. . . ESOPHAGEAL EXTRACELLULAR MATRIX HYDROGEL MITIGATES METAPLASTIC... (4*)|(C.R. BARD (B.D.))
- Sa1147. . . ANALYSIS OF SOCIO-ECONOMIC FACTORS AFFECTING THE... (4*)
- Sa1148. . . THE MAJORITY OF PATIENTS WITH CONFIRMED... (5*)
- Sa1149. . . INCIDENCE OF HIGH GRADE DYSPLASIA (HGD)... (5*)
- Sa1150. . . BACK TO THE FUTURE - MULTIMODAL... (5*)
- Sa1151. . . MUTATIONAL LOAD PREDICTS RISK OF PROGRESSION... (5*)
- Sa1152. . . AGE OF DIAGNOSIS IN FAMILIAL ESOPHAGEAL... (2*)
- Sa1153. . . NON-INVASIVE SCREENING FOR BARRETT'S ESOPHAGUS USING... (5*)|(The eNose Company, Zutphen, NL, provided Aeonose device for study but no funding.)
- Sa1154. . . CLINICAL CONSEQUENCES OF NON-ADHERENCE IN SURVEILLANCE... (5*)
- Sa1155. . . INCIDENCE OF DYSPLASIA IN OBESE VERSUS... (5*)
- Sa1156. . . PARTICIPATION IN NON-ENDOSCOPIC SCREENING TECHNIQUES FOR... (2*)
- Sa1157. . . ULTRA-SHORT SEGMENT BARRETT'S OESOPHAGUS: IS IT... (5*)
- Sa1158. . . LINKED COLOR IMAGING (LCI), A NOVEL... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1159. . . . THE IMPACTS OF ON-DEMAND VERSUS CONTINUOUS... (4*)
- Sa1160. . . . THE NATURAL HISTORY OF LOW GRADE... (5*)
- Sa1161. . . . LATE RECURRENCE OF DYSPLASTIC BARRETT'S ESOPHAGUS... (5*)
- Sa1162. . . . UTILITY AND YIELD OF POSITRON EMISSION... (5*)
- Sa1163. . . . THE RISK OF PREVALENT AND INCIDENT... (5*)
- Sa1164. . . . MEN WITH ESOPHAGEAL ADENOCARCINOMA RISK FACTORS... (5*)
- Sa1165. . . . GASTROESOPHAGEAL REFLUX INDUCES ISOLG-P53 ADDUCTS IN... (2*)
- Sa1166. . . . ESOPHAGEAL INFUSION OF MENTHOL DOES NOT... (2*)|(.)
- Sa1167. . . . HUMAN ESOPHAGEAL MYOFIBROBLASTS EXPOSED TO GASTRO-ESOPHAGEAL... (2*)
- Sa1168. . . . REDUCED ESOPHAGEAL CONTRACTILITY IS A RISK... (5*)
- Sa1169. . . . GERD SYMPTOMS EXACERBATION AFTER PPI DISCONTINUATION... (4*)
- Sa1170. . . . ASSESSMENT OF GASTROESOPHAGEAL REFLUX DISEASE BY... (5*)
- Sa1171. . . . ASSOCIATION BETWEEN SKELETAL MUSCLE ATTENUATION AND... (5*)
- Sa1172. . . . WEIGHT REGAIN FOLLOWING ROUX-EN-Y GASTRIC BYPASS... (5*)
- Sa1173. . . . SALIVA SECRETION IN PATIENTS WITH PPI-RESISTANT... (4*)
- Sa1174. . . . ESOPHAGEAL MUCOSAL INNERVATION IN FUNCTIONAL HEARTBURN... (4*)
- Sa1175. . . . EARLY ADULTHOOD CHRONIC ANTIBIOTIC USE AND... (2*)|(UM1 CA186107, K24 DK098311, R01DK088782)
- Sa1176. . . . IMPACT OF PRE-TRANSPLANT REFLUX TESTING ON... (5*)
- Sa1177. . . . GASTROESOPHAGEAL REFLUX IS ASSOCIATED WITH CHRONIC... (5*)
- Sa1178. . . . ABNORMAL REFLUX ON COMBINED HYPOPHARYNGEAL-ESOPHAGEAL IMPEDANCE-PH... (5*)
- Sa1179. . . . PROTON PUMP INHIBITOR THERAPY REDUCES RISK... (5*)
- Sa1180. . . . COMPARISON OF ESOPHAGEAL FUNCTION TESTING PROFILES... (5*)
- Sa1181. . . . IDENTIFYING GASTROESOPHAGEAL REFLUX DISEASE POST-LUNG TRANSPLANT... (5*)
- Sa1182. . . . AN EXPLORATORY LATENT CLASS ANALYSIS OF... (7*)
- Sa1183. . . . STRAIN DIFFERENCES IN ACID MEDIATED ESOPHAGO-CARDIOVASCULAR... (2*)
- Sa1184. . . . INCREASED SENSITIVITY OF COUGH REFLEX IS... (2*)|(.)
- Sa1185. . . . BARIUM SWALLOW FINDINGS DO NOT CORRELATE... (5*)
- Sa1186. . . . EFFICACY OF PNEUMATIC DILATATION FOR SEVERE... (5*)
- Sa1187. . . . ON ORDINARY DOSE OF PPI, RESIDUAL... (5*)
- Sa1188. . . . ABNORMAL BOLUS REFLUX ON IMPEDANCE-PH MONITORING... (5*)
- Sa1189. . . . GASTROESOPHAGEAL REFLUX DISEASE IS AN INDEPENDENT... (5*)
- Sa1190. . . . PREVALENCE OF DYSBIOSIS IN PATIENTS ON... (5*)
- Sa1191. . . . MEASURING HEARTBURN SEVERITY AND REGURGITATION FREQUENCY... (3*)|(Ironwood Pharmaceuticals, Inc.)
- Sa1192. . . . AMELIORATING EFFECTS AND AUTONOMIC MECHANISMS OF... (5*)
- Sa1193. . . . PATIENT AND PHYSICIAN PERSPECTIVES AND PRACTICE... (5*)
- Sa1194. . . . 1-YEAR INTERIM ANALYSIS RESULTS OF VISION... (3*)|(Takeda Pharmaceutical Company Limited)
- Sa1195. . . . TREATMENT OUTCOMES IN PATIENTS WITH GLOBUS... (4*)
- Sa1196. . . . A SLEEP POSITIONING DEVICE REDUCES ESOPHAGEAL... (5*)
- Sa1197. . . . PROTON PUMP INHIBITORS THERAPY AND THE... (5*)
- Sa1198. . . . MANAGEMENT PATTERNS FOR NONACID REFLUX PATIENTS... (5*)
- Sa1199. . . . PREVALENCE AND PROFILE OF PATIENTS WITH... (3*)
- Sa1200. . . . HYPERGASTRINEMIA SECONDARY TO LONG-TERM PROTON PUMP... (2*)
- Sa1201. . . . SIGNIFICANT DIFFERENCE IN THE PROPORTION OF... (1*)
- Sa1202. . . . CONCOMITANT AZITHROMYCIN AND HIGH DOSE PROTON... (5*)
- Sa1203. . . . ACUTE EFFECT OF CURCUMINOID ON REFLUX... (2*)
- Sa1204. . . . A COMPARISON OF DIFFERENT TREATMENTS FOR... (1*)
- Sa1205. . . . PREDICTING FACTORS OF RECURRENCE IN PATIENTS... (4*)
- Sa1206. . . . LONG TERM PROTON PUMP INHIBITOR USE... (5*)
- Sa1207. . . . THE EFFECT OF A MEDICAL DEVICE... (3*)|(SOFAR S.p.A)
- Sa1208. . . . SERUM CONCENTRATION AND PHARMACOKINETICS OF SINGLE... (4*)
- Sa1293. . . . TRANSPYLORIC FEED IN GASTROESOPHAGEAL REFLUX ASSOCIATED... (5*)
- Sa1294. . . . PHARYNGEAL AND UPPER ESOPHAGEAL SPHINCTER MOTOR... (5*)
- Sa1295. . . . SERPINB12 AS A POSSIBLE MARKER OF... (5*)
- Sa1296. . . . MIR-597-5P IS ASSOCIATED WITH TUMOR INVASION... (2*)
- Sa1297. . . . THERAPEUTIC EFFECT OF NIVOLUMAB THERAPY ON... (5*)
- Sa1298. . . . GASTRIC XANTHOMA IS A USEFUL PREDICTOR... (5*)
- Sa1299. . . . WOMEN WITH GASTRIC CANCER ARE SIGNIFICANTLY... (5*)
- Sa1300. . . . HER2 REGULATES THE CANCER STEM CELL... (5*)
- Sa1301. . . . SEVERE ATROPHIC GASTRITIS IS A RISK... (5*)
- Sa1302. . . . THE ANTITUMOR EFFECT OF TALAPORFIN PHOTO... (5*)
- Sa1303. . . . THE EFFECT OF TALAPORFIN-MEDIATED PHOTODYNAMIC THERAPY... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1304. . . . CLINICOPATHOLOGIC FEATURES OF SUBMUCOSAL PAPILLARY GASTRIC... (5*)	Sa1324. . . . PATIENT-REPORTED SYMPTOM BURDEN IN PANCREATIC CANCER... (5*)	Sa1356. . . . DEPRESSION AS A SYMPTOM OF PANCREATIC... (5*)
Sa1305. . . . GENETIC POLYMORPHISMS AS RISK FACTORS FOR... (2*)	Sa1325. . . . GEOGRAPHICAL COST VARIATION OF ACUTE PANCREATITIS... (5*)	Sa1357. . . . PANCREATIC CANCER IN LIVER TRANSPLANT RECIPIENTS... (5*)
Sa1306. . . . BIOMARKERS IN MULTIVISCERAL AND INTESTINAL TRANSPLANTATION... (5*)	Sa1337. . . . EXERCISE-INDUCED MYOKINES AS A MECHANISM FOR... (5*)	Sa1358. . . . EPIDEMIOLOGY, ENVIRONMENTAL AND METABOLIC RISK FACTORS... (5*)
Sa1307. . . . CHRONIC MORPHINE TREATMENT IMPAIRS THE ANTINOCICEPTIVE... (6*)	Sa1338. . . . DEVELOPMENT OF A NOVEL CIRCULATING TUMOR... (2*)	Sa1359. . . . CHOLECYSTITIS IN PANCREATIC CARCINOMA: A POORLY... (5*)
Sa1308. . . . ABDOMINAL PAIN IN QUIESCENT INFLAMMATORY BOWEL... (4*)	Sa1339. . . . ANALYSIS OF 1200 CANCER-RELATED GENES FOR... (2*)	Sa1360. . . . HEAT SHOCK PROTEIN 27 (HSP27) EXPRESSION... (5*)
Sa1309. . . . ANTIBIOTICS TREATMENT AFFECTS BODY METABOLISM AND... (5*)	Sa1340. . . . TUMOR SUPPRESSOR ROLE OF MIR-107 AND... (2*)	Sa1361. . . . UTILITY OF LIQUID BIOPSY USING URINE... (4*)
Sa1310. . . . ALTERATION OF COLONIC MUCOSAL PERMEABILITY UNDER... (5*)	Sa1341. . . . PANCREATIC ACINAR CARCINOMA HAS DISTINCT MUTATION... (4*)	Sa1362. . . . PROTON PUMP INHIBITOR (PPI) AND HISTAMINE-2... (5*)
Sa1311. . . . ANTI-INFLAMMATORY AND VISCERAL PAIN RELIEVING EFFECTS... (4*)	Sa1342. . . . BROWN ADIPOSE TISSUE ACTIVATION DETECTED BY... (5*)	Sa1363. . . . PREDICTIVE FACTORS FOR THE DEVELOPMENT OF... (5*)
Sa1312. . . . AMELIORATING EFFECTS OF SACRAL NERVE STIMULATION... (5*)	Sa1343. . . . RATES OF PANCREATIC NEOPLASIA IN A... (4*)	Sa1364. . . . A NEW INVESTIGATION OF DRUG REPURPOSING... (5*)
Sa1313. . . . DEVELOPMENT AND VALIDATION OF A TEST-SPECIFIC... (5*)	Sa1344. . . . DEVELOPMENT OF A PREOPERATIVE PREDICTIVE RISK... (5*)	Sa1365. . . . PATIENT-REPORTED BURDEN OF INTENSIFIED SURVEILLANCE AND... (4*)
Sa1314. . . . DELETION OF SCAVENGER RECEPTOR PROTECTS AGAINST... (4*)	Sa1345. . . . PROGNOSTIC FACTORS FOR PATIENTS WITH BORDERLINE... (5*)	Sa1366. . . . INCREASED MEDIUM-TERM RISK OF PANCREATIC CANCER... (5*)
Sa1315. . . . REDUCED ABDOMINAL PAIN PERCEPTION IN INFLAMMATORY... (4*)	Sa1346. . . . ASSOCIATION BETWEEN HELICOBACTER PYLORI INFECTION AND... (5*)	Sa1367. . . . HALF OF SPORADIC PANCREATIC DUCTAL ADENOCARCINOMA... (5*)
Sa1316. . . . ETHNIC DISPARITIES IN MORTALITY RATES FOLLOWING... (5*)	Sa1347. . . . COMPARISON OF EFFICACY BETWEEN ADJUVANT CHEMOTHERAPY... (5*)	Sa1368. . . . GENOMIC PROFILING OF PANCREATIC DUCTAL ADENOCARCINOMA... (5*)
Sa1317. . . . GLOBAL INCIDENCE OF ACUTE PANCREATITIS THROUGH... (5*) (Nil)	Sa1348. . . . EUS DETECTION OF TRACE ASCITES IN... (5*)	Sa1369. . . . DEPRESSION PRECEDING PANCREATIC CANCER: A LONGITUDINAL... (5*)
Sa1318. . . . DIFFERENCES IN OUTCOMES AND ETIOLOGIES OF... (5*)	Sa1349. . . . HIGH FAT, HIGH CALORIE DIET EFFECTS... (2*)	Sa1370. . . . EARLY DETECTION OF PANCREATIC CANCER LEADS... (5*)
Sa1319. . . . OUTCOMES OF ACUTE PANCREATITIS IN JULY:... (5*)	Sa1350. . . . UPDATED INTERNATIONAL CANCER OF THE PANCREAS... (4*)	Sa1371. . . . EUS AND CT SCAN DIAGNOSTIC YIELD... (5*)
Sa1320. . . . THE CURRENT STATE OF ACUTE PANCREATITIS... (5*)	Sa1351. . . . ELEVATED HEMOGLOBIN A1C IS ASSOCIATED WITH... (4*)	Sa1372. . . . PANCREATIC DUCTAL ADENOCARCINOMA DETECTED AFTER ACUTE... (5*)
Sa1321. . . . SEVERE ACUTE PANCREATITIS INCIDENCE AND OUTCOMES... (5*)	Sa1352. . . . RISING INCIDENCE OF PANCREATIC CANCER IN... (5*)	Sa1374. . . . IMPACT OF ABO BLOOD TYPE IN... (5*)
Sa1322. . . . EFFECT OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION... (5*)	Sa1353. . . . FACTORS AFFECTING EUS-FNA DIAGNOSTIC YIELD FOR... (5*)	Sa1375. . . . THE UTILITY OF CA 19-9 IN... (5*)
Sa1323. . . . THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)	Sa1354. . . . SEX AND AGE DISPARITIES IN PANCREATIC... (2*)	Sa1376. . . . EXPRESSION OF NOTCH RECEPTORS AND THEIR... (2*)
	Sa1355. . . . OUTCOMES OF NEOADJUVANT CHEMORADIATION WITH AND... (4*)	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1377. . . . REDUCTION IN AMYLASE/LIPASE SUPERFLUOUS TESTING: A... (5*)	Sa1398. . . . NOVEL BIO-DEGRADABLE STENT IN PATIENTS WITH... (5*)	Sa1547. . . . RAPID CHOLESTEROL (CH) CRYSTALLIZATION VIA THE... (2*)
Sa1378. . . . RIFAXIMIN IN SELECTIVE DIGESTIVE DECONTAMINATION IN... (5*)	Sa1399. . . . PANCREATIC FUNCTIONAL AND STRUCTURAL EVALUATION WITH... (5*)	Sa1548. . . . INVESTIGATIONS INTO VIRAL ETIOLOGY OF PRIMARY... (6*)
Sa1379. . . . ACUTE PANCREATITIS IN SARCOIDOSIS: IS THERE... (5*)	Sa1523. . . . UTILITY OF SHEAR WAVE ELASTOGRAPHY TO... (4*)	Sa1549. . . . CAUSATIVE PATHOGENS PATTERN IN ENDOSCOPIC ULTRASOUND-GUIDED... (5*)
Sa1380. . . . ACUTE PANCREATITIS NATIONAL OUTCOMES IN THE... (5*)	Sa1524. . . . VALIDATION AND OPTIMIZATION OF AN EARLY... (4*)	Sa1550. . . . THE EFFECT OF STATIN WITH EZETIMIBE... (5*)
Sa1381. . . . SYSTEMIC ANTICOAGULATION IS ASSOCIATED WITH DECREASED... (5*)	Sa1532. . . . NON-CALCULOUS BENIGN CHOLANGITIS IS MORE LIKELY... (5*)	Sa1551. . . . SULFASALAZINE COMPARED TO MESALAMINE IN PRIMARY... (5*)
Sa1382. . . . THE EPIDEMIOLOGY OF ACUTE PANCREATITIS IN... (5*)	Sa1533. . . . ASSOCIATION BETWEEN BACTEREMIA AND 30-DAY MORTALITY... (4*)	Sa1552. . . . FIBROSCAN ASSESSMENT OF PATIENTS UNDERGOING ENDOSCOPY... (3*) (1) (Echosens)
Sa1383. . . . THE IMPACT OF OPIOID AND NON-OPIOID... (5*)	Sa1534. . . . PRIMARY BILIARY CHOLANGITIS PATIENTS WHO ARE... (5*)	Sa1553. . . . RELIABILITY AND VALIDITY ASSESSMENT IF THE... (3*) (1) (Intercept Pharmaceuticals)
Sa1384. . . . EARLY FEEDING IN ACUTE PANCREATITIS IN... (5*)	Sa1535. . . . PREDICTORS OF 30-DAY READMISSION AFTER INPATIENT... (5*)	Sa1554. . . . FIBROSCAN RISK ASSESSMENT OF NON-ALCOHOLIC FATTY... (3*) (Echosens)
Sa1385. . . . PANCREATITIS IN TYPE 2 DIABETES: A... (5*)	Sa1536. . . . ENDOSCOPIC SPHINCTEROTOMY ON THIENOPYRIDINE THERAPY HAS... (5*)	Sa1555. . . . LIVER DISEASE AMONG OLDER MEXICAN AMERICANS... (2*)
Sa1386. . . . CONTINUOUS REGIONAL ARTERIAL INFUSION OF PROTEASE... (5*)	Sa1537. . . . ROLE OF PROPHYLACTIC CHOLECYSTECTOMY AFTER ENDOSCOPIC... (5*)	Sa1556. . . . PERCEPTIONS AND KNOWLEDGE ABOUT ADVANCE CARE... (5*)
Sa1387. . . . HOMA-ESTIMATED INSULIN RESISTANCE AS AN INDEPENDENT... (5*)	Sa1538. . . . THE EPIDEMIOLOGY OF ULCERATIVE COLITIS-PRIMARY BILIARY... (5*)	Sa1645. . . . A NEW PEDIATRIC INTESTINAL PSEUDO-OBSTRUCTION SYNDROM... (5*)
Sa1388. . . . IS AGGRESSIVE FLUID RESUSCITATION THE BEST... (5*)	Sa1539. . . . POTENTIAL REPURPOSING OF ANGIOTENSIN INHIBITORS OR... (6*)	Sa1646. . . . GASTROINTESTINAL (GI) FEATURES OF 22Q11.2 DELETION... (5*)
Sa1389. . . . INTENSIVE-FLUSHING TREATMENT IN ABDOMINAL CAVITY DURING... (5*)	Sa1540. . . . INCREASED ODDS OF ACUTE CHOLANGITIS IN... (5*)	Sa1647. . . . FEASIBILITY OF A SPIRULINA BREATH TEST... (4*) (tionwide Children's Hospital 4 provided a total of \$1250 for patient incentives. (Each healthy volunteer who underwent the breath test received an incentive of \$50.) Cairn Diagnostics provided the GEBT kits (with the meal components and test tubes for)
Sa1391. . . . SEVERITY IN ACUTE PANCREATITIS: EFFECT OF... (4*)	Sa1541. . . . METABOLOMIC ANALYSIS OF PRIMARY SCLEROSING CHOLANGITIS... (6*) (Pfizer Inc.)	Sa1648. . . . SACRAL NERVE STIMULATION FOR CHILDREN WITH... (5*)
Sa1392. . . . DOES ANTI-INTERLEUKIN MEDICATIONS IMPACT ACUTE PANCREATITIS... (5*)	Sa1542. . . . DETECTION OF LOW PHOSPHOLIPID ASSOCIATED CHOLELITHIASIS... (5*)	Sa1649. . . . OXYTOCIN PLASMA CONCENTRATIONS IN ADOLESCENTS WITH... (2*)
Sa1393. . . . RELATION BETWEEN PREGNANCY AND ACUTE PANCREATITIS:... (4*)	Sa1543. . . . DECREASED ODDS OF MORTALITY IN PATIENTS... (5*)	Sa1650. . . . ENDORECTAL BALLOON (ERB) DURING IMAGE GUIDED... (2*)
Sa1394. . . . INCIDENCE OF ACUTE PANCREATITIS IS NOT... (5*)	Sa1544. . . . EVALUATION OF HYPERBILIRUBINEMIA IN PATIENTS WHO... (5*)	Sa1651. . . . DOES COACHING IMPROVE A TRAINEES' ABILITY... (5*)
Sa1395. . . . ACUTE PANCREATITIS IN ADVANCED CHRONIC KIDNEY... (5*)	Sa1545. . . . LONG TERM TREATMENT OF PRIMARY BILIARY... (5*)	Sa1652. . . . TOWARDS AN OPTIMAL TOOL FOR ASSESSMENT... (2*) (Intone MV.)
Sa1396. . . . EVALUATION OF REAL-TIME PANCREATIC PARENCHYMAL AND... (5*)	Sa1546. . . . PREDICTING LATE CBD STONE AFTER LAPAROSCOPIC... (5*)	
Sa1397. . . . CHRONIC ASYMPTOMATIC PANCREATIC HYPERENZYMEMIA (CAPH): META-ANALYSIS... (5*)		

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1653. . . . CLINICAL UTILITY OF TRANSLUMBOSACRAL ANORECTAL MAGNETIC... (2*)
- Sa1654. . . . VALIDATION OF A PROSPECTIVE STOOL DIARY... (5*)
- Sa1655. . . . CAN THE RESULTS OF ANORECTAL INVESTIGATIONS... (6*)
- Sa1656. . . . REPETITIVE TRANSPERINEAL MAGNETIC STIMULATION (TPMS) ATTENUATES... (4*)
- Sa1657. . . . ANAL TAPE A GENUINE EXTERNAL DEVICE FOR... (5*)
- Sa1658. . . . INFLUENCE OF A DEFECATION POSTURE MODIFICATION... (5*)
- Sa1659. . . . COMPARISON OF CHANGES IN RECTAL AREA... (2*)
- Sa1660. . . . COEXISTENCE OF FECAL INCONTINENCE AND CONSTIPATION... (5*)
- Sa1661. . . . IDENTIFYING SUBTYPES IN PATIENTS WITH FUNCTIONAL... (2*)
- Sa1662. . . . CHARACTERISTICS OF PATIENTS WHO 'FAIL' BIOFEEDBACK... (5*)
- Sa1663. . . . FECOBIONICS DEFECATORY FUNCTION TESTING IN HEALTHY... (2*)
- Sa1664. . . . ARE DYSSYNERGIC DEFECATION AND ALTERED RECTAL... (5*)
- Sa1665. . . . SPONTANEOUS INTERNAL ANAL SPHINCTER RELAXATION ON... (5*)
- Sa1666. . . . INTEGRATION OF SMOOTH MUSCLE AND NEURAL... (2*)
- Sa1667. . . . USE OF [LY55,MELEU9,NLE10]-NKA(4-10) (LMN-NKA) AS A... (2*)|(Dignify Therapeutics, LLC)
- Sa1668. . . . ON-DEMAND, DRUG-INDUCED DEFECATION FOLLOWING INTRAVENOUS (IV),... (2*)|(Dignify Therapeutics, LLC)
- Sa1669. . . . FLATUS INCONTINENCE IN WOMEN: COMPARISON WITH... (5*)
- Sa1670. . . . LONG TERM CLINICAL AND PHYSIOLOGICAL CONSEQUENCES... (5*)|(no funding)
- Sa1671. . . . ANATOMICAL DEFECTS OF THE ANAL SPHINCTER... (2*)
- Sa1672. . . . EVALUATION OF DIFFERENCES IN SYMPTOM AND... (4*)
- Sa1673. . . . EVALUATION OF COMPLIANCE AND RECTAL SENSITIVITY... (5*)
- Sa1674. . . . OBESITY IS INDEPENDENTLY ASSOCIATED WITH INCREASED... (5*)
- Sa1675. . . . THE IMMEDIATE AND DELAYED EFFECTS OF... (5*)
- Sa1676. . . . IDENTIFICATION AND CHARACTERIZATION OF RVM NEURONS... (2*)
- Sa1677. . . . CHRONIC COLONIC ADMINISTRATION OF THE GUANYLATE... (3*)|(Ironwood Pharmaceuticals)
- Sa1678. . . . FOLIC ACID ATTENUATES CHRONIC VISCERAL HYPERSENSITIVITY... (2*)|(The present work was supported in part by grants from the tior Science Foundation of Chi (81471137 and 31730040).)
- Sa1679. . . . MULTIPLE RATHER THAN SPECIFIC ANTIBODIES WERE... (2*)
- Sa1680. . . . SECOND GENERATION ANTI-CDTB AND ANTI-VINCULIN TESTING... (5*)
- Sa1681. . . . GC-C AGONISM WITH LINACLOTIDE ATTENUATES CHRONIC... (3*)|(Ironwood Pharmaceuticals, Inc.)
- Sa1682. . . . METABOLIC ALTERATIONS TO FECAL GUT MICROBIOTA... (2*)|(This study was supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan and by Research Grant from Miyarisan Pharmaceutical Co., Ltd., Tokyo, Japan.)
- Sa1683. . . . POTENTIAL CLINICAL VALUE OF LACTOBACILLUS RHAMNOSUS... (2*)
- Sa1684. . . . ALTERATION OF MICROBIOTA BY MATERNAL SEPARATION... (2*)
- Sa1685. . . . PROTEOMIC CHARACTERIZATION OF IBS VS CONTROL... (3*)|(Nestlé Institute of Health Sciences)
- Sa1686. . . . ASSESSMENT OF THE FECAL MICROBIOME AND... (4*)
- Sa1687. . . . EXPOSURE TO PETS IS ASSOCIATED WITH... (5*)
- Sa1688. . . . INDUCTION OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN... (4*)
- Sa1689. . . . PILOT STUDY OF TERMINAL ILEUM MUCOSA... (5*)
- Sa1690. . . . EFFECT OF CONSUMPTION OF NOPAL FIBER... (2*)
- Sa1691. . . . PROSPECTIVE EVALUATION OF THE CLINICAL IMPACT... (4*)
- Sa1692. . . . CLINICAL POTENTIAL OF CIRCULATING TUMOR CELLS... (2*)
- Sa1693. . . . COHESIN SA1 REGULATES FATTY ACID METABOLISM,... (2*)
- Sa1694. . . . CONVENIENT METHOD TO CAPTURE CIRCULATING TUMOR... (5*)
- Sa1695. . . . EVALUATING THE THERAPEUTIC ROLE OF METFORMIN... (4*)
- Sa1696. . . . STAT3-MEDIATED GENE AND MIRNA EXPRESSION PROFILING... (4*)
- Sa1697. . . . IS COMPUTED TOMOGRAPHY AN ACCURATE DIAGNOSTIC... (4*)
- Sa1698. . . . INITIAL EXPERIENCE WITH PEPTIDE RECEPTOR RADIONUCLIDE... (5*)
- Sa1699. . . . ENDOSCOPIC SUBMUCOSAL RESECTION WITH AN ENDOSCOPIC... (5*)
- Sa1700. . . . CHANGE IN INCIDENCE, CHARACTERISTICS AND MANAGEMENT... (4*)
- Sa1701. . . . RECURRENCE RATES AFTER ENDOSCOPIC RESECTION OF... (5*)
- Sa1702. . . . OPERATIVE RESECTION OF DUODENAL CARCINOID TUMORS:... (5*)|(Shria Kumar is supported by a tior Institutes of Health T32 grant (5 T32 DK 7740-22). dim Mahmud is supported by a tior Institutes of Health T32 grant (2-T32-DK007740-21A1).)
- Sa1703. . . . IS SURVEILLANCE WITH GASTRIC ACID MEASUREMENT... (2*)
- Sa1704. . . . ENDOSCOPIC MANAGEMENT OF DUODENAL NEUROENDOCRINE TUMORS... (5*)
- Sa1705. . . . CHARACTERISTICS AND ENDOSCOPIC MANAGEMENT OF GASTRIC... (5*)
- Sa1706. . . . MAP9 DEFICIENCY SPONTANEOUSLY DRIVES COLON TUMORIGENESIS... (2*)
- Sa1707. . . . USING ENDOSCOPIC FINE NEEDLE BIOPSIES OF... (2*)
- Sa1708. . . . SELENOPROTEIN P MODIFIES WNT-DRIVEN SPORADIC COLORECTAL... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1709. . . . TARGETING DR5 IN BOTH MDSCS AND... (2*)((The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).)

Sa1710. . . . TRPV1 INHIBITS GASTRIC CANCER DEVELOPMENT VIA... (2*)((tiol Key Research and Development Program of Chi (No. 2016YFC1302200) and tiol tural Science Foundation of Chi (No. 81570477))

Sa1711. . . . BONE MARROW-DERIVED MYOFIBROBLASTS PROMOTES GASTRIC CANCER... (2*)((The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).)

Sa1712. . . . THE EXPRESSION OF CIRCULAR RNA, CDR1-AS,... (2*)

Sa1713. . . . MIR-143 SUPPRESSES TUMORIGENESIS AND PROGRESSION OF... (2*)

Sa1714. . . . OXALIPLATIN INHIBITS DIFFERENTIATION OF M-MDSCS INTO... (2*)

Sa1715. . . . DECREASED P62 PROTEIN EXPRESSION IS ASSOCIATED... (5*)

Sa1716. . . . STAT6 SIGNALING IN COLON CANCER CELLS... (4*)

Sa1717. . . . DEVELOPMENT OF A SWALLOWABLE DIGANOSTIC CAPSULE... (3*)((Progenity Inc.)

Sa1718. . . . A NEAR-INFRARED PROBE FOR IN VIVO... (6*)

Sa1719. . . . COMPARISON OF TWO CUT-OFF VALUES OF... (2*)

Sa1720. . . . EFFECT OF COLONOSCOPY ASSISTED DEVICES ON... (5*)

Sa1721. . . . MORE LESIONS PER PATIENT DETECTED WITH... (3*)((Norgine)

Sa1722. . . . ASSESSMENT OF COLONOSCOPY QUALITY IN NON-ACADEMIC... (5*)

Sa1723. . . . MUCOSAL HEALING DEFINED BY ADVANCED ELECTRONIC... (5*)

Sa1724. . . . MOXIFLOXACIN PROMOTES MULTIPHOTON MICROSCOPIC IMAGING FOR... (5*)

Sa1725. . . . LEOPARD STUDY - ITALIAN MULTICENTER PROSPECTIVE... (1*)

Sa1726. . . . IN VIVO AND EX VIVO MICROSTRUCTURE... (5*)

Sa1727. . . . OUTCOMES OF GI POLYPS RESECTED USING... (5*)

Sa1728. . . . THE PROGNOSTIC VALUE OF A NEW... (1*)

Sa1729. . . . RISK FACTORS FOR COLONIC DIVERTICULOSIS: A... (1*)

Sa1730. . . . THE HISTOLOGICAL HEALING IN ULCERATIVE COLITIS... (5*)

Sa1731. . . . A TRANS-NASAL, IMAGE-GUIDED APPROACH FOR BRUSH... (6*)

Sa1732. . . . PREDICTORS OF 30 DAYS READMISSIONS AFTER... (5*)

Sa1733. . . . ETIOLOGIES AND TRENDS OF 30 DAYS... (5*)

Sa1734. . . . EVALUATING THE EFFICACY OF HEMOSTATIC NANOPOWDER... (5*)

Sa1735. . . . BASELINE BOWEL STIFFNESS ON REAL-TIME SHEAR... (5*)

Sa1736. . . . THE ROLE OF "ROSE" FOR ERCP-GUIDED... (5*)

Sa1737. . . . FXR AGONIST M480, EXHIBITS EFFICACY IN... (3*)((Metacrine)

Sa1738. . . . OLORINAB (FORMERLY APD371), A PERIPHERALLY RESTRICTED,... (3*)((Are Pharmaceuticals Inc. and NHMRC Australia.)

Sa1739. . . . USING THE ZONULIN TRANSGENIC MOUSE MODEL... (2*)

Sa1740. . . . SPONTANEOUS MOUSE COLITIS PRODUCED BY DELETION... (2*)

Sa1741. . . . IDENTIFICATION AND CHARACTERIZATION OF THE FIRST... (2*)

Sa1742. . . . INTERLEUKIN-10 KNOCKOUT MICE DO NOT EXHIBIT... (6*)

Sa1743. . . . INVESTIGATION OF THE RELATIONSHIP BETWEEN ASPIRIN-INDUCED... (1*)

Sa1744. . . . A NOVEL PORCINE MODEL OF CROHN'S... (2*)

Sa1745. . . . GLACIAL ACETIC ACID-INDUCED ULCERATIVE COLITIS LESIONS... (4*)

Sa1746. . . . ORAL CALCIUM NANOPARTICLE THERAPY AIDS IN... (4*)

Sa1747. . . . FXR AGONISTS WITH SUSTAINED ACTIVITY EXHIBIT... (3*)((Metacrine)

Sa1748. . . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN):... (3*)((received arm-length funding from Pendopharm Inc.)

Sa1749. . . . GASTROENTEROLOGY-RELATED HASHTAG UTILIZATION ON INSTAGRAM AND... (5*)

Sa1750. . . . PREVALENCE AND OUTCOMES OF PORTOMESENTERIC VEIN... (5*)

Sa1751. . . . OUTCOME, COMPLICATION AND LONG-TERM FOLLOW UP... (5*)

Sa1752. . . . VALIDATION OF A FECAL INCONTINENCE BOWEL... (2*)((Medspira Scientific provided software and physiological recorders at discounted prices.)

Sa1753. . . . IBD NURSE INTERVENTION FOR PATIENTS ASSIGNED... (3*)((This work was supported by the Pfizer independent grants for learning & change)

Sa1754. . . . SLEEP DISTURBANCE AND TRAVEL INTERRUPTION WITH... (3*)((Pendopharm)

Sa1755. . . . PRESENTING SYMPTOM SEVERITY AND HEALTH-RELATED QUALITY... (5*)

Sa1756. . . . EFFECTS OF PHARMACEUTICAL DIRECT-TO-CONSUMER ADVERTISING (DTCA)... (5*)

Sa1757. . . . IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED... (5*)

Sa1758. . . . THE RELATIONSHIP BETWEEN SERUM BILIRUBIN AND... (2*)

Sa1759. . . . TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN... (5*)

Sa1760. . . . RISK FACTORS FOR POST-OPERATIVE CROHN'S DISEASE... (5*)

Sa1761. . . . CHITINASE 3-LIKE-1 PROTEIN: A NOVEL BIOMARKER... (6*)

Sa1762. . . . LARGE-SCALE PROTEOMICS IDENTIFIES ANTI-TNF RESPONSE SIGNATURE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1763. . . . A MULTI-PROTEIN SERUM TEST PREDICTS MUCOSAL...** (3*)|(Prometheus Laboratories performed a blood assay and covered the cost for that assay.)
- Sa1764. . . . PERIPHERAL BLOOD EOSINOPHILIA IS A BIOMARKER...** (2*)
- Sa1766. . . . INVESTIGATIONS OF THE CHARACTERISTICS AND ANTI-TNF α ...** (5*)
- Sa1767. . . . SOMASCAN AS A DISCOVERY PLATFORM TO...** (6*)
- Sa1768. . . . THE INTESTINAL MICROBIOME IN INFLAMMATORY BOWEL...** (2*)|(This Tobacco Formula grant is under the Pennsylvania Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)
- Sa1769. . . . WORLDWIDE INCIDENCE OF OLDER-ONSET INFLAMMATORY BOWEL...** (2*)
- Sa1770. . . . DE-NOVO INFLAMMATORY BOWEL DISEASE AFTER BARIATRIC...** (5*)
- Sa1771. . . . THE GLOBAL BURDEN OF INFLAMMATORY BOWEL...** (5*)
- Sa1772. . . . PREVALENCE OF CERVICAL DYSPLASIA IN WOMEN...** (5*)
- Sa1773. . . . NONALCOHOLIC LIVER DISEASE SIGNIFICANTLY MORE PREVALENT...** (5*)
- Sa1774. . . . INCREASED PREVALENCE OF NONALCOHOLIC LIVER DISEASE...** (5*)
- Sa1775. . . . CROHN'S DISEASE AND ULCERATIVE COLITIS WAS...** (5*)
- Sa1776. . . . THE 30-YEAR TREND ANALYSIS IN THE...** (2*)|(This work was supported by a Korean Health Technology R&D Project grant from the Korea Health Industry Development Institute (A120176) and by a research grant from Janssen Korea Ltd.)
- Sa1777. . . . OVARIAN CANCER AND UTERINE CANCER ARE...** (5*)
- Sa1778. . . . INCREASED RISK OF MENINGITIS IN PATIENTS...** (6*)|(Crohn's and Colitis Foundation (Grant Number 568735 to BK))
- Sa1779. . . . HOSPITALIZATIONS FOR IBD THROUGHOUT THE WORLD:...** (2*)
- Sa1780. . . . REVISITING THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL...** (5*)
- Sa1781. . . . THE RISK OF INFLAMMATORY BOWEL DISEASE...** (5*)
- Sa1782. . . . EFFECT OF VACCINATION AND IMMUNOSUPPRESSIVE MEDICATIONS...** (5*)
- Sa1783. . . . INCIDENCE OF INDETERMINATE COLITIS IN THE...** (5*)
- Sa1784. . . . INFLAMMATORY BOWEL DISEASE IN UK PRIMARY...** (6*)
- Sa1785. . . . THE PREVALENCE AND EPIDEMIOLOGY OF POUCHITIS...** (5*)
- Sa1786. . . . ASSESSMENT OF METAL EXPOSURES IN DECIDUOUS...** (4*)
- Sa1787. . . . THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE...** (5*)
- Sa1788. . . . NATURAL HISTORY OF DIABETES MELLITUS AND...** (2*)
- Sa1789. . . . DOSE-RESPONSE RELATIONSHIP BETWEEN CIGARETTE SMOKING AND...** (5*)
- Sa1790. . . . MULTI-PARAMETER DATA-SETS ARE REQUIRED TO IDENTIFY...** (1*)
- Sa1791. . . . ASSOCIATION BETWEEN ALBUMIN GLOBULIN RATIO AND...** (5*)
- Sa1792. . . . THE INCIDENCE OF INFLAMMATORY BOWEL DISEASE:...** (4*)
- Sa1793. . . . EVALUATION OF THE 10-YEAR CARDIOVASCULAR DISEASE...** (4*)
- Sa1794. . . . EXTRA INTESTINAL MANIFESTATIONS AND OTHER COMORBIDITIES...** (3*)|(Janssen Immunology sponsored)
- Sa1795. . . . SEXUAL FUNCTION IN PATIENTS WITH INFLAMMATORY...** (5*)
- Sa1796. . . . ASSOCIATION BETWEEN USE OF ANTIHYPERTENSIVE AGENTS...** (5*)
- Sa1797. . . . FERTILITY, CONCEPTION AND DELIVERY IN PATIENTS...** (5*)
- Sa1798. . . . THE PREVALENCE OF INFLAMMATORY BOWEL DISEASE...** (2*)|(Funding for Oria M. Damas: This work was supported by NIH N3U54MD010722-03S1. Funding for Maria T. Abreu: This work was supported by The Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory and Martin Kalser Chair.)
- Sa1799. . . . CHARACTERIZATION OF WOMEN WITH INFLAMMATORY BOWEL...** (2*)
- Sa1800. . . . EPIDEMIOLOGY, NATIONAL TRENDS AND OUTCOMES OF...** (5*)
- Sa1801. . . . EMERGING IBD DEMOGRAPHICS IN SOUTH ASIA...** (5*)
- Sa1802. . . . DOES CLOSTRIDIUM DIFFICILE INCREASE THE RISK...** (5*)
- Sa1803. . . . TOTAL ABDOMINAL COLECTOMY AMONGST HOSPITALIZED PATIENTS...** (5*)
- Sa1804. . . . INCIDENCE OF OBSTRUCTIVE COMPLICATIONS AFTER INTRA-ABDOMINAL...** (5*)
- Sa1805. . . . MEDICATION PRESCRIPTION PATTERNS IN ULCERATIVE COLITIS...** (2*)|(Funds for statistical support provided by Pfizer)
- Sa1806. . . . INFLAMMATORY BOWEL DISEASE AND MEDICATION USE...** (5*)
- Sa1807. . . . RATES OF COLECTOMY IN PATIENTS WITH...** (5*)
- Sa1808. . . . TRENDS OF 5-ASA MEDICATION USE IN...** (5*)
- Sa1809. . . . ADMISSION TRENDS AND ECONOMIC BURDEN OF...** (5*)
- Sa1810. . . . SURGERY AND HOSPITALIZATIONS RATES IN INFLAMMATORY...** (1*)|(5)|(The study was supported by the McGill CAS Research Support Program.)
- Sa1811. . . . GENOTYPE AND POST-OPERATIVE IMMUNOSUPPRESSION IMPACT SURGICAL...** (2*)
- Sa1812. . . . ENDOSCOPIC AND DEEP REMISSION AT 1...** (5*)
- Sa1813. . . . CUFFITIS IS ASSOCIATED WITH A SIGNIFICANT...** (5*)
- Sa1814. . . . EARLY COMBINED IMMUNOSUPPRESSION IS MORE EFFECTIVE...** (3*)|(Robarts clinical trials)
- Sa1815. . . . THE IMPACT OF OPIOID ABUSE/DEPENDENCE DISORDER...** (5*)
- Sa1816. . . . ELEVATED FECAL CALPROTECTIN IN HEALTHY FIRST...** (6*)
- Sa1817. . . . FIBROSIS CONSTITUTES LESS THAN 0.5 OF...** (4*)
- Sa1818. . . . INNATE IMMUNE DYSREGULATION, DETECTABLE UP TO...**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

(3*)|(Support for this study was provided by Janssen Pharmaceuticals and Prometheus Laboratories under a Cooperative Research and Development Agreement entitled 'Antimicrobial antibodies as predictors of inflammatory bowel diseases' NCRADA number NMR-11-3920.)

Sa1819. . . . RETROSPECTIVE STUDY ON INCIDENCE RATES OF... (5*)

Sa1820. . . . NON-ADHERENCE TO SELF-INJECTABLE BIOLOGIC MEDICATION IN... (5*)

Sa1821. . . . DOES INFLAMMATION IN IBD BURNOUT OVER... (2*)

Sa1822. . . . ELDERLY-ONSET VS ADULT-ONSET ULCERATIVE COLITIS: A... (5*)

Sa1823. . . . FEMALE ADOLESCENTS WITH ULCERATIVE COLITIS MAY... (2*)

Sa1824. . . . OBESITY IS FREQUENT IN INFLAMMATORY DISEASE... (2*)

Sa1825. . . . SOUTH ASIAN IMMIGRANTS IN THE UNITED... (5*)

Sa1826. . . . CLINICAL CHARACTERISTICS OF NASH/NAFLD PATIENTS IN... (5*)

Sa1827. . . . THE NATURAL COURSE OF INFLAMMATORY BOWEL... (5*)

Sa1828. . . . CONSUMPTION OF DIETARY TRIGGER FOODS AMONG... (2*)

Sa1829. . . . DIET STABILITY IN PERSONS WITH IBD:... (2*)

Sa1830. . . . INSTABILITY IN SATURATED FAT AND SUGAR... (2*)

Sa1831. . . . ELEVATED SERUM IMMUNOGLOBULIN G4 FAILS TO... (5*)

Sa1832. . . . CROHN'S LIKE DISEASE OF THE ILEAL... (5*)

Sa1833. . . . MUCOSAL EOSINOPHILIA IS AN INDEPENDENT PREDICTOR... (2*)

Sa1834. . . . OUTCOME AFTER DISCONTINUATION OF IMMUNOSUPPRESSANT OR... (5*)

Sa1835. . . . CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH... (5*)

Sa1836. . . . NUTRITIONAL STATUS EFFECT ON HEALTH CARE... (5*)

Sa1837. . . . EVALUATION AND MANAGEMENT OF POUCHITIS IN... (5*)

Sa1838. . . . NONALCOHOLIC FATTY LIVER DISEASE WITH ADVANCED... (5*)

Sa1839. . . . THE DILEMMA IN COMPLICATED ILEAL POUCH... (5*)

Sa1841. . . . PREDICTIVE FACTORS OF A SUBSEQUENT ANO-PERINEAL... (5*)

Sa1842. . . . DELAYED DIAGNOSIS OF CROHN'S DISEASE IS... (7*)

Sa1843. . . . PREGNANCY COUNSELING BENEFICIAL IN PATIENTS WITH... (3*)|(UCB sponsored)

Sa1844. . . . CLINICAL SIGNIFICANCE OF GRANULOMAS IN CROHN'S... (5*)

Sa1845. . . . FOLLOW-UP OF ULCERATIVE COLITIS PATIENTS WITH... (5*)

Sa1846. . . . FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE... (2*)|(This work was supported by NIH N3U54MD010722-03S1, The Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory, and Martin Kaiser Chair.)

Sa1847. . . . ADVERSE ANTEPARTUM OUTCOMES IN PREGNANT WOMEN... (5*)

Sa1848. . . . TEMPORAL TREND IN DISEASE CHARACTERISTIC, TREATMENT... (5*)

Sa1849. . . . ASSOCIATION OF SEROLOGIC MARKERS AND SURGERY... (5*)

Sa1850. . . . FAMILIAL MEDITERRANEAN FEVER IN THE UNITED... (5*)

Sa1851. . . . WESTERN VERSUS MEDITERRANEAN DIETARY MARKERS DIFFER... (4*)

Sa1852. . . . HOW DO DIETARY PATTERNS FOR INFLAMMATORY... (4*)

Sa1853. . . . PSEUDOPOLYPS IN INFLAMMATORY BOWEL DISEASE: HISTOLOGIC... (2*)

Sa1854. . . . IMPACT OF BARIATRIC SURGERY ON THE... (5*)

Sa1855. . . . ANALYSIS OF THE CLINICAL, GASTROSCOPIC, AND... (5*)

Sa1856. . . . RISK FACTORS ASSOCIATED WITH PROXIMAL DISEASE... (5*)

Sa1857. . . . UPPER GASTROINTESTINAL TRACT PHENOTYPE OF CROHN'S... (5*)

Sa1858. . . . RATE AND RISK FACTORS ASSOCIATED WITH... (2*)

Sa1859. . . . THE IMPACT OF TOBACCO SMOKING ON... (5*)

Sa1860. . . . RISK FACTORS FOR REPEATED VISITS TO... (5*)

Sa1861. . . . IMPACT OF BIOLOGIC THERAPY ON RESOLUTION... (2*)

Sa1862. . . . REAL WORLD USE OF THE IBD... (5*)

Sa1863. . . . PATIENT EMPOWERMENT THROUGH AN EDUCATIONAL INTERVENTION... (3*)|(Funding provided through an unrestricted educational grant from Abbvie.)

Sa1864. . . . GUT-BRAIN-AXIS REVISITED: SHEDDING LIGHT ON THE... (2*)

Sa1865. . . . THERE IS MORE THAN PHARMACOLOGY: COMPREHENSIVE... (6*)

Sa1866. . . . ASSOCIATION OF PSYCHIATRIC COMORBIDITIES WITH OPIOID... (5*)

Sa1867. . . . SEXUAL QUALITY OF LIFE IN INFLAMMATORY... (4*)

Sa1868. . . . FERTILITY IMPACT OF INITIAL SURGICAL MODALITY... (5*)

Sa1869. . . . PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE TO... (4*)

Sa1870. . . . THE USE OF AN EMR PATIENT... (5*)

Sa1871. . . . HIGH INFlixIMAB TROUGH LEVELS HAVE NO... (3*)|

Sa1872. . . . MEASURING THE MEDIATING EFFECTS OF TOFACITINIB... (3*)|(Pfizer Inc)

Sa1873. . . . MEASURING THE MEDIATING EFFECTS OF MAYO... (3*)|(Pfizer Inc)

Sa1874. . . . THE VISCERAL SENSITIVITY INDEX: A NOVEL... (4*)

Sa1875. . . . DISEASE-RELATED WORRIES AND CONCERNS IN PATIENTS... (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Catherine DeBrosse, PhD, a)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1876. . . . BODY IMAGE DISSATISFACTION IS INCREASED IN... (5*)	Sa1893. . . . A SINGLE CELL SURVEY OF LARGE... (3*)	Sa1913. . . . IDENTIFYING REGULATORS OF MICROBIOME-ENCODED BILE ACID... (2*)
Sa1877. . . . INDIVIDUALISED, UNSUPERVISED EXERCISE PROGRAM ACHIEVES HIGH... (4*)	Sa1894. . . . ENTERIC GLIAL MHC II CONTRIBUTES TO... (2*)	Sa1914. . . . THE PREDICTION MODEL FOR GASTRIC MICROBIOME... (2*)
Sa1878. . . . EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED... (3*) (Takeda)	Sa1895. . . . CHARACTERIZATION AND MODELING OF THE CREEPING... (3*)	Sa1915. . . . ALTERED CIRCADIAN RHYTHM CYCLING OF MICROBES... (2*)
Sa1879. . . . DISABILITY IN PATIENTS WITH ILEAL POUCH... (5*)	Sa1896. . . . SERUM BIOMARKERS OF DEGRADATION AND FORMATION... (5*)	Sa1916. . . . DIFFERENT EFFECTS OF HISTAMINE 2 RECEPTOR... (4*) (Chung Shan Medical University Hospital, Taichung, Taiwan (CSH-2014-D-004-Y2))
Sa1880. . . . LONGITUDINAL PSYCHOLOGICAL HEALTH IN VETERANS WITH... (5*)	Sa1897. . . . HDAC INHIBITORS DRIVE TGF- β 1-MEDIATED STRENGTHENING AND... (2*)	Sa1917. . . . A MICROBIAL SIGNATURE PREDICTS ADVANCED FIBROSIS... (4*)
Sa1881. . . . EFFECTS OF INTRAVENOUS VEDOLIZUMAB ON HEALTH-RELATED... (3*) (Takeda)	Sa1898. . . . LIPIDOMIC PROFILING REVEALS ALTERED LIPID COMPOSITION... (5*)	Sa1918. . . . JEJUNAL BUT NOT COLONIC HYDROGEN SULFIDE... (2*)
Sa1882. . . . PSYCHIATRIC OUTCOMES ARE SIGNIFICANTLY IMPACTED WITH... (4*)	Sa1899. . . . FIBROSIS IN PEDIATRIC PATIENTS WITH ULCERATIVE... (2*)	Sa1919. . . . INTESTINAL MICROBIOME CHANGES AFTER AN ANTIBIOTIC... (4*) (Monica Lester Charitable Trust)
Sa1883. . . . ALTERATIONS IN FUNCTIONAL AND MICROSTRUCTURAL DEFAULT... (2*)	Sa1900. . . . INTEROBSERVER AGREEMENT AMONG ENDOSCOPISTS IN EVALUATING... (6*) (Kenneth-Rainin Foundation)	Sa1920. . . . ORAL HEALTH AND THE COLONIC MUCOSA-ASSOCIATED... (2*)
Sa1884. . . . UNMET NEED OF INFLAMMATORY BOWEL DISEASE... (3*) (Janssen Inc. provided an educational grant to the Gastrointestinal Society. The doctors were not paid for their participation.)	Sa1901. . . . EXPRESSION OF INTEGRIN A4B7 AND MADCAM1... (3*) (Takeda Pharmaceuticals)	Sa1921. . . . ALTERING NITROGEN-SENSING IN E. COLI CAUSES... (7*)
Sa1885. . . . PERCEIVED DISEASE SEVERITY AND TREATMENT SATISFACTION... (3*) (Pfizer Inc)	Sa1902. . . . A COMPARISON OF DIVERTICULITIS IN CROHN'S... (5*)	Sa1922. . . . DISTINCT SHIFTS IN GUT MICROBIOTA COMPOSITION... (2*)
Sa1886. . . . SEXUAL DYSFUNCTION IN PATIENTS WITH INFLAMMATORY... (5*)	Sa1903. . . . THE ROLE OF SUB-MUCOSAL COLLAGEN DEPOSITION... (5*)	Sa1923. . . . THE IMPACT OF INTESTINAL DYSBIOSIS IN... (4*)
Sa1887. . . . GENERAL HEALTH STATUS IN PATIENTS WITH... (3*) (This study was funded by Janssen Research & Development, LLC)	Sa1904. . . . LONG-TERM SAFETY AND OUTCOMES OF COLONOSCOPIC... (5*)	Sa1924. . . . EFFECT OF SHORT CHAIN FATTY ACIDS... (4*)
Sa1888. . . . USTEKINUMAB THERAPY INDUCED CLINICALLY MEANINGFUL IMPROVEMENT... (3*) (This study was funded by Janssen Research & Development, LLC)	Sa1905. . . . A PHASE I RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED... (3*) (Study funded by 4D Pharma. RH and RKR supported by Career Researcher Fellowships from NHS Research Scotland.)	Sa1925. . . . ALTERATION IN GUT MICROBIOTA IS ASSOCIATED... (2*)
Sa1889. . . . DOES PREGNANCY ADVERSELY IMPACT THE HEALTH... (4*)	Sa1906. . . . DOSE ESCALATION WITH ORIGINATOR INFliximab IS... (3*) (Janssen Scientific Affairs, LLC supported this study)	Sa1926. . . . SELECTIVE MICROBIOTA TRANSPLANTATION IS EFFECTIVE FOR... (1*)
Sa1890. . . . THE ASSESSMENT OF INDIVIDUAL PATIENT PREFERENCES... (6*)	Sa1907. . . . ANTIBIOTICS WORSEN VISCERAL BUT NOT SOMATIC... (6*)	Sa1927. . . . ASSOCIATIONS OF EARLY LIFE ADVERSITY AND... (2*)
Sa1891. . . . A SURVEY OF DISCLOSURE PREFERENCES IN... (5*)	Sa1908. . . . ABERRANT ENTERIC NEUROMUSCULAR SYSTEM AND DYSBIOSIS... (2*)	Sa1928. . . . HUMAN BREAST MILK PROMOTES THE SECRETION... (3*) (BioGaia AB)
Sa1892. . . . NUTRITIONAL STATUS CORRELATES WITH QUALITY OF... (5*)	Sa1909. . . . DEEP SEQUENCING OF THE ENTIRE HUMAN... (4*)	Sa1929. . . . DISTINGUISHING DISEASE AND ANTIBIOTIC EFFECTS IN... (2*) (This work was supported by a Tobacco Formula grant, under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)
	Sa1910. . . . LIFE COURSE ANTIBIOTIC USE AND ALTERATIONS... (2*)	Sa1930. . . . FECAL MICROBIOTA TRANSPLANTATION: PERCEPTIONS AND EXPERIENCES... (4*)
	Sa1911. . . . ANALYSIS OF THE SMALL INTESTINAL MICROBIOME... (4*)	
	Sa1912. . . . REVEALING THE ENTIRE INTESTINAL MICROBIOTA AND... (4*)	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1931. . . . PHYSICO-CHEMISTRY, PROTEOMICS AND IN VIVO COMPARATIVE... (5*)

Sa1932. . . . EFFECT OF SACCHAROMYCES BOULARDII CNCM I-745... (3*)|(The current project was partially funded by a Biocodex grant, however they were not involved neither in the study design, patients recruitment nor data alysis. USFQ, UTE and UDLA (Private Universities in Ecuador) also funded partially the current research)

Sa1933. . . . GUT MICROBIOME CROSS-TALK: PLAUSIBLE OR JUST... (5*)

Sa1934. . . . THE FECAL-ANTI CANDIDA ACTIVITY CAN BE... (5*)

Sa1935. . . . COMPARING FAECAL VOLATILE ORGANIC COMPOUNDS FOLLOWING... (5*)

Sa1936. . . . EFFICACY AND SAFETY OF SACCHAROMYCES BOULARDII... (4*)

Sa1937. . . . FIVE CASES OF BACILLUS LICHENIFORMIS BACTEREMIA... (1*)

Sa1938. . . . ENTEROBACTERIACEAE ARE ESSENTIAL FOR THE MODULATION... (3*)

Sa1939. . . . THE GUT MICROBIOME AS A NOVEL... (7*)

Sa1940. . . . FECAL AND MUCOSAL MICROBIOTA PROFILING IN... (2*)

Sa1941. . . . STRUCTURED PATIENT GROUP EDUCATION VERSUS STRUCTURED... (2*)|

Sa1942. . . . REAL-WORLD IMPLEMENTATION OF THE LOW FODMAP... (2*)

Sa1943. . . . IMPACT OF IRRITABLE BOWEL SYNDROME ON... (5*)

Sa1944. . . . DIFFERENCES OF GASTROINTESTINAL (GI) SYMPTOMS BETWEEN... (5*)

Sa1945. . . . FECAL MICROBIOTA TRANSPLANTATION IN IRRITABLE BOWEL... (5*)

Sa1946. . . . THE MOST BOTHERSOME SYMPTOM IN FUNCTIONAL... (4*)

Sa1947. . . . RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COLESEVELAM... (5*)

Sa1948. . . . NEEDLELESS TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION IMPROVES IRRITABLE... (5*)

Sa1949. . . . POSTMENOPAUSAL WOMEN WITH IRRITABLE BOWEL SYNDROME... (5*)

Sa1950. . . . EFFECT OF SYMPTOM SEVERITY AND GENDER... (5*)

Sa1951. . . . VALIDITY AND SAFETY OF SYMPTOM IMPROVEMENT... (2*)

Sa1952. . . . ROLE OF LOW-GRADE INFLAMMATION IN THE... (5*)

Sa1953. . . . PICTOGRAMS ARE HIGHLY EFFECTIVE FOR DIAGNOSING... (4*)

Sa1954. . . . POST INFECTION IBS (PI-IBS) IS VERY... (4*)

Sa1955. . . . IS ROME IV CRITERIA FOR IBS... (5*)

Sa1956. . . . ANXIETY, DEPRESSION AND STRUCTURAL FACTORS IMPACT... (2*)

Sa1957. . . . INCIDENCE, PREVALENCE AND RISK FACTORS ASSOCIATED... (3*)|(This project was supported by a grant from Prometheus laboratories.)

Sa1958. . . . MEASURING DIET INTAKE AND GASTROINTESTINAL SYMPTOMS... (2*)

Sa1959. . . . EVALUATION OF THE PSYCHOSOCIAL FEATURES OF... (2*)

Sa1960. . . . A SURVEY-BASED STUDY OF IRRITABLE BOWEL... (5*)

Sa2004. . . . HIGH METHYL DIET IMPAIRS E.COLI OVERGROWTH,... (4*)

Sa2005. . . . EXPERT CONSENSUS ON MANAGING IRON DEFICIENCY... (3*)|(Vifor Pharma)

Sa2006. . . . MODERATE ETHANOL CONSUMPTION INHIBITS VILLUS CELL... (2*)

Sa2007. . . . ASPIRIN/NSAID USE GREATER THAN 4 YEARS... (2*)|

Sa2008. . . . RISK OF METACHRONOUS SESSILE SERRATED ADENOMAS... (5*)

Sa2009. . . . COMBINATORIAL BLOCKADE OF DE NOVO CHOLESTEROL... (2*)

Sa2010. . . . LIPOPHILIC STATINS INHIBIT YAP NUCLEAR LOCALIZATION,... (2*)

Sa2011. . . . USEFULNESS OF TRACE ACETALDEHYDE/ETHANOL MEASUREMENTS IN... (5*)

Sa2012. . . . REGULATION OF COLON CARCINOGENESIS BY THE... (5*)

Sa2013. . . . ASPIRIN IS PROTECTIVE AGAINST GASTRIC CANCER... (2*)

Sa2014. . . . ASPIRIN USE AND THE INCIDENCE OF... (2*)

Sa2015. . . . 5-AMINOSALICYLIC ACID INHIBITS XENOBIOTIC METABOLISM IN... (4*)

Sa2016. . . . TRANSCRIPTIONAL AND POST-TRANSLATIONAL IMPLICATIONS OF COHESIN... (2*)

Sa2017. . . . PREEMPTIVE ADALIMUMAB AMELIORATED CACHEXIA THROUGH CONCERTED... (4*)

Sa2018. . . . COLORECTAL NEOPLASMS IN NEW USERS OF... (4*)

Sa2019. . . . CHEMOPREVENTION OF COLORECTAL CANCER IN THE... (5*)

Sa2020. . . . TARGETING CYCLOOXYGENASE 2 (COX-2) WITH EXERCISE-INDUCED... (2*)

Sa2021. . . . A MULTICENTER STUDY OF THE SAFETY... (3*)|(Covidien/Medtronic)

Sa2022. . . . EXPLORING RELATIONSHIPS BETWEEN HANDGRIP STRENGTH, MID-UPPER... (3*)|(Baxter Cada)

Sa2023. . . . 13C-CAFFEINE BREATH TEST FOR THE IDENTIFICATION... (4*)

Sa2024. . . . ASSOCIATION BETWEEN MALNUTRITION, NUTRITIONAL ASSESSMENT TOOLS,... (4*)

Sa2025. . . . DYSREGULATION OF LIVER MITOCHONDRIAL FUNCTION AND... (3*)|(Tsumura & Co.)

Sa2026. . . . IMPROVEMENT IN NUTRITION STATUS IS ASSOCIATED... (4*)

Sa2027. . . . VALIDATION OF THE MODIFIED NUTRIC SCORE... (5*)

Sa2028. . . . DIETARY FIBER IS ESSENTIAL TO MAINTAIN... (6*)

Sa2029. . . . HABITUAL DIETARY INTAKE OF DUTCH IBD... (5*)

Sa2030. . . . RANDOMIZED CLINICAL TRIAL TO COMPARE TWO... (5*)

Sa2031. . . . HIGH PREVALENCE OF FOOD AVOIDANCE DIETS... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa2032. . . . ALCOHOL CONSUMPTION AND THE COLONIC MUCOSA-ASSOCIATED... (2*)

Sa2033. . . . SHORT- AND LONG-TERM ALCOHOL INTAKE AND... (2*)

Sa2034. . . . INTRAPERITONEAL TREATMENT WITH KISSPEPTIN MODIFIES FEEDING... (4*)

Sa2035. . . . DIETARY INTERVENTIONS RAPIDLY ALTER METABOLOMICS PROFILE... (6*)

Sa2036. . . . AN EVALUATION OF DIETARY INTAKE, MACRO... (4*)|(5)

Sa2037. . . . EFFECT OF CALCIUM AND VITAMIN D... (2*)

Sa2038. . . . LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL... (2*)

Sa2039. . . . UNDERSTANDING HOW DIFFERENCES IN SOCIOECONOMIC STATUS,... (5*)

Sa2040. . . . VITAMIN B12 MALABSORPTION AND DEFICIENCY FOLLOWING... (5*)

Sa2041. . . . DIETARY ADHERENCE IN FUNCTIONAL GASTROINTESTINAL DISORDERS:... (5*)

Su1006. . . . INTERACTION BETWEEN LONG NONCODING RNA UC.173... (2*)

Su1007. . . . NLRP3 INFLAMMASOME-MEDIATED IL-1 β ACTIVATION ENHANCES 5-FU... (4*)

Su1008. . . . MIR874-3P IS INVERSELY CORRELATED WITH ITS... (7*)|(We like to acknowledge the Intertiol Organization for the study of Inflammatory Bowel Disease (IOIBD), and the tiol Institute of Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium [NIDDK IBDGC] for their financial support.)

Su1009. . . . LOSS OF RAB25 AGGRAVATES A HYPERTROPHIC... (2*)

Su1010. . . . ABNORMAL ACTIVATION OF HNRNPA0 INHIBITS CANCER... (2*)

Su1011. . . . HUMAN LAMINA PROPRIA LYMPHATIC CELLS AS... (5*)

Su1012. . . . MECHANICAL STIMULI AFFECT ENTEROTOXIGENIC E. COLI... (2*)|(Emulate Inc.)

Su1013. . . . INCREASED BASOPHIL RECRUITMENT TO THE COLON... (4*)

Su1014. . . . IMMUNE PROFILING OF THE HUMAN GASTRIC... (4*)

Su1015. . . . WNT SIGNALING REGULATES SIRT2 EXPRESSION IN... (2*)

Su1016. . . . PROTEIN KINASE D REGULATES THE NUCLEAR... (2*)

Su1017. . . . ESTABLISHMENT AND CHARACTERIZATION OF A LEAKY... (3*)|(Innovate Biopharmaceuticals Inc, Raleigh NC)

Su1018. . . . INTESTINAL BARRIER DYSFUNCTION ORCHESTRATES THE ONSET... (6*)|(Primary Source: Intertiol Foundation for Ethical Research Additioal Source 1: Bio & Medical Technology Development Program of the tiol Research Foundation funded by the Ministry of Science and ICT Additioal Source 2: Cancer Research Institute Additioal Source)

Su1019. . . . LARAZOTIDE PROTECTS THE INTESTINAL TIGHT JUNCTION... (3*)|(Innovate Biopharmaceuticals Inc., Raleigh, NC, USA)

Su1020. . . . NAFAMOSTAT MESYLATE, A BROAD SPECTRUM SERINE... (4*)

Su1021. . . . PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN... (5*)

Su1022. . . . INTERLEUKIN 4 RECEPTOR α DEFICIENCY ALLEVIATES... (5*)

Su1028. . . . WHOLE-GENOME SEQUENCING OF AFRICAN AMERICANS IDENTIFIES... (6*)

Su1029. . . . TIO2 NANOPARTICLES ABROGATE THE PROTECTIVE EFFECT... (2*)

Su1030. . . . UTILITY OF TARGETED NEXT-GENERATION SEQUENCING PANEL... (2*)

Su1031. . . . PREVALENCE OF GERMLINE MUTATIONS AND VARIABLE... (2*)

Su1032. . . . MIST+ ISTHMUS STEM CELLS CONTRIBUTE TO... (2*)

Su1034. . . . REBAMIPIDE REDUCES GASTRIC EPITHELIAL CELL APOPTOSIS... (4*)

Su1035. . . . SCREENING ANTI-FIBROTIC AGENTS: EXPLORATION OF PROMISING... (4*)

Su1036. . . . SULFORAPHANE ALLEVIATES DEXTRAN SODIUM SULFATE (DSS)-INDUCED... (2*)

Su1037. . . . HEPATOCARCINOGENESIS WITHOUT CIRRHOSIS IN THE ELDERLY... (4*)

Su1038. . . . NOD1 DEFICIENT GASTRIC STEM CELLS FAIL... (4*)

Su1039. . . . HUMAN DIFFERENTIATED ENTEROID MONOLAYERS EXHIBIT EGFR/MEK... (2*)

Su1040. . . . EARLY ACTIVATION OF SOX9-POSITIVE CELLS IN... (2*)

Su1041. . . . NEW DIAGNOSTIC APPROACH FOR BILIARY TRACT... (2*)|(Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science)

Su1042. . . . HUMAN CYTOKINE PRODUCTION BY THE INTACT... (2*)

Su1043. . . . EXPLORING GLP2 ACTIVITY AND CELLULAR TARGETS... (4*)

Su1044. . . . OPTIMIZATION OF CULTURE CONDITIONS FOR IMPROVED... (3*)|(AbbVie)

Su1045. . . . MINIMUM ESSENTIAL ORGANOIDS CULTURE MEDIA (MEOM)... (2*)

Su1046. . . . CRISPR/CAS9-MEDIATED GENOME EDITING OF MULTI-DRUG RESISTANCE... (4*)

Su1047. . . . THE CHARACTERIZATION OF THE FUNCTION OF... (2*)|(JSPS KAKENHI Grants Numbers 15K10124 (KY and YIK) and grants from the tiol Center for Global Health and Medicine (26-117 and 29-1019).)

Su1048. . . . INTESTINAL EPITHELIAL BARRIER ABNORMALITIES AND CHANGES... (2*)

Su1049. . . . MULTIPLEX NANOSCALE HIGH RESOLUTION FLOW CYTOMETRY... (4*)

Su1050. . . . COMPARISON OF FISH VERSUS DDPCR-BASED GENE... (4*)

Su1051. . . . CONSTRUCTION OF COLORECTAL CANCER SUBTYPES BASED... (5*)

Su1052. . . . A NOVEL MICRORNA PANEL FOR NON-INVASIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1053. . . . HIGH RISK POPULATION SCREENING FOR COLORECTAL... (5*)	Su1074. . . . ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN... (2*)	Su1115. . . . ACTIVATION OF EGFR-DNA-PK PATHWAY BY IGF2R... (4*)
Su1054. . . . PYRROLINE-5-CARBOXYLATE REDUCTASE 1(PYCR1) UPREGULATION CONTRIBUTES TO... (2*)	Su1096. . . . CALCIUM SIGNALING IN THE REGULATION OF... (2*)	Su1116. . . . EOSINOPHILS ARE PRESENT IN HUMAN AND... (5*)
Su1055. . . . REPRIMO-LIKE: A POTENTIAL TUMOR SUPPRESSOR AND... (2*)	Su1097. . . . NCX1/CA/NF-KB SIGNAL PATHWAY COULD BE A... (2*)	Su1117. . . . APURINIC/APYRIMIDINIC ENDONUCLEASE-1 IS ASSOCIATED WITH ANGIOGENESIS... (1*)
Su1056. . . . A CHEMORADIOTHERAPY TREATMENT RESPONSE MRNA SIGNATURE... (7*)	Su1098. . . . TUMOR-DERIVED EXOSOMES PROMOTE TUMOR GROWTH AND... (4*)	Su1118. . . . MEDICATION EFFECTS ON METHYLATION-RELATED BIOLOGICAL AGING... (2*)
Su1057. . . . INCREASED EXPRESSION OF THE LONG NONCODING... (2*)	Su1099. . . . MYOARCHITECTURE OF THE SLING FIBERS OF... (2*)	Su1119. . . . IS THE AGE OF DIAGNOSIS OF... (5*)
Su1058. . . . POTENTIAL OF URINARY CYSTEINE-RICH PROTEIN 61... (3*) (the Kobayashi Foundation for Cancer Research)	Su1100. . . . MUCOSAL BARRIER DYSFUNCTION OF ATROPHIC MUCOSA... (5*)	Su1120. . . . HAS ACCURACY OF CLINICAL STAGING OF... (5*)
Su1059. . . . IMMUNE CELL INFILTRATION AND TUMOUR LOCATION... (5*)	Su1101. . . . CAN NSAID-INDUCED INJURY OF GASTRIC EPITHELIAL... (2*)	Su1121. . . . M1A DISEASE SHOULD BE RECONSIDERED IN... (5*)
Su1060. . . . CLINICAL UTILITY OF THE QUANTITATIVE MONITORING... (2*)	Su1102. . . . CARBON MONOXIDE RELEASED FROM ITS PHARMACOLOGICAL... (4*) (Grant from tIol Science Centre, Poland (UMO-2016/23/N/NZ4/01890).)	Su1122. . . . COMPREHENSIVE MUTATIONAL ANALYSIS OF BACKGROUND MUCOSA... (5*)
Su1061. . . . IDENTIFICATION OF A ROBUST MICRORNA SIGNATURE... (2*)	Su1103. . . . DOES PPI PLAY A PROTECTIVE ROLE... (5*)	Su1123. . . . ADDED VALUE OF MRI TO ENDOSCOPIC... (5*)
Su1062. . . . MOLECULAR DEPENDENCIES IN ESOPHAGEAL ADENOCARCINOMA: A... (2*)	Su1104. . . . A RANDOMIZED CONTROLLED STUDY ON THE... (5*)	Su1124. . . . LONG TERM RESULTS OF ENDOSCOPIC TREATMENT... (4*)
Su1063. . . . MIR-4715-3P MODULATES AURKA AND INDUCES FERROPTOSIS... (2*)	Su1105. . . . ESOPHAGEAL MUCOSAL IMMUNE RESPONSE TO CANDIDA... (5*)	Su1125. . . . ESOPHAGEAL STENT PLACEMENT FOR POST-OPERATIVE COMPLICATIONS... (5*)
Su1065. . . . CANCER-DERIVED EXOSOMES ACTIVATE FIBROBLASTS THROUGH SUPPRESSION... (5*)	Su1106. . . . TACROLIMUS-INDUCED PAN-ESOPHAGEAL AND DUODENAL ULCERATION: A... (5*)	Su1126. . . . CLINICAL PREDICTORS OF LOCALLYADVANCED ESOPHAGEAL ADENOCARCINOMA... (5*)
Su1066. . . . NOVEL METABOLOMIC PREDICTORS OF INCIDENT COLORECTAL... (2*)	Su1107. . . . CLINICAL SIGNIFICANCE OF SERUM MARKERS IN... (5*)	Su1127. . . . INCREASED SOX2 EXPRESSION IN THE EARLY... (2*)
Su1067. . . . GENETIC COLORECTAL CANCER RISK VARIANTS ASSOCIATED... (2*)	Su1108. . . . COLLAGENOUS GASTRITIS: A RARE CAUSE OF... (5*)	Su1128. . . . CLINICAL EPIDEMIOLOGY OF ESOPHAGEAL CANCER: NATIONWIDE... (7*) (Korean College of Helicobacter and Upper Gastrointestil Research)
Su1068. . . . MUTATIONAL LANDSCAPE OF EARLY-ONSET COLORECTAL CANCER... (2*)	Su1109. . . . DEVELOPMENT OF NEOSQUAMOUS EPITHELIUM IN THE... (5*)	Su1129. . . . PREDICTIVE SIGNIFICANCE OF ENDOSONOGRAPHIC (EUS) STAGING... (1*)
Su1069. . . . THE ROLE OF RARE VARIANTS IN... (2*)	Su1110. . . . EVALUATION OF SMALL BOWEL INJURY IN... (5*)	Su1130. . . . OUTCOMES AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER... (5*)
Su1070. . . . MORPHOLOGICAL AND MOLECULAR RISK MARKERS FOR... (5*)	Su1111. . . . GRADING OF ACUTE ESOPHAGEAL GRAFT VERSUS... (5*)	Su1131. . . . HIGH CHOLESTEROL AND HEMOGLOBIN A1C LEVELS... (4*)
Su1071. . . . NOVEL LONG NON-CODING RNA MOLECULAR SUBTYPES... (4*)	Su1112. . . . ESOPHAGEAL PEMPFIGUS: THE EXPERIENCE FROM A... (5*)	Su1132. . . . NOVEL APPLICATION OF IMPEDANCE-PH TECHNOLOGY SHOWS... (5*)
Su1072. . . . HELICOBACTER PYLORI-RELATED DNA METHYLATION IN PRIMARY... (2*)	Su1113. . . . RISK FACTORS, ENDOSCOPIC FEATURES, AND CLINICAL... (5*)	Su1133. . . . ACID SUPPRESSION DOES NOT IMPROVE LARYNGOMALACIA... (2*)
Su1073. . . . GENE NETWORK DIFFERENCES OF COLON CANCER... (5*)	Su1114. . . . SWOLLEN STIMULANTS OF ORAL CAVITY MAY... (5*)	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1146. . . . USE OF FECAL OCCULT BLOOD TESTING... (2*)
- Su1147. . . . BLEEDING AND THROMBOSIS RISK IN CRITICALLY... (5*)
- Su1148. . . . RISK OF ADVANCED METACHRONOUS NEOPLASIA IS... (5*)
- Su1149. . . . ARE PPIs ASSOCIATED WITH DEMENTIA? ... (5*)
- Su1150. . . . RISK OF TUBERCULOSIS IN PATIENTS WITH... (5*)
- Su1151. . . . EARLY VS DELAYED ERCP IN ACUTE... (5*)
- Su1152. . . . IMPACT OF NURSE OR TRAINEE PARTICIPATION... (5*)
- Su1247. . . . SCREENING FOR GASTRIC INTESTINAL METAPLASIA: WHAT... (4*)
- Su1248. . . . COMBINATION OF HELICOBACTER PYLORI STATUS AND... (5*)
- Su1249. . . . DEMOGRAPHIC, LIFESTYLE AND DIETARY RISK FACTORS... (5*)
- Su1250. . . . FEASIBILITY OF GASTRIC INTESTINAL METAPLASIA SURVEILLANCE... (5*)
- Su1251. . . . CLINICOPATHOLOGICAL FEATURES OF SPORADIC NON-AMPULLARY DUODENAL... (5*)
- Su1252. . . . INCIDENT DIAGNOSES OF GASTRIC INTESTINAL METAPLASIA... (5*)
- Su1253. . . . EVALUATION OF DNA AND RNA EXTRACTION... (4*)
- Su1254. . . . OLGA AND OLGIM STAGE DISTRIBUTION ACCORDING... (5*)
- Su1255. . . . AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS (AMAG) ... (5*)
- Su1257. . . . CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMORS USING... (5*)
- Su1258. . . . MISSED OPPORTUNITIES FOR SCREENING OR SURVEILLANCE... (5*)
- Su1259. . . . THE INCIDENCE OF GASTRIC CANCER IN... (5*)
- Su1260. . . . LOW PREVALENCE OF HELICOBACTER PYLORI-POSITIVE PEPTIC... (5*)
- Su1261. . . . SMOKING, HELICOBACTER PYLORI SEROLOGY, AND GASTRIC... (2*)
- Su1262. . . . PREVALENCE OF HELICOBACTER PYLORI INFECTION IN... (5*)
- Su1263. . . . ASSESSMENT OF GASTRIC PREMALIGNANT LESIONS BY... (2*)
- Su1264. . . . HELICOBACTER PYLORI ANTIBODY PREVALENCE BY YEAR... (2*)
- Su1265. . . . PROSPECTIVE COMPARISON VALIDATION STUDY OF 13C-UREA... (5*)
- Su1266. . . . HELICOBACTER PYLORI TESTING AND TREATMENT IN... (3*)|(Otsuka Pharmaceutical Development and Commercialization, Inc. (Rockville, MD))
- Su1267. . . . MANAGEMENT OF HELICOBACTER PYLORI INFECTION AT... (5*)
- Su1268. . . . HELICOBACTER PYLORI INFECTION: PRACTICE PATTERNS IN... (5*)
- Su1269. . . . HELICOBACTER PYLORI INFECTION AND IRON DEFICIENCY... (5*)
- Su1270. . . . CLINICAL PERFORMANCE OF THE H. PYLORI... (3*)
- Su1271. . . . CHANGES IN GUT MICROBIOTA AFTER HELICOBACTER... (5*)
- Su1272. . . . THE RATIO OF PEPSINOGEN I TO... (4*)
- Su1273. . . . HELICOBACTER PYLORI ERADICATION CANNOT RESTORE THE... (2*)|(This work was supported by the tiol Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2017R1C1B5075233))
- Su1274. . . . HELICOBACTER PYLORI INFECTION AMONG YOUNG PEOPLE... (5*)
- Su1275. . . . HELICOBACTER PYLORI IN SOUTH TEXAS: ERADICATION... (5*)
- Su1276. . . . LONG-TERM FOLLOW UP OF ENDOSCOPIC/HISTOLOGICAL ATROPHY,... (5*)
- Su1277. . . . THE MANAGEMENT OF H. PYLORI IS... (5*)
- Su1278. . . . ASSOCIATION OF HELICOBACTER PYLORI INFECTION AND... (4*)
- Su1279. . . . IMPACT OF PRIOR EXPOSURE TO MACROLIDE... (5*)
- Su1280. . . . EFFICACIES OF TAILORED THERAPY VERSUS GUIDELINE-RECOMMENDED... (4*)
- Su1281. . . . TETRACYCLINE-LEVOFLOXACIN QUADRUPLE THERAPY ACHIEVES A HIGHER... (4*)
- Su1282. . . . ERADICATION RATES OF TRIPLE, TRIPLE WITH... (5*)
- Su1283. . . . TEN-DAY CONCOMITANT, 10-DAY SEQUENTIAL, AND 7-DAY... (2*)|(Ministry of Health and Welfare, Republic of Korea)
- Su1284. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SIFAXOXACIN... (5*)
- Su1285. . . . SYNERGISTIC INHIBITORY EFFECTS OF NANOPARTICLE HEATING... (2*)
- Su1286. . . . A POTASSIUM-COMPETITIVE ACID BLOCKER-BASED REGIMEN AS... (5*)
- Su1287. . . . A PHASE 1, RANDOMIZED, DOUBLE-BLIND STUDY... (3*)|(Takeda Pharmaceutical Company Limited)
- Su1288. . . . FIRST LINE HELICOBACTER PYLORIERADICATION IN PATIENTS... (5*)
- Su1289. . . . INFLUENCE OF CLOSTRIDIUM BUTYRICUM AS PROBIOTICS... (5*)
- Su1290. . . . EFFICACY AND SAFETY OF LACTOBACILLUS REUTERI... (5*)
- Su1291. . . . EFFECTIVENESS OF HIGH DOSE DUAL THERAPY... (1*)
- Su1292. . . . TRIPLE-DRUG BLISTER-PACKAGED DRUG WITH VONOPRAZAN IMPROVES... (5*)
- Su1293. . . . LONG-TERM EFFET FOR LIPID METABOLISM BY... (5*)
- Su1294. . . . ERADICATION RATIO AND ADVERSE EVENTS INCIDENCE... (1*)
- Su1295. . . . SUSCEPTIBILITY-BASED THIRD LINE RESCUE THERAPY FOR... (4*)
- Su1296. . . . SUPERBUG OR SOMETHING ELSE: FACTORS CONTRIBUTING... (5*)
- Su1297. . . . GENETIC AND BACTERIAL FACTORS FOR OUTCOME... (5*)
- Su1298. . . . CLARITHROMYCIN VERSUS METRONIDAZOLE CONTAINING FIRST-LINE VONOPRAZAN... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1299. . . . A RANDOMIZED CONTROLLED STUDY FOR LEVOFLOXACIN-BASED... (4*)

Su1300. . . . NATION-WIDE ANTIBIOTIC RESISTANCE MAPPING OF HELICOBACTER... (2*)

Su1301. . . . CHANGES OF GASTRIC CORPUS MICROBIOTA AFTER... (5*)

Su1302. . . . PRESENTATION, CLINICAL COURSE AND OUTCOME IN... (5*)

Su1303. . . . PEDIATRIC CAPSULE ENDOSCOPY: ACHIEVING 0 CAPSULE... (5*)

Su1304. . . . A NOVEL HISTOLOGY INDEX FOR EVALUATION... (6*)

Su1305. . . . SEROTONIN ACTING VIA 5-HT3 RECEPTORS MEDIATES... (2*)

Su1306. . . . A NOVEL POTENT POST-SYNAPTIC SIGNALING PATHWAY... (2*)

Su1307. . . . EZH2 REGULATES GASTRIC PACEMAKER STEM CELL... (2*)

Su1308. . . . FIRST IN MAN PATCH CLAMP RECORDINGS IN FRESHLY... (2*)

Su1309. . . . IMPACT OF GUT SURGICAL MANIPULATION ON... (2*)

Su1310. . . . BETA 2 ADRENERGIC RECEPTOR MEDIATES THE... (2*)

Su1311. . . . OPTOGENETIC ANALYSIS OF CHOLINERGIC NERVE PATHWAYS... (2*)

Su1312. . . . ABNORMAL BIOELECTRICAL SLOW-WAVE IN PATIENTS WITH... (2*)

Su1313. . . . ROLE OF ETV1 IN REGULATING GASTROINTESTINAL... (2*)

Su1314. . . . INTERSTITIAL CELLS OF CAJAL PLAY A... (5*)

Su1315. . . . EPIGENETIC CHANGES IN GASTRIC ANTRAL SMOOTH... (5*)

Su1316. . . . DAIKENCHUTO, A TRADITIONAL JAPANESE (KAMPO) MEDICINE,... (2*)

Su1317. . . . INHIBITING FATTY ACID AMIDE HYDROLASE AMELIORATES... (4*)

Su1318. . . . P2X2 RECEPTOR SIGNALING INDUCES ENTERIC GLIA... (2*)

Su1319. . . . KAMPO FORMULA DAIKENCHUTO FACILITATES MUCOSAL HYPEREMIC... (2*)

Su1320. . . . IDENTIFICATION OF NOVEL NEURONAL MARKERS IN... (2*)

Su1418. . . . ROLE OF THERAPEUTIC ANTICOAGULATION IN SPLANCHNIC... (5*)

Su1419. . . . ONE YEAR RISK OF OPIOID ADDICTION... (5*)

Su1420. . . . MULTI-ORGAN FAILURE IS THE STRONGEST DETERMINANT... (5*)

Su1421. . . . TRENDS AND TIMING OF CHOLECYSTECTOMY IN... (5*)

Su1422. . . . THE IMPACT OF OPIOID ABUSE/DEPENDENCE DISORDER... (5*)

Su1423. . . . GASTROINTESTINAL FAILURE IS A PREDICTOR OF... (5*)

Su1424. . . . IS EARLY CT OVERUTILIZED IN MANAGEMENT... (5*)

Su1425. . . . ANNULAR PANCREAS AND ITS ASSOCIATION WITH... (5*)

Su1426. . . . PATIENTS TAKING ANTI-TUMOR NECROSIS FACTOR α ... (5*)

Su1427. . . . A MULTIVARIATE MODEL FOR PREDICTION OF... (5*)

Su1428. . . . DOES INTRACELLULAR FLUID SHIFT CONTRIBUTE TO... (4*)

Su1429. . . . NEUTROPHIL CD64 EXPRESSION IS A NOVEL... (4*)

Su1430. . . . ISOLATED EXTRA-PANCREATIC NECROSIS IS ASSOCIATED WITH... (5*)

Su1431. . . . NECROTIZING ACUTE PANCREATITIS: CAN MRI DIFFUSION-WEIGHTED... (5*)

Su1432. . . . THE CLINICAL SPECTRUM OF GROOVE PANCREATITIS... (5*)

Su1433. . . . ACUTE PANCREATITIS IN PATIENTS WITH HEMOPHILIA:... (5*)

Su1434. . . . ACUTE PANCREATITIS IN PATIENTS WITH HEART... (5*)

Su1435. . . . AGGRESSIVE FLUID REPLACEMENT IN ACUTE PANCREATITIS;... (5*)

Su1436. . . . ORGAN FAILURE PERSISTING FOR MORE THAN... (5*)

Su1437. . . . IDENTIFYING REDUCED PANCREATIC FUNCTION AND FAT... (3*)|(Abbvie, Inc)

Su1438. . . . METABOLOMIC PROFILING IDENTIFIES PHOSPHOLIPID SIGNATURE IN... (4*)|(nil)

Su1439. . . . RISK FACTORS FOR DIABETES MELLITUS IN... (5*)

Su1440. . . . COEXISTENCE OF ALCOHOLIC LIVER DISEASE (ALD)... (4*)

Su1441. . . . ASSOCIATION OF AUTOIMMUNE DISEASES IN CHILDREN... (2*)

Su1442. . . . METABOLIC SYNDROME RELATED DISORDERS ARE LESS... (5*)

Su1443. . . . PREVALENCE, TREND AND DETERMINANTS OF LEAVING... (5*)

Su1444. . . . RISK FACTORS AND NOMOGRAM FOR STEATORRHEA... (5*)

Su1445. . . . IS CHRONIC PANCREATITIS WITH HIGH BMI... (5*)

Su1446. . . . CLINICAL CHARACTERISTICS OF PATIENTS WITH SYMPTOMS... (2*)

Su1447. . . . CLINICAL FEATURES OF IGG4 NEGATIVE AUTOIMMUNE... (5*)

Su1448. . . . PREDICTIVE VALUE OF ISLET PROCESSING PARAMETERS... (5*)

Su1449. . . . DO PATIENTS WITH CHRONIC PANCREATITIS RECEIVE... (5*)

Su1450. . . . CHRONIC PANCREATITIS ASSOCIATED WITH CYSTIC FIBROSIS... (5*)

Su1451. . . . AMMANN PAIN TYPE AND THE NATURAL... (4*)

Su1452. . . . CHARACTERIZATION OF NUTRITIONAL STATUS THROUGH PHASE... (5*)

Su1453. . . . DIAGNOSIS AND TREATMENT OF AUTOIMMUNE PANCREATITIS:... (4*)

Su1454. . . . PANCREATIC CYSTIC LESIONS: ACTIVE VERSUS PASSIVE... (7*)

Su1455. . . . NATURAL HISTORY OF PANCREATIC CYSTIC LESIONS... (7*)

Su1456. . . . ASSESSMENT OF ENDOSCOPIC ULTRASOUND (EUS) AND... (5*)

Su1457. . . . COMPARISON OF DOTATATE PET-CT SCAN AND... (5*)

Su1458. . . . PANCREATIC ISLET CELL TUMORS: NATIONWIDE ANALYSIS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1459. . . . IMAGING RESOURCE UTILIZATION IN ACTIVE PANCREATIC... (5*)

Su1460. . . . PANCREATIC MIXED ACINAR CELL/NEUROENDOCRINE CARCINOMA: GENOMIC... (4*)

Su1519. . . . RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS... (3*)|(Salix Pharmaceuticals)

Su1520. . . . A NATIONAL ESTIMATE OF COMPENSATED AND... (5*)

Su1521. . . . COMBINATION THERAPY VS MONOTHERAPY FOR EUS-GUIDED... (5*)

Su1522. . . . PREVALENCE OF UPPER GASTROINTESTINAL NEOPLASIA IN... (5*)

Su1523. . . . IMPACT OF TRANSFER STATUS ON OUTCOMES... (5*)

Su1524. . . . FLASH GLUCOSE-SENSING TECHNOLOGY AS A REPLACEMENT... (5*)

Su1525. . . . SUPRAHEPATIC INFERIOR CAVAL VEIN OCCLUSION AND... (4*)

Su1526. . . . COMPLICATIONS OF PORTAL TRIAD OBSTRUCTION AND... (4*)

Su1527. . . . POTENTIALLY PREVENTABLE READMISSIONS AND COMPLICATIONS IN... (2*)|(Partly from Investigator Initiated Grants from Grifols and Valeant and from NCATS NIH)

Su1528. . . . ENDOSCOPIC FINDINGS IN PATIENTS WITH CIRRHOSIS... (5*)

Su1529. . . . PORTAL TRIAD OBSTRUCTION AND REPERFUSION IN... (4*)

Su1530. . . . PRE-EXISTING LIVER DISEASE INCREASES RISK OF... (5*)

Su1531. . . . SPLENECTOMY IN RATS INDUCED PORTAL AND... (4*)

Su1532. . . . COMPLICATIONS OF SUPRAHEPATIC INFERIOR CAVAL VEIN... (4*)

Su1533. . . . ADMISSION SERUM UREA IS A BETTER... (5*)

Su1534. . . . BPC 157 GIVEN DURING REPERFUSION COUNTERACTS... (4*)

Su1535. . . . SAFETY AND EFFICACY OF COMBINED ENDOSCOPIC... (5*)

Su1536. . . . PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN... (5*)

Su1537. . . . NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING IN PATIENTS... (5*)

Su1538. . . . ASSOCIATION BETWEEN VARICEAL BLEED AND HELICOBACTER... (5*)

Su1539. . . . PENTADECAPEPTIDE BPC 157 COUNTERACTS PORTAL HYPERTENSION... (4*)

Su1571. . . . GABA IN THE GUT: DISTRIBUTION OF... (4*)

Su1572. . . . ENTERIC NERVOUS SYSTEM: A NOVEL NEURO-EPITHELIAL... (4*)

Su1573. . . . CHOLINERGIC-INDUCED ANION SECRETION IN MOUSE JEJUNAL... (2*)

Su1574. . . . CLOSTRIDIODES DIFFICILE INFECTION INDUCES INCREASED S100B... (2*)|(CAPES/PROCAD CAPES/FUNCAP/PRONEX CAPES/PDSE University of Virginia/Department of Infectious Diseases)

Su1575. . . . ESTROGEN INCREASES THE EXPRESSION OF BKCA... (5*)

Su1576. . . . METABOLOMIC PROFILING OF SUBJECTS WITH FUNCTIONAL... (2*)

Su1577. . . . UNDERSTANDING THE ROLE OF BILE ACIDS... (2*)

Su1578. . . . CHRONIC INTRACOLONIC ADMINISTRATION OF LINALOTIDE INHIBITS... (2*)|(Supported by Ironwood Pharmaceuticals Inc, Allergan)

Su1579. . . . ENTERIC NEURONAL SILENT AND MEMORY PROPERTIES... (2*)

Su1580. . . . A LONGITUDINAL STUDY EXAMINING THE EFFECT... (2*)

Su1581. . . . GPCR-CONTAINING B7-2+ EXTRACELLULAR VESICLES FROM IMMUNE... (2*)

Su1582. . . . ANTI-INFLAMMATORY AND EPITHELIAL PROTECTIVE EFFECTS OF... (3*)

Su1583. . . . MORTALITY RISK IN IRRITABLE BOWEL SYNDROME... (7*)

Su1584. . . . PSYCHOLOGICAL, PHYSICAL COMORBIDITIES AND FUNCTIONAL IMPAIRMENT... (2*)|(Study was funded by NIDDK K23 103911 and Intramural Research Program of the NIMH (ZIAHM002806).)

Su1585. . . . RACIAL DISPARITY IN HEALTH CARE UTILIZATION... (5*)

Su1586. . . . RACIAL DISPARITIES IN PATIENTS WITH IRRITABLE... (5*)

Su1587. . . . NEW PATIENT REPORTED OUTCOME MEASURE: DIARY... (3*)|(This study was funded by Allergan plc and Ironwood Pharmaceuticals.)

Su1588. . . . HOW COST AFFECTS TREATMENT CHOICE FOR... (5*)

Su1589. . . . PREDICTIVE FACTORS OF RESPONSE TO RIFAXIMIN... (5*)

Su1590. . . . STUDY ON THE EFFECTIVENESS OF HERBAL... (5*)

Su1591. . . . COMMUNICATION BETWEEN CLINICIANS AND PATIENTS WITH... (3*)|(Synergy Pharmaceuticals)

Su1592. . . . THE INTESTINAL GAS QUESTIONNAIRE (IGQ): PSYCHOMETRIC... (3*)|(Da funded the study)

Su1593. . . . LOW FODMAPS DIET IMPROVES FUNCTIONAL GASTROINTESTINAL... (5*)

Su1594. . . . REDUCTION IN OVERALL HOSPITALIZATIONS FOR FUNCTIONAL... (5*)

Su1595. . . . DIETARY EDUCATION IN FUNCTIONAL GASTROINTESTINAL DISORDERS... (5*)

Su1596. . . . RELATIONSHIP BETWEEN IDEAL (BRISTOL TYPE IV)... (5*)

Su1597. . . . INCREASING INPATIENT BURDEN OF CONSTIPATION AND... (5*)

Su1598. . . . ESTIMATION OF OPIOID USE FOR THE... (3*)|(The funding for this study was provided by Ironwood Pharmaceuticals, Inc. Writing assistance by Complete HealthVizion, funded by Ironwood Pharmaceuticals, Inc.)

Su1599. . . . PANCREATITIS FOLLOWING ELUXADOLINE USE: 1-YEAR REASSESSMENT... (5*)

Su1600. . . . MANAGEMENT OF FUNCTIONAL ABDOMINAL PAIN IN... (5*)

Su1601. . . . DIAGNOSTIC ACCURACY OF TWO HOUR AND... (5*)

Su1602. . . . NOVEL USE OF TIMED BARIUM ESOPHAGRAM... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1603. . . . WHEN ANTEGRADE ENEMAS GO RETROGRADE: SIGNIFICANCE... (5*)
- Su1604. . . . A PRELIMINARY STUDY OF THE IMPACT... (5*)
- Su1605. . . . ALTERATIONS IN BRAIN FUNCTIONAL CONNECTIVITY IN... (2*)
- Su1606. . . . AUTONOMIC NERVOUS SYSTEM RESPONSE IN IRRITABLE... (2*)
- Su1607. . . . SOCIAL STRAIN AND LOW SOCIAL SUPPORT... (4*)
- Su1608. . . . VAGUS NERVES PROVIDE A ROBUST AFFERENT... (2*)
- Su1609. . . . NEUROMODULATION AND COLON MOTILITY MAPPING IN... (2*)
- Su1610. . . . DYSREGULATION OF PARKINSON'S DISEASE RELATED GENES... (2*)
- Su1611. . . . COLORECTAL DISTENSION MODULATES THE PAG FUNCTIONAL... (2*)
- Su1612. . . . EFFECT OF VISCERO-VISCERAL INTERACTION ON FMRI... (2*)
- Su1613. . . . THE ASSOCIATION OF VISCERAL ADIPOSITY WITH... (2*)
- Su1614. . . . HYPOGLYCEMIC EFFECTS OF CHRONIC VAGAL NERVE... (5*)
- Su1615. . . . PROMOTING EFFECTS AND AUTONOMIC MECHANISMS OF... (5*)
- Su1616. . . . ANTI-INFLAMMATORY EFFECTS AND MECHANISMS OF SACRAL... (2*)
- Su1617. . . . NEUROANATOMICAL AND CONNECTIVITY ABNORMALITIES IDENTIFIED IN... (4*)
- Su1618. . . . SEXUALLY DIMORPHIC BRAIN SIGNATURES IN STIMULUS... (2*)
- Su1619. . . . RIKKUNSHITO IMPROVES CCK AND STRESS-INDUCED ANOREXIA... (4*)
- Su1620. . . . NERVE FIBER SPROUTING AND NEURO-IMMUNE INTERACTIONS... (4*)
- Su1621. . . . AMELIORATING EFFECTS OF SACRAL NERVE STIMULATION... (2*)
- Su1622. . . . DETERMINE GINGER CONSTITUENT 6-SHOGAOL-INDUCED EFFECT ON... (5*)
- Su1623. . . . ABNORMAL PERIPHERAL AUTONOMIC AND CENTRAL AUTONOMIC... (2*)
- Su1624. . . . GENETIC ETHNICITY AFFECTS RESPONSE VARIABILITY IN... (4*)
- Su1625. . . . IN VIVO AND IN VITRO EFFECTS... (2*)|(NIH/NIDDK)
- Su1626. . . . POST-STROKE CONSTIPATION IS ASSOCIATED WITH IMPAIRED... (5*)
- Su1627. . . . OPIOID USAGE IS SIGNIFICANTLY ASSOCIATED WITH... (5*)
- Su1628. . . . INVASIVE AND NONINVASIVE VAGAL NERVE STIMULATION... (5*)
- Su1629. . . . THE AGEING GUT: SYMPTOMS COMPATIBLE WITH... (4*)|
- Su1630. . . . SENSORY DOMAINS, NOT STOOL FREQUENCY, PREDICT... (5*)
- Su1631. . . . MACHINE LEARNING WITH PAIN MEASURES ALONE... (5*)
- Su1632. . . . PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: RESULTS... (5*)
- Su1633. . . . LACTOBACILLUS RHAMNOSUS GG SUPERNATANT IMPROVES DEFECATION... (5*)
- Su1634. . . . IRRITABLE BOWEL SYNDROME AND STRUCTURAL ABNORMALITIES... (5*)
- Su1635. . . . ORAL IRON SUPPLEMENTATION, MICROBIOME RELATED METHANOGENESIS... (5*)
- Su1636. . . . THE PLACEBO RESPONSE IN CHRONIC IDIOPATHIC... (5*)
- Su1637. . . . THE RELATIONSHIPS AMONG FECAL MICROBIOTA AND... (2*)|(This study was supported by Dalian municipal science and technology plan project (NO. 2015F11GH098).)
- Su1638. . . . CSP01, A NOVEL SUPERABSORBENT HYDROGEL, REDUCES... (3*)|(Gelesis Inc.)
- Su1639. . . . DAIKENCHUTO (TU-100), A TRADITIONAL JAPANESE HERBAL... (3*)|(Tsumura & Co.)
- Su1640. . . . PERSISTENT IMPROVEMENT IN CHRONIC CONSTIPATION WITH... (5*)
- Su1641. . . . RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL TO... (3*)|(Study sponsored by Bustar Alimentos S.A.P.I de C.V)
- Su1642. . . . SUPERIOR PERFORMANCE OF GASTROINTESTINAL ULTRASOUND OVER... (5*)
- Su1643. . . . DEVELOPMENT OF VALIDATED QUESTIONNAIRE EVALUATING PARENT- PERCEIVED... (4*)
- Su1644. . . . INTEROBSERVER ANALYSIS TRIAL ON COLONIC MOTOR... (4*)
- Su1645. . . . NALOXEGOL RESTORES CODEINE-INDUCED INHIBITION OF HIGH-AMPLITUDE... (4*)|(No industry or commercial source funding was received for this study.)
- Su1646. . . . THE INFLUENCE OF BRAIN METASTASES ON... (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.)
- Su1647. . . . THE INFLUENCE OF AGE ON CENTRAL... (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.)
- Su1648. . . . EFFICACY VARIABLES IN CANCER VERSUS NONCANCER... (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.)
- Su1649. . . . WHY PATIENTS WITH CHRONIC CONSTIPATION OR... (5*)
- Su1650. . . . SACRAL NERVE STIMULATION FOR SLOW TRANSIT... (2*)
- Su1651. . . . A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON... (5*)
- Su1652. . . . CONSTIPATION MANAGEMENT STRATEGIES: CONSUMER PREFERENCES AND... (3*)|(Sanofi)
- Su1653. . . . THE STUDY ON HEALTH-RELATED QUALITY OF... (5*)
- Su1654. . . . THE PREVALENCE OF HLA-DQ GENES, CELIAC... (5*)
- Su1655. . . . ADMINISTRATION OF NEOSTIGMINE AND GLYCOPYRROLATE BY... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1657. . . . FECAL MICROBIAL MARKERS IN COLORECTAL CANCER... (5*)	Su1778. . . . THE TORONTO IBD GLOBAL ENDOSCOPIC REPORTING... (5*)	Su1798. . . . THE INFLUENZA VACCINATION AND PEDIATRIC INFLAMMATORY... (5*)
Su1658. . . . MACHINE LEARNING ENABLES DETECTION OF EARLY-STAGE... (5*)	Su1779. . . . TEXT MESSAGE-BASED TELEMEDICINE DOES NOT IMPROVE... (2*)	Su1799. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND... (3*)
Su1659. . . . POSITIVE FAECAL OCCULT BLOOD TEST AFTER... (5*)	Su1780. . . . INSURANCE GENEROSITY AND INFLAMMATORY BOWEL DISEASE:... (2*)	Su1800. . . . EFFECT OF ADDITION OF AN IMMUNOMODULATOR... (5*)
Su1660. . . . COLORECTAL CANCER SCREENING: COMPLIANCE WITH MULTI-TARGET... (3*) (Exact Sciences)	Su1781. . . . THE ECONOMIC BURDEN OF ULCERATIVE COLITIS... (3*) (Funded by Janssen Scientific Affairs, LLC)	Su1801. . . . A NOVEL SALT OF RESOLVIN E1... (2*) (This work was funded in part by Thetis Pharmaceuticals.)
Su1661. . . . A FAVORABLE SURVIVAL OF THE SCREENING-DETECTED... (5*)	Su1782. . . . REDUCTION OF OPIOID USE AND DEPRESSION... (5*) (There are no industry or commercial sources.)	Su1802. . . . SLCO2A1 DEFICIENCY EXACERBATES EXPERIMENTAL COLITIS VIA... (5*)
Su1662. . . . TIME TO DIAGNOSIS OF EARLY-ONSET VS... (2*)	Su1783. . . . RATES OF TREATMENT INEFFECTIVENESS AFTER INITIATING... (6*)	Su1803. . . . TWEAK/FN14 AMELIORATES EXPERIMENTAL ILEITIS BY REGULATING... (2*)
Su1663. . . . WATER EXCHANGE (WE) ENHANCED DETECTION OF... (2*)	Su1784. . . . REINVENTING INFLAMMATORY BOWEL DISEASE (IBD) CLINICAL... (5*)	Su1804. . . . THE COMMON IBD COMPLICATIONS IRON DEFICIENCY... (2*)
Su1664. . . . HIGH YIELD OF TOTAL AND RIGHT-SIDED... (4*)	Su1785. . . . RECENT TRENDS IN DIAGNOSTIC PREVALENCE AND... (3*)	Su1805. . . . WHEAT AMYLASE/TRYPsin INHIBITORS AGGRAVATE EOSINOPHILIC ESOPHAGITIS... (2*)
Su1665. . . . USE OF SCREENING COLONOSCOPY IN AFRICAN... (5*)	Su1786. . . . REDUCTION IN COSTS OF CARE IN... (3*) (Project Sor is a joint venture between Blue Cross Illinois, SorMD Inc.)	Su1806. . . . BERBERINE REGULATES LYSOPHOSPHATIDYLCHOLINE TO PROTECT DSS-INDUCED... (2*) (This work was kindly funded by grants from tior tural Science Foundation of Chi (Project No. 81560676), Logan Charitable Foundation, Hong Kong Baptist University Research Grant (No. LIUYE/15-16/01-CLNC) and Shenzhen Science and Technology Innovation Commi)
Su1666. . . . PREDICTORS OF MODIFIABLE FAILURES TO SCREEN... (2*)	Su1787. . . . DEVELOPMENT OF A DEEP LEARNING ALGORITHM... (5*)	Su1807. . . . POST-OPERATIVE RECURRENCE AFTER ILEO-CAECAL RESECTION FOR... (5*) (Lesaffre Intertiol, Lesaffre Group, Marcq-en-Barœul, France)
Su1667. . . . INCREASING UPTAKE OF COLON CANCER SCREENING... (5*)	Su1788. . . . MONITORING RESPONSE TO ANTI-TNF THERAPY IN... (3*) (AbbVie Deutschland GmbH & Co. KG)	Su1808. . . . DOWNREGULATION OF RALGTPASE-ACTIVATING PROTEIN LEADS TO... (2*) (Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI))
Su1668. . . . THE CORRELATION OF FIT LEVELS WITH... (5*) (The first author completed this research as part of a Newman Fellowship, which was funded by Boston Scientific.)	Su1789. . . . PATIENTS WHO UNDERGO COLECTOMY FOR PEDIATRIC... (2*)	Su1809. . . . A COMPARISION STUDY OF SYSTEMIC VERSUS... (3*) (Progenity Inc.)
Su1754. . . . OVERESTIMATION OF THE PREVALENCE OF EOSINOPHILIC... (2*)	Su1790. . . . INFLIXIMAB RESCUE LESS EFFECTIVE IN PREVENTING... (2*)	Su1810. . . . COMBINATORIAL TREATMENT WITH A HIF-HYDROXYLASE INHIBITOR... (2*) (Sigmoid Pharma)
Su1771. . . . SYSTEMS GENOMICS OF ULCERATIVE COLITIS: COMBINING... (6*)	Su1791. . . . LONGTERM OUTCOME OF PEDIATRIC PATIENTS WITH... (5*)	Su1811. . . . NOVEL INSIGHT INTO MECHANISM OF PROTECTIVE... (4*) (tior Science Centre, Poland (grant number UMO-2015/19/B/NZ4/03130).)
Su1772. . . . INFLAMMATION-DEPENDENT TRANSCRIPTIONAL RE-PROGRAMMING OF THE HIF... (2*)	Su1792. . . . ELEVATION OF PLASMA ONCOSTATIN M IS... (2*)	Su1812. . . . TREATMENT WITH HYDROLYZED DIET SUPPLEMENTED WITH... (3*) (Bioiberica SAU)
Su1773. . . . INTESTINAL ORGANOIDS DERIVED FROM HUMAN INDUCED... (5*)	Su1793. . . . TRENDS OF UTILIZATION OF TUMOR NECROSIS... (7*)	
Su1774. . . . AN INTERPLAY OF PAK1 AND NRF2... (2*)	Su1794. . . . PROPOSED MODIFICATION OF PARIS CLASSIFICATION TO... (2*)	
Su1775. . . . ARTIFICIAL SWEETENER ACESULFAMEPOTASSIUMENHANCED LYMPHOCYTE MIGRATION TO... (4*)	Su1795. . . . UTILIZATION OF ANTI-TNF THERAPY (BIOLOGICS) IN... (6*)	
Su1776. . . . ASSOCIATION OF BIOLOGIC PRESCRIBING FOR INFLAMMATORY... (5*)	Su1796. . . . ROOM FOR IMPROVEMENT IN TRANSITION OF... (5*)	
Su1777. . . . RECEIPT OF PREVENTIVE CARE SERVICES AMONG... (5*)	Su1797. . . . CHILDREN WITH CROHN'S DISEASE WHO RESPOND... (5*)	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1813. . . THERAPEUTIC EFFICACY OF BILE ACID SEQUESTRATION... (2*)	Science Foundation of Guangdong Province, Chi grant 2016A030313009; Science and Technology Innovation Commission of Shenzhen Municipality, Chi grant JCYJ20150331142757394.)	Su1848. . . CLINICAL CHARACTERISTICS AND RISK FACTORS FOR... (5*)
Su1814. . . DETERMINATION OF MINIMAL EFFICACIOUS DOSES OF... (3*) (Karyopharm Therapeutics)		Su1849. . . RISK OF NEW OR RECURRENT CANCER... (5*)
Su1815. . . GRAPE SEED EXTRACT AND EMU OIL... (4*)	Su1832. . . INHIBITION OF INTESTINAL EPITHELIAL CELL PYROPTOSIS... (3*) (Takeda Pharmaceutical Company Ltd)	Su1850. . . RATE OF SERIOUS INFECTION IN ELDERLY... (4*)
Su1816. . . PROTECTION BY CCR6 BLOCKADE IN A... (4*)	Su1833. . . ELEVATED CAP-D3 LEVELS IN INTESTINAL EPITHELIAL... (2*)	Su1851. . . ANTI-TNF INDUCED LYMPHOCYTOSIS IN PATIENTS WITH... (5*)
Su1817. . . BIOTIN SUPPLEMENTATION AMELIORATES MURINE COLITIS BY... (2*)	Su1834. . . REDUCED AQUAPORIN 5 EXPRESSION IN COLORECTAL... (4*)	Su1852. . . POST-OPERATIVE COMPLICATIONS FOLLOWING ELECTIVE SURGERY IN... (5*)
Su1818. . . PRECLINICAL EFFICACY AND SAFETY OF NX-13:... (5*)	Su1835. . . VEDOLIZUMAB USE IS NOT ASSOCIATED WITH... (3*) (Medical writing assistance was provided by Fraser Harris of Oxford PharmaGenesis, Oxford, UK, and was supported by Takeda Pharmaceutical Company Ltd.)	Su1853. . . TUBERCULOSIS INFECTION UNDER ANTI-TNF THERAPY --... (5*)
Su1819. . . NEW CLASS OF ANTI-INFLAMMATORY THERAPEUTICS BASED... (2*) (Inwex Ltd. is an employer of Remigiusz Szczepaniak)	Su1836. . . HIGH EXPOSURE TO INFLIXIMAB IS ASSOCIATED... (5*)	Su1854. . . PROFILE OF PATIENTS WITH INFLAMMATORY BOWEL... (5*)
Su1820. . . THE EFFECT OF PROBIOTIC LACTOBACILLUS CASEI... (1*) (PROGRES Q40-15 from Charles University.)	Su1837. . . HIGHER DISCONTINUATION RATES OF ANTI-TNF THERAPY... (2*) (The IBDREAM registry is facilitated by Janssen, Pfizer, MSD, Takeda, Celgene, AbbVie, DrFalk, MundiPharma.)	Su1855. . . VEDOLIZUMAB IS NOT ASSOCIATED WITH INCREASED... (5*)
Su1821. . . TARAXACUM OFFICINALE EXTRACTS AMELIORATES MURINE EXPERIMENTAL... (2*)	Su1838. . . COMPARATIVE RISK OF SERIOUS INFECTIONS WITH... (2*)	Su1856. . . A PILOT STUDY COMPARING POSTOPERATIVE OUTCOMES... (5*)
Su1822. . . NP-120 AND NP-178: REPURPOSED NEUROLOGICAL DRUGS... (3*) (SH Pharmaceuticals (a subsidiary of Breathtec Biomedical Inc.))	Su1839. . . RISKS OF CANCERS IN THIOPURINES USERS... (5*)	Su1857. . . COMPARATIVE SAFETY AND EFFECTIVENESS OF TUMOR... (5*)
Su1823. . . TRADITIONAL CHINESE MEDICINE-DERIVED MIRS368 ALLEVIATES ULCERATIVE... (2*)	Su1840. . . HIGHER ADALIMUMAB SERUM LEVELS DO NOT... (4*)	Su1858. . . REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB... (3*) (The study was sponsored by Takeda Pharmaceuticals Company Ltd. Evidera was funded by Takeda Pharmaceuticals Company Ltd to conduct this study and provide medical writing assistance. The abstract was prepared by Evidera; no additiol medical writing assista)
Su1824. . . EFFECT OF ZOFENOPRIL ON ACETIC ACID-INDUCED... (2*)	Su1841. . . FACTORS ASSOCIATED WITH WEIGHT GAIN IN... (5*)	Su1859. . . REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB... (3*) (This study was sponsored by Takeda Pharmaceuticals Company Ltd. Evidera was funded by Takeda Pharmaceuticals Company Ltd to conduct this study and provide medical writing assistance. The abstract was prepared by Evidera; no additiol medical writing assist)
Su1825. . . FIBROBLAST GROWTH FACTOR 21 DEPLETION ATTENUATES... (2*)	Su1842. . . CHARACTERISTICS OF HEPATOSPLENIC T-CELL LYMPHOMA IN... (3*) (Janssen Scientific Affairs, LLC supported this study)	Su1860. . . COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH... (3*) (This study was sponsored by Takeda Pharmaceutical Company, Ltd.)
Su1826. . . SMALL INTESTINAL EPITHELIAL MICROVILLI-ASSOCIATED DEFECTS PRESENT... (2*)	Su1843. . . SAFETY AND EFFICACY OF GLUCAGON-LIKE-PEPTIDE-2 ANALOGUE... (5*)	Su1861. . . COMPARATIVE EFFICACY AND SPEED OF ONSET... (1*)
Su1827. . . ORGANOIDS DERIVED FROM INFLAMED AND NON... (4*)	Su1844. . . HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INFLAMMATORY BOWEL DISEASE... (5*)	Su1862. . . LOW-DOSE METHOTREXATE IS EQUALLY EFFECTIVE AS... (5*)
Su1828. . . MIR-124 MEDIATES THE IMPAIRMENT OF INTESTINAL... (2*)	Su1845. . . HOME INFUSION OF BIOLOGIC MEDICATIONS IN... (5*)	Su1863. . . COMPARATIVE EFFICACY OF VEDOLIZUMAB AND ADALIMUMAB... (5*)
Su1829. . . LACTOBACILLUS ACIDOPHILUS CAUSES AN ENHANCEMENT OF... (2*)	Su1846. . . OUTCOMES OF PREGNANCY IN IBD PATIETNS... (5*)	
Su1830. . . INDUCIBLE NITRIC OXIDE MEDIATED PHOSPHORYLATION REGULATES... (2*)	Su1847. . . RAPID 30-MINUTE INFLIXIMAB INFUSION PROTOCOLS ARE... (1*) (This research was supported by a Pfizer Grant.)	
Su1831. . . ACTIVATION OF ADENOSINE A3 RECEPTOR INHIBITS... (2*) (tural		

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1864. . . . THE FRAGILITY OF LANDMARK RANDOMIZED TRIALS... (5*)

Su1865. . . . REAL-WORLD SHORT-TERM EFFECTIVENESS OF USTEKINUMAB IN... (5*)

Su1866. . . . INTEGRATING EFFICACY AND SAFETY OF VEDOLIZUMAB... (3*)|(Takeda)

Su1867. . . . SUSTAINABILITY OF BIOLOGIC THERAPIES IS LESS... (5*)

Su1868. . . . COMPARATIVE EFFICACY AND SAFETY OF PROBIOTICS... (5*)

Su1869. . . . EFFECT OF THALIDOMIDE ON CLINICAL REMISSION... (5*)

Su1870. . . . IDENTIFYING THE OPTIMAL TREATMENT SEQUENCE WITH... (3*)|(This research was funded by an investigator-initiated grant from Janssen Pharmaceuticals)

Su1871. . . . CURCUMIN USE IN ULCERATIVE COLITIS -... (5*)

Su1872. . . . EVALUATION OF REAL-WORLD MAINTENANCE DOSING FOR... (3*)|(Funded by Janssen Scientific Affairs LLC, USA.)

Su1873. . . . REMISSION TO VEDOLIZUMAB IS NOT HIGHER... (5*)

Su1874. . . . SUBCUTANEOUSLY ADMINISTERED ANTI-TNFS FOR THE TREATMENT... (3*)|(Janssen Inc.)

Su1875. . . . DEVELOPMENT OF TARGETED THERAPEUTIC ANTIBODIES FOR... (3*)|(Progenity Inc.)

Su1876. . . . INFLIXIMAB INDUCTION REGIMES IN STEROID REFRACTORY... (5*)

Su1877. . . . IMPACT OF IMMUNOSUPPRESSIVE THERAPY ON THE... (5*)

Su1878. . . . INTERLEUKIN-33 DELAYS RECOVERY OF MUCOSAL INFLAMMATION... (4*)

Su1880. . . . SECONDARY BILE ACIDS PROTECT AGAINST INTESTINAL... (6*)

Su1881. . . . THE NUCLEAR RECEPTOR LRH-1 IS A... (2*)

Su1882. . . . CYCLIC GMP-AMP SYNTHASE (CGAS) PLAYS A... (2*)

Su1883. . . . COLON IL-33 IS PRIMARILY PRODUCED BY... (2*)

Su1884. . . . COMBINED RNASEQ AND CYTOF ANALYSIS OF... (4*)|(CCFA CDA)

Su1885. . . . ANALYSIS OF HUMAN COLONIC TISSUE AND... (2*)|

Su1886. . . . SACRAL NERVE STIMULATION INHIBITS THE MAPK/NF-KB... (5*)

Su1887. . . . ENDOGENOUS OPIOIDS IN CHRONIC COLITIS INDUCE... (6*)

Su1888. . . . ESTROGEN RECEPTOR β ACTIVATION INHIBITS INFLAMMATION... (2*)

Su1889. . . . T HELPER 2 (TH2)-MEDIATED REGULATION OF... (2*)

Su1890. . . . PREDICTED FECAL MICROBIOTA SIGNATURES ARE ASSOCIATED... (2*)

Su1891. . . . MONOCYTE/MACROPHAGE PHENOTYPIC ALTERATION WITH ENHANCED PRO-INFLAMMATORY... (2*)

Su1892. . . . PERIOSTIN PROMOTES ENDOPLASMIC RETICULUM STRESS-MEDIATED FIBROSIS... (6*)

Su1893. . . . LYSOPHOSPHATIDYLSERINE DETERIORATES MURINE TNBS-INDUCED COLITIS... (5*)

Su1894. . . . THE JAK INHIBITOR-TOFACITINIB INHIBITS SIGNALING PATHWAYS... (3*)|(Pfizer provided support for the study through an independent research grant)

Su1895. . . . TARGETING AMPK β 1 AS A NOVEL STRATEGY... (4*)

Su1896. . . . RECOMBINANT RNASET2 MODULATES IFN γ SECRETION: A... (2*)

Su1897. . . . INTESTINAL IMMUNE CONDITIONING WITH HELMINTHS EMPLOY... (2*)

Su1898. . . . HEPATOCYTE GROWTH FACTOR AND MET, NOVEL... (4*)

Su1899. . . . EXPRESSION PROFILES OF HELPER T-CELL-RELATED GENES... (5*)

Su1900. . . . DIFFERENCES IN INFLAMMATION-RELATED GENE EXPRESSION IN... (3*)|(GlaxoSmithKline Investigator Initiated Grant)

Su1901. . . . SPECIFIC ISOFORMS OF THE LONG NON-CODING... (4*)

Su1902. . . . PHOSPHATASE SHP2 EXACERBATES INTESTINAL INFLAMMATION BY... (2*)

Su1903. . . . EARLY MEASUREMENT OF SERUM CYTOKINES AS... (4*)

Su1904. . . . SELECTIN-INHIBITION BY DOUBLY GLYCOSYLATED LYSOZYME MUTANTS... (5*)

Su1905. . . . B2 STRICTURING BEHAVIOR ASSOCIATED WITH TGF... (2*)

Su1906. . . . MARKERS FOR SEVERE, REFRACTORY CROHN'S DISEASE... (4*)

Su1907. . . . DIAGNOSTIC ACCURACY OF THE SERUM-BASED MUCOSAL... (4*)|(This study was supported in part by a collaborative grant from Prometheus Laboratories Inc, and grants to Drs. Sandborn and Dulai from the Litwin IBD Pioneers Program and American College of Gastroenterology Clinical Research Award. Serum assays for the)

Su1908. . . . A VALIDATED SERUM HEADSPACE METABOLOME PROFILE... (4*)

Su1909. . . . PREDICTING ENDOSCOPIC RESPONSE IN USTEKINUMAB TREATED... (4*)|

Su1910. . . . A NOVEL QUANTITATIVE PROTEIN EXPRESSION PROFILE... (2*)|(nostring Technologies participated in this research under their Technology Access Program (TAP).)

Su1911. . . . IDENTIFICATION OF SERUM PROTEIN BIOMARKERS FOR... (6*)

Su1912. . . . A SEROLOGICAL BIOMARKER OF TYPE VIII... (3*)|(Nordic Bioscience A/S)

Su1913. . . . ANTI-MAA (MALONDIALDEHYDE-ACETALDEHYDE ADDUCTS) IMMUNOGLOBULIN ISOTYPES IN... (4*)

Su1914. . . . ASSOCIATION BETWEEN SEROLOGICAL MARKERS AND RATE... (5*)

Su1915. . . . METABOLOMICS UNCOVERS UNIQUE DISEASE SIGNATURES IN... (2*)

Su1916. . . . ABSENCE OF PERIANAL SYMPTOMS DOES NOT... (5*)

Su1917. . . . CLINICAL AND ENDOSCOPIC FEATURES OF XIAP... (5*)

Su1918. . . . A 1-YEAR CROSS-SECTIONAL INFLAMMATORY BOWEL DISEASE... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1919. . . . MONITORING VITAMIN D METABOLISM IN INFLAMMATORY... (3*)|(Immundiagnostik AG, Bensheim, Germany)
- Su1920. . . . PHENOTYPE CLASSIFYING CROHN'S DISEASE INTO ILEAL... (2*)
- Su1921. . . . VALIDATION OF SCORING SYSTEMS FOR DIFFERENTIATING... (5*)
- Su1922. . . . PERFORMANCE OF A NOVEL FECAL CALPROTECTIN... (3*)
- Su1923. . . . NOVEL ASSOCIATIONS OF PLATELETS WITH CLINICAL... (2*)
- Su1924. . . . THE USE OF ALVIMOPAN AS PROPHYLAXIS... (5*)
- Su1925. . . . NON-ADHERENCE TO MAINTENANCE MEDICATIONS IS COMMON... (2*)
- Su1926. . . . RISK OF INFECTIONS AND HOSPITALISATIONS IN... (5*)
- Su1927. . . . CONTINUING 5-ASA THERAPY IN MODERATE-TO-SEVERE ULCERATIVE... (4*)
- Su1928. . . . TOFACITINIB IMPROVES CLINICAL DISEASE ACTIVITY IN... (5*)
- Su1929. . . . OUTCOMES FOLLOWING INTRAVENOUS STEROID USE IN... (5*)
- Su1930. . . . SAFETY AND EFFICACY OF OLORINAB, A... (3*)|(Are Pharmaceuticals, Inc.)
- Su1931. . . . DOES CORTICOSTEROID THERPAY AFFECT PROGNOSIS IN... (5*)
- Su1932. . . . SAFETY OF RECOMBINANT ZOSTER VACCINE (RZV-SHINGRIX)... (5*)
- Su1933. . . . ANTI-MYCOBACTERIUM PARATUBERCULOUS THERAPY IN CROHN'S DISEASE:... (5*)
- Su1934. . . . SAFETY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE... (3*)
- Su1935. . . . SAFETY AND EFFECTIVENESS OF GRANULOCYTE AND... (3*)
- Su1936. . . . ENDOSCOPIC EVALUATION FOR GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE:... (5*)
- Su1937. . . . THE MANITOBA LIVING WITH IBD STUDY:... (2*)
- Su1941. . . . HELICOBACTER PYLORI CAGA PROTEIN NEGATIVELY REGULATES... (5*)
- Su1942. . . . CRYPTOSPORIDIUM PARVUM INFECTION INDUCES AUTOPHAGY IN... (2*)
- Su1943. . . . LONG-TERM EHEC INFECTION STIMULATES MUCUS PRODUCTION... (5*)
- Su1944. . . . METASTATIC ASSOCIATED COLON CANCER 1 (MACC1)... (2*)
- Su1945. . . . DIFFERENTIAL RESPONSE OF INTESTINAL EPITHELIAL CELLS... (6*)
- Su1946. . . . DISRUPTION OF INTESTINAL EPITHELIUM WITH THE... (2*)
- Su1947. . . . HYA, A METABOLITE OF LINOLEIC ACID... (5*)
- Su1948. . . . CHARACTERISTICS AND INFLUENCING FACTORS OF GUT... (5*)
- Su1949. . . . SMALL INTESTINAL ASPIRATES REQUIRE SPECIFIC TREATMENT... (4*)
- Su1950. . . . RISK FACTORS FOR CENTRAL LINE-ASSOCIATED BLOODSTREAM... (5*)
- Su1951. . . . GLOBAL DISPARITIES AND NEW INDICATIONS IN... (5*)
- Su1952. . . . PATIENTS' PERSPECTIVE AND COMPLIANCE AFFECT THE... (1*)
- Su1953. . . . PATIENT PERCEPTIONS OF FECAL MICROBIOTA TRANSPLANTATION... (5*)
- Su1954. . . . LONG-TERM EFFICACY OF RIFAXIMIN TO MANAGE... (1*)
- Su1955. . . . CLOSTRIDIUM DIFFICILE-ASSOCIATED OUTCOMES AMONG HOSPITALIZED INFLAMMATORY... (5*)
- Su1956. . . . IS DIARRHEA THE ONLY SYMPTOM OF... (5*)
- Su1957. . . . CLOSTRIDIUM DIFFICILE SCREENING IN HOSPITALIZED PATIENTS... (5*)
- Su1958. . . . GEOSPATIAL DISTRIBUTION AND TRENDS IN COMMUNITY... (5*)
- Su1959. . . . TRENDS IN INCIDENCE, MORTALITY, AND COSTS... (5*)
- Su1960. . . . ASSESSMENT OF CLOSTRIDIUM DIFFICILE EPIDEMIOLOGY AMONG... (7*)|(Merck Cada)
- Su1961. . . . COST-EFFECTIVENESS OF TREATMENT REGIMENS FOR CLOSTRIDIUM... (2*)
- Su1962. . . . DOES HIGHER SERUM PROCALCITONIN LEVELS PREDICT... (5*)
- Su1963. . . . AMINO ACID SENSING IS AN ESSENTIAL... (2*)
- Su1964. . . . THE FOOD ADDITIVE EDTA INCREASES INTESTINAL... (7*)
- Su1965. . . . CROHN'S LIKE LYMPHOID REACTION IS ASSOCIATED... (5*)
- Su1966. . . . NOVEL EVIDENCE FOR SERUM MIR-203 LEVELS... (4*)
- Su1967. . . . HIGH RIBOFLAVIN INTAKE PROTECTS AGAINST SESSILE... (2*)
- Su1968. . . . INCREASED PREVALENCE OF TYPE 2 DIABETES... (2*)
- Su1969. . . . PSOAS MUSCLE INDEX AFFECTS THE LONG-TERM... (5*)
- Su1970. . . . THE ASSOCIATION OF LACTOSE INTOLERANCE WITH... (5*)
- Su1971. . . . ASSOCIATION BETWEEN SARCOPENIA AND GASTRIC CARCINOGENESIS:... (5*)
- Su1972. . . . GASTRIC MICROBIOME IN PATIENTS WITH INTESTINAL... (2*)
- Su1973. . . . CAN INTRAGASTRIC BALLOON THERAPY NORMALIZE THE... (5*)
- Su1974. . . . FECAL MICROBIOTA TRANSPLANT IN GRAFT VERSUS... (5*)
- Su1975. . . . GERM-FREE C57BL/6 MICE ARE SUSCEPTIBLE TO... (4*)
- Su1976. . . . IMPACTS OF ADDITIVE FOOD E171 (TITANIUM... (4*)
- Su1977. . . . THE SAFETY AND EFFICACY OF FECAL... (5*)
- Su1978. . . . ASSOCIATION OF FUSOBACTERIUM NUCLEATUM IN COLORECTAL... (2*)
- Su1979. . . . UPREGULATED CLAUDIN-1 EXPRESSION INDUCES GUT DYSBIOSIS... (2*)|
- Su1980. . . . THE NETWORK CONSTRUCTION AND MODULE ORGANIZATION... (2*)
- Su1981. . . . INDUCTION OF SPECIFIC CARCINOGENIC MICRO-RNAS EXPRESSION... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1982. . . MUCOSA-ASSOCIATED MICROBIOTA IN THE UPPER GUT... (1*)
- Su1983. . . LACK OF PREVENTIVE DENTAL CARE IS... (2*)
- Su1984. . . THE DIFFERENCE OF GUT MICROBIOME IN... (5*)
- Su1985. . . PRELIMINARY DATA ON ORAL AND FECAL... (5*)
- Su1986. . . GUT DYSBIOSIS INDUCED ABNORMAL BILE ACIDS... (5*)
- Su1987. . . THE CHANGE OF THE GUT MICROBIOTA... (5*)
- Su1988. . . MUCOSA-ASSOCIATED MICROBIOTA DIVERSITY SIGNIFICANTLY DIFFERS IN... (5*)
- Su1989. . . ASSOCIATIONS BETWEEN GASTROESOPHAGEAL HISTOPATHOLOGY AND THE... (5*)
- Su1990. . . FUSOBACTERIUM NUCLEATUM INFECTION ASSOCIATES WITH TWO... (2*)
- Su1991. . . DIFFERENCES IN THE GASTROESOPHAGEAL MICROBIOME AND... (2*)
- Su1992. . . INFECTION BY PATHOGENIC E. COLI INDUCES... (2*)
- Su1993. . . DIET AND OBESITY RATHER THAN ETHNICITY... (4*)
- Su1994. . . THE COMMON FOOD ADDITIVES SODIUM SULFITE... (6*)
- Su1995. . . HIGH-FAT DIET-INDUCED GUT MICROBIOTA DYSBIOSIS PROMOTE... (2*)
- Su1996. . . ALTERED GUT MICROBIOTA INDUCED BY A... (2*)
- Su1997. . . COCONUT OIL DIET AS ADJUVANT FOR... (2*)
- Su1998. . . EARLY LIFE SOLID FOOD INGESTION REMODELS... (5*)
- Su1999. . . THE EFFECT OF DIETARY FIBER INTAKE... (2*)
- Su2000. . . CROHN'S DISEASE PATIENTS IN REMISSION CONSUMING... (6*)
- Su2001. . . EFFECT OF A MODIFIED AMERICAN DIET... (2*)
- Su2002. . . ALTERATIONS IN THE SMALL BOWEL MICROBIOTA... (4*)
- Su2003. . . MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE... (4*)
- Su2004. . . DISRUPTION OF CIRCADIAN RHYTHM REDUCES THERMOGENESIS... (2*)
- Su2005. . . AGE-RELATED DYSMETABOLISM IS ASSOCIATED WITH CHANGES... (2*)
- Su2006. . . FUSOBACTERIUM NUCLEATUM MAY PROMOTE GLYCOLYSIS VIA... (2*)
- Su2008. . . MECHANISM OF INHIBITION OF VILLUS CELL... (2*)
- Su2009. . . NUTRITIONAL ASSESSMENT IN PATIENTS UNDERGOING GASTRIC... (5*)
- Su2010. . . MORTALITY AND OUTCOMES IN PATIENTS WITH... (3*)|(Study funding provided by Shire)
- Su2011. . . SHORT BOWEL SYNDROME PATIENTS WITH RESIDUAL... (2*)
- Su2012. . . ETIOLOGY OF AND PREDICTIVE FACTORS FOR... (5*)
- Su2013. . . EFFECTS OF GLEPAGLUTIDE, A NOVEL LONG-ACTING... (3*)|(The trial was sponsored by Zealand Pharma, Denmark.)
- Su2014. . . HOME PARENTERAL NUTRITION PATIENTS WITH SEVERE... (5*)
- Su2015. . . EFFECT OF APRAGLUTIDE, A NOVEL LONG-ACTING... (3*)
- Su2016. . . ADIPOSE-DERIVED SECRETOME (ADS) MEDIATES THE STIMULATION... (2*)
- Su2018. . . LONG NON-CODING RNA ZFAS1 PROMOTES PROLIFERATION... (2*)
- Su2019. . . INTESTINAL GROWTH IN GLUCAGON RECEPTOR KNOCKOUT... (6*)
- Su2020. . . NUTRITIONAL CARE PATHWAYS OF PATIENTS WITH... (3*)|(THIS RESEARCH WAS FUNDED BY CALEA, FRESENIUS KABI, UK.)
- Su2021. . . IS HOME PARENTERAL NUTRITION BURDERSOME IN... (3*)|(Calea-Fresenius Kabi)
- Su2022. . . TOLERANCE AND OUTCOME OF NUTRITION SUPPORT... (5*)
- Su2023. . . A RETROSPECTIVE STUDY ON ICU ADMISSION... (5*)
- Su2024. . . USE OF PREOPERATIVE TOTAL PARENTERAL NUTRITION... (5*)
- Su2025. . . SHOULD A DIAGNOSIS OF CANCER PRECLUDE... (5*)
- Su2026. . . HOME PARENTERAL NUTRITION (HPN): INDICATIONS FOR... (5*)
- Su2027. . . PERCUTANEOUS TRANSESOPHAGEAL GASTRO-TUBING AS AN ALTERNATIVE... (5*)
- Su2028. . . NATURAL HISTORY OF PERCUTANEOUS ENTERAL GASTROSTOMY... (5*)
- Su2029. . . USEFULNESS OF BRANCHED-CHAIN AMINO ACID-ENRICHED ENTERAL... (5*)
- Su2039. . . USE OF PATIENT-DERIVED TUMOR XENOGRAFT MODEL... (1*)
- Su2040. . . DIVERSE TUMOR SUSCEPTIBILITY IN COLLABORATIVE CROSS... (2*)
- Su2042. . . DERIVATION OF OESOPHAGEAL ORGANOIDS TO RECAPITULATE... (7*)
- Su2043. . . A NOVEL CANINE INTESTINAL ORGANOID MODEL... (4*)
- Su2044. . . EXOSOMES RELEASED FROM PATIENT-DERIVED ORGANOIDS CONTAIN... (2*)|(This study was supported by JSPS KAKENHI Grant number JP18K15803.)
- Su2045. . . VASCULAR SHUT DOWN EFFECTS OF PHOTODYNAMIC... (5*)
- Su2046. . . MORPHOLOGIC DIFFERENCE OF PATIENTS-DERIVED IMMORTAL ESOPHAGEAL... (2*)
- Su2047. . . FUNCTIONAL LUMEN IMAGING PROBE IS USEFUL... (5*)
- Su2048. . . ENDOSCOPIC RETEROGRADE APPENDICOGRAPY: AN EFFECTIVE DIAGNOSTIC... (5*)
- Su2049. . . NONINVASIVE POINT-OF-CARE MEASUREMENT OF GUT PERMEABILTY... (6*)|(Support received from MediBeacon Inc.)
- Su2050. . . NEAR INFRARED (NIR) FLUORESCENCE READOUTS OF... (3*)|(Abbvie)
- Su2051. . . INTRACOLIC MOLECULAR ULTRASOUND IMAGING FOR NON-INVASIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su2052. . . . ABILITY OF DWI TO CHARACTERIZE BOWEL... (5*)

Su2053. . . . MUCOSAL INTEGRITY TESTING IS A POTENTIAL... (5*)

Su2054. . . . ASSESSMENT OF ENDOSCOPIC BAND LIGATION IN... (5*)

Su2055. . . . CHARACTERIZING INTESTINAL STRICTURES OF CROHN'S DISEASE... (2*)

Su2056. . . . CLINICAL SIGNIFICANCE OF ROBOT CAPSULE ENDOSCOPY... (2*)

Su2057. . . . DIAGNOSTIC YIELD OF VOLUMETRIC LASER ENDOMICROSCOPY... (5*)

Su2058. . . . INTERPRETATION OF VOLUMETRIC LASER ENDOMICROSCOPY IN... (5*)

Su2059. . . . NOVEL MULTI-VIEW IMAGING DEVICE TO IMPROVE... (2*)

Su2060. . . . A NEW SECOND GENERATION ENDOSCOPE FOR... (4*)|(FUJI FILM)

Su2061. . . . A MULTI-SPECTROSCOPIC APPROACH TO DISEASE DIAGNOSIS:... (4*)

Su2062. . . . MEASUREMENT OF MUCOSAL MITOCHONDRIAL OXYGEN DURING... (6*)

Su2063. . . . COLITIS ON CT – DOES THIS... (5*)

Mo1000. . . . IMPACT OF A CITYWIDE BENCHMARKING INTERVENTION... (2*)

Mo1001. . . . COLORECTAL CANCER RISK FACTORS ACCORDING TO... (5*)

Mo1002. . . . THE IMPACT OF A TAILORED INTERVENTION... (5*)

Mo1003. . . . BREATH ANALYSIS CAN BE USED TO... (3*)|(The eNose company supplied the eNose devices free of charge.)

Mo1004. . . . IMPACT OF FIT CUT-OFF VALUES ON... (5*)

Mo1005. . . . HEARTBURN AND THE AMERICAN COLLEGE OF... (5*)

Mo1006. . . . OBSTRUCTION AND PERFORATION AS INITIAL PRESENTATION... (6*)

Mo1007. . . . IDENTIFICATION OF RISK FACTORS FOR EARLY... (5*)

Mo1008. . . . SCREENING FOR HEAD AND NECK SECOND... (5*)

Mo1009. . . . USE OF COMMUNITY HEALTH WORKERS IN... (6*)

Mo1010. . . . INCREASING INCIDENCE OF STAGE I PANCREATIC... (5*)

Mo1011. . . . UTILIZING SOCIAL MEDIA TO SHARE SCIENTIFIC... (4*)|(5)

Mo1100. . . . HYPERURICEMIA AMELIORATES INTESTINAL INFLAMMATION ALONG WITH... (4*)

Mo1101. . . . SUPERIOR MESENTERIC VEIN OCCLUSION IN RATS... (4*)

Mo1102. . . . ASPIRIN AND ISCHEMIA IN THE MURINE... (4*)

Mo1103. . . . RESTRICTIVE EXPRESSION OF METALLOENDOPEPTIDASE ADAM-LIKE DECYSIN... (2*)

Mo1104. . . . THE TRANS-GOLGI NETWORK PROTEIN AFTIPHILIN REGULATES... (2*)

Mo1106. . . . IMMUNOLOGIC DISSECTION OF COLITIS RELATED TO... (2*)

Mo1107. . . . IRON PREVENTS HYPOXIA-INDUCED INFLAMMATION IN THE... (2*)

Mo1108. . . . RESCUE OF RESTITUTION DEFECT IN A... (2*)

Mo1109. . . . SEVERE WOUND CONTRACTION PROMOTES BARRETT'S ESOPHAGUS... (1*)

Mo1110. . . . ER STRESS PATHWAY ACTIVATION AFTER DOXORUBICIN... (2*)

Mo1111. . . . THE METFORMIN INHIBITS MDSC AND M2... (5*)

Mo1112. . . . MICRORNA-24 IS OVEREXPRESSED IN ULCERATIVE COLITIS... (2*)

Mo1113. . . . 3-OXO-C12:2 N-ACYL HOMOSERINE LACTONE, A QUORUM... (4*)

Mo1114. . . . DOXORUBICIN EXPOSURE DECREASES INTESTINAL EPITHELIAL BARRIER... (2*)

Mo1115. . . . PRO-INFLAMMATORY AND PRO-FIBROTIC STEM CELL VARIANTS... (2*)

Mo1116. . . . MOLECULAR CHARACTERIZATION OF COLONIC MAIT CELLS... (4*)

Mo1117. . . . GAVAGE AS-MIR-214-3P REDUCES INFLAMMATION IN EXPERIMENTAL... (2*)

Mo1118. . . . PRESERVATION OF JEJUNAL ACTIVE INTESTINAL STEM... (2*)

Mo1119. . . . THE ROLE OF EXTRACELLULAR DNA IN... (2*)

Mo1120. . . . A TRIAL FOR THE ADMINISTRATION OF... (5*)

Mo1121. . . . PH-DEPENDENT G PROTEIN-COUPLED RECEPTOR GPR68 (OGR1)... (2*)

Mo1122. . . . GENE EXPRESSION PROFILING AND FLOW CYTOMETRY... (4*)

Mo1126. . . . RAPID RECURRENCE OF SYMPTOMS, ENDOSCOPIC FINDINGS,... (2*)

Mo1127. . . . MAST CELLS IN ADDITION TO EOSINOPHILS... (3*)|(Allakos, Inc. This work was also funded in part by the Division of Intramural Research, NIAID, NIH)

Mo1128. . . . VONOPRAZAN SHOWS EFFICACY SIMILAR TO THAT... (5*)

Mo1129. . . . EFFICACY OF BUDESONIDE ORODISPERSIBLE TABLETS FOR... (3*)|(This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany)

Mo1130. . . . BUDESONIDE ORODISPERSIBLE TABLETS CAN EFFECTIVELY INDUCE... (3*)|(This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany.)

Mo1131. . . . CLINICAL AND ENDOSCOPIC CHARACTERISTICS ACCURATELY PREDICT... (2*)

Mo1132. . . . DIETARY ELIMINATION THERAPY IS EFFECTIVE FOR... (2*)

Mo1133. . . . HIGH PATIENT-REPORTED DISEASE BURDEN FOR EOSINOPHILIC... (2*)

Mo1134. . . . ESOPHAGEAL LICHEN PLANUS: DIAGNOSTIC CRITERIA AND... (5*)

Mo1135. . . . ROLE OF REFLUX IN THE PATHOGENESIS... (5*)

Mo1136. . . . EOSINOPHIL COUNT ON BASELINE ENDOSCOPY PREDICTS... (5*)

Mo1137. . . . QUALITY IMPROVEMENT IN THE MANAGEMENT OF... (5*)

Mo1138. . . . A COMPREHENSIVE ASSESSMENT OF EOSINOPHILIC OESOPHAGITIS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1139. . . . CAN IGG4 BE USED AS AN... (5*)

Mo1140. . . . EOSINOPHILIC OESOPHAGITIS IN CHILDREN AND ADULTS:... (5*)

Mo1141. . . . FECAL EOSINOPHIL CATIONIC PROTEIN AS POTENTIAL... (5*)

Mo1142. . . . ACHALASIA IS A COMMON FINDING IN... (5*)

Mo1143. . . . ESOPHAGEAL MOTILITY DISORDERS IN EOSINOPHILIC ESOPHAGITIS... (5*)

Mo1144. . . . EOSINOPHILIC GASTROINTESTINAL DISEASE FOLLOWING INTESTINAL TRANSPLANT... (5*)

Mo1145. . . . EOSINOPHILIC ESOPHAGITIS IS ASSOCIATED WITH A... (5*)

Mo1146. . . . CLINICAL MANIFESTATION, COURSE OF DISEASE AND... (5*)

Mo1147. . . . ASSOCIATION OF ALLERGENIC HOUSING COMPOUNENTS AND... (2*)

Mo1148. . . . ESOPHAGEAL LAMINA PROPRIA FIBROSIS OCCURS IN... (4*)

Mo1149. . . . PREVALENCE OF EOSINOPHILIC ESOPHAGITIS IN CROHN'S... (5*)

Mo1150. . . . SUBSTANTIAL BURDEN OF PSYCHIATRIC COMORBIDITIES AND... (5*)

Mo1151. . . . PSYCHIATRIC COMORBIDITY IS ASSOCIATED WITH DEMOGRAPHIC... (5*)

Mo1152. . . . VALIDATION OF A MODEL TO PREDICT... (2*)

Mo1153. . . . BIOMARKERS OF DISEASE ACTIVITY AND TREATMENT... (5*)

Mo1154. . . . PREVALENCE AND CHARACTERISTICS OF EOSINOPHILIC ESOPHAGITIS... (3*)|(This study was funded by Shire Human Genetic Therapies, Inc.)

Mo1155. . . . PATTERNS OF CARE IN THE MANAGEMENT... (5*)

Mo1156. . . . ENDOSCOPIC FEATURES OF GERD PREDICT PARTIAL... (2*)

Mo1157. . . . THE ASSOCIATION OF EOSINOPHILIC ESOPHAGITIS AND... (5*)

Mo1158. . . . CLINICAL FEATURES AND TREATMENT OUTCOMES ACCORDING... (5*)

Mo1159. . . . LYMPHOCYTIC ESOPHAGITIS: A CASE SERIES OF... (5*)

Mo1160. . . . EATING BEHAVIOR IN PATIENTS WITH EOSINOPHILIC... (5*)

Mo1161. . . . THE ENDOSCOPIC BURDEN OF EOSINOPHILIC ESOPHAGITIS... (5*)

Mo1162. . . . THE ENDOSCOPICALLY NORMAL ESOPHAGUS IN EOSINOPHILIC... (2*)

Mo1163. . . . EG AND EOE PATIENT BIOPSIES HAVE... (3*)|(Allakos, Inc.)

Mo1164. . . . THE UTILITY OF EPITHELIAL EOSINOPHILIC DERIVED... (1*)

Mo1165. . . . THE THIAZOLIDINEDIONES AS POTENTIAL THERAPEUTIC AGENTS... (2*)

Mo1166. . . . DISRUPTION OF ESOPHAGEAL EPITHELIAL BARRIER FUNCTION... (5*)

Mo1167. . . . EFFECT OF VARYING TIME INTERVALS ON... (4*)

Mo1168. . . . SERUM MILK-SPECIFIC IGG4 LEVELS ARE ASSOCIATED... (2*)

Mo1169. . . . AUTOMATED ANALYSIS OF EOSINOPHIL PEROXIDASE FOR... (2*)

Mo1249. . . . INVESTIGATING THE ROLE OF INTEGRINS IN... (2*)

Mo1250. . . . CONTRIBUTION OF THE INTESTINAL EPITHELIUM IN... (2*)

Mo1251. . . . NATIONAL TRENDS AND OUTCOMES OF GASTROINTESTINAL... (5*)

Mo1252. . . . A COMPARISON OF LOGISTIC REGRESSION AND... (5*)

Mo1253. . . . THE RISK OF GASTROINTESTINAL BLEEDING OF... (5*)

Mo1254. . . . GASTROINTESTINAL BLEEDING DURING DIRECT ORAL ANTICOAGULANT... (5*)

Mo1255. . . . GUIDELINE ADHERENCE AND EFFECTS OF ASPIRIN... (5*)

Mo1256. . . . PREVALENCE AND PREDICTORS OF GASTROINTESTINAL BLEEDING... (5*)

Mo1257. . . . RISK OF GASTROINTESTINAL BLEEDING HOSPITALIZATION IN... (5*)

Mo1258. . . . ONLINE SYMPTOM CHECKERS FOR GASTROINTESTINAL BLEEDING:... (5*)

Mo1259. . . . ANTEGRADE DEEP ENTEROSCOPY SHOULD BE CONSIDERED... (5*)

Mo1260. . . . MANAGEMENT OF ACUTE GASTROINTESTINAL BLEEDING IN... (5*)

Mo1261. . . . ENDOSCOPIC AND CLINICAL MANAGEMENT OF GASTROINTESTINAL... (5*)

Mo1262. . . . ADHERENCE TO LOWER GASTROINTESTINAL HEMORRHAGE GUIDELINES... (5*)

Mo1263. . . . ACUTE UPPER GASTROINTESTINAL BLEEDING: EVALUATING PHYSICIAN... (2*)

Mo1264. . . . HELICOBACTER PYLORI INFECTION DECREASES NA,K-ATPASE EXPRESSION... (2*)

Mo1265. . . . DYSBIOSIS OF THE GASTRIC MICROBIOTA IN... (2*)

Mo1266. . . . SOCIO-ENVIRONMENTAL FACTORS AND COLOMBIAN HOST GENE... (2*)

Mo1267. . . . ROLE OF IL-22 IN HELICOBACTER PYLORI-INDUCED... (2*)

Mo1268. . . . VITAMIN K DEFICIENCY IN ANTIBIOTIC-TREATED, H... (2*)

Mo1269. . . . DEVELOPMENT OF NEOPLASIA IN THE ABSENCE... (2*)

Mo1270. . . . PARACRINE LOOPS BETWEEN HELICOBACTER PYLORI, FIBROBLASTS... (4*)|(This study receives funding from Jagiellonian University Medical College (statutory grant).)

Mo1271. . . . THE INFLUENCE OF H. PYLORI INFECTION... (5*)

Mo1272. . . . SHORT-TERM EFFECTS OF AMBIENT FINE PARTICULATE... (4*)

Mo1273. . . . A SYSTEMATIC REVIEW AND META-ANALYSIS. ANALYSING... (5*)

Mo1274. . . . NON-VITAMIN K ORAL ANTICOAGULANTS HAVE LOWER... (1*)

Mo1275. . . . THE EFFECT OF LOW-DOSE ASPIRIN ON... (3*)|(This study was funded by Bayer AG)

Mo1276. . . . NO DIFFERENCES IN GI BLEEDING RISK... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1277. . . . ANTIPLATELET VERSUS ANTICOAGULANT EFFECTS IN NON-VARICEAL... (5*)

Mo1278. . . . UPPER GASTROINTESTINAL BLEEDING IN THE PRESENCE... (5*)

Mo1279. . . . PREDICTION OF DIEULAFOY'S LESION OR PEPTIC... (2*)|(Supported by VA Clinical Merit Review Grant (CLIN – 013-07F) and NIH CURE: DDRC Grant (NIH-NIDDK 41301) Human Studies CORE.)

Mo1280. . . . DEMAND ISCHEMIA IS ASSOCIATED WITH INCREASED... (5*)

Mo1281. . . . THE IMPACT OF URGENT UPPER ENDOSCOPY... (4*)

Mo1282. . . . CHARACTERISTICS OF PATIENTS WITH NON-HELICOBACTER PYLORI... (4*)

Mo1283. . . . ACUTE KIDNEY INJURY IS ASSOCIATED WITH... (5*)

Mo1284. . . . COMPARING OUTCOMES IN UPPER GASTROINTESTINAL BLEEDING... (2*)

Mo1285. . . . RECENT TRENDS IN BLEEDING LOCATION AND... (5*)

Mo1286. . . . CAN CLINICAL FACTORS AND DEMOGRAPHICS DETERMINE... (5*)

Mo1287. . . . CHARLSON COMORBIDITY INDEX, HEMOGLOBIN LEVEL AND... (5*)

Mo1288. . . . THALIDOMIDE IS AN EFFECTIVE TREATMENT FOR... (1*)

Mo1289. . . . INTERMITTENT DOSING OF PROTON PUMP INHIBITOR... (5*)

Mo1290. . . . COMPARISON OF RISK SCORING SYSTEMS IN... (5*)

Mo1291. . . . FACTORS AFFECTING REBLEEDING AND MORTALITY IN... (5*)

Mo1292. . . . END- STAGE RENAL DISEASE IS ASSOCIATED... (5*)

Mo1293. . . . CLINICAL OUTCOMES IN PATIENTS WITH ACUTE... (5*)

Mo1294. . . . RISK FACTORS OF POOR PROGNOSIS AND... (5*)

Mo1295. . . . MANAGEMENT OF ANTITHROMBOTIC THERAPY AFTER GASTROINTESTINAL... (6*)

Mo1296. . . . PROTON PUMP INHIBITOR TREATMENT INITIATED PRIOR... (5*)

Mo1297. . . . SARCOPENIA IS INDEPENDENTLY ASSOCIATED WITH AN... (5*)

Mo1298. . . . DIAGNOSTIC YIELD OF ISOLATED DEAMIDATED GLIADIN... (5*)

Mo1362. . . . PANCREATIC TRIGLYCERIDE LIPASE (PNLIP) MEDIATED UNSATURATED... (4*)

Mo1363. . . . GABA INHIBITED NERVE-ACTIVITY-MEDIATED INSULIN SECRETION: A... (2*)

Mo1364. . . . ECT2 IS REGULATED BY YAP AND... (2*)

Mo1365. . . . SENSITIVITY OF COMPUTERIZED TOMOGRAPHY DURING PRE-DIAGNOSTIC... (5*)

Mo1366. . . . DETECTION AND CHARACTERIZATION OF EARLY DUCT... (2*)

Mo1367. . . . MICRORNA-296-5P PROMOTES EMT PROCESS AND CELL... (2*)

Mo1368. . . . SUCCESSFUL GROWTH OF RECOMBINANT CO-CULTURED PANCREATIC... (5*)

Mo1369. . . . ROLE OF IL-18R AND IL-1R SIGNALING... (2*)

Mo1370. . . . PANCREATIC CANCER DETECTION BY PLASMA ASSAY... (4*)|(Exact Sciences)

Mo1371. . . . SURVIVAL OF RESECTABLE PANCREATIC CANCER: THE... (5*)

Mo1372. . . . GENETIC SUSCEPTIBILITY TO CHRONIC INFLAMMATORY INTESTINAL... (2*)

Mo1373. . . . IS THERE AN ASSOCIATION BETWEEN PREVIOUSLY-IDENTIFIED... (5*)

Mo1374. . . . 12 YEARS OF PROSPECTIVE PANCREATIC CANCER... (4*)

Mo1375. . . . CLINICAL COURSE AND RISK FACTORS OF... (5*)

Mo1376. . . . FAMILIAL PANCREATIC CANCER PATIENTS HAVE BETTER... (5*)

Mo1377. . . . THE CLINICOPATHOLOGIC CHARACTERISTICS OF MUCINOUS CYST... (5*)

Mo1378. . . . AUTOPHAGY INHIBITION ENHANCES ANTIPROLIFERATIVE EFFECT OF... (5*)

Mo1379. . . . NOTABLE FINDINGS FOR EARLY DIAGNOSIS OF... (5*)

Mo1380. . . . THE RELATIONSHIP BETWEEN THE PD-L1 EXPRESSION... (5*)

Mo1381. . . . ANTIOXIDANTS AS POSSIBLE ANTI-PROLIFERATIVE AGENTS FOR... (4*)

Mo1382. . . . SUCCESSFUL ESTABLISHMENT OF PANCREATIC CANCER PATIENT-DERIVED... (4*)

Mo1383. . . . DIAGNOSTIC YIELD OF EUS-FNA FOR SOLID... (5*)

Mo1384. . . . ADULT MOUSE MODEL OF PANCREATIC CANCER... (2*)

Mo1385. . . . IGF-1 (INSULIN LIKE GROWTH FACTOR 1)... (2*)

Mo1386. . . . STATINS INHIBIT PROLIFERATION OF PANCREATIC DUCTAL... (2*)

Mo1387. . . . STATINS INHIBIT YAP ACTIVATION IN RESPONSE... (2*)

Mo1388. . . . TARGETED NEXT GENERATION SEQUENCING FOR PREDICTING... (5*)

Mo1389. . . . DETECTION SYSTEM OF CIRCULATING TUMOR DNA... (6*)|(This study was funded by The Osaka Foundation for The Prevention of Cancer and Life-style related Diseases (Public Interest Incorporated Foundation).)

Mo1390. . . . SYNERGISTIC EFFECT OF VERTEPORFIN-PDT WITH GEMCITABINE... (2*)

Mo1391. . . . CIRCULATING EXTRACELLULAR VESICLE LNCRNA LINC02280 IS... (2*)

Mo1392. . . . THE UTILITY OF HIGH INTENSITY FOCUSED... (5*)

Mo1393. . . . THE AUTOPHAGY-RELATED-PROTEIN VMP1 IS SECRETED IN... (4*)

Mo1394. . . . ROLE OF GENETIC EVALUATION IN CHILDREN... (5*)

Mo1395. . . . METABOLIC REPROGRAMMING AND SUBSEQUENT AUTOPHAGY TRIGGERED... (2*)

Mo1396. . . . THE EXPRESSION OF GNAS IN PANCREATIC... (2*)

Mo1397. . . . DYSFUNCTION OF RAB PROTEINS AND ENDO-LYSOSOMAL... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1398. . . . ACTIVATION OF P21-ACTIVATED KINASE 4 (PAK4)... (2*)	Mo1498. . . . A NOVEL APPROACH FOR THE GENETIC... (5*)	Mo1545. . . . CHARACTERIZATION OF ABDOMINAL PAIN RESPONSE TO... (3*) (Funded by Salix Pharmaceuticals.)
Mo1399. . . . HIGH LEVELS OF AMINO ACIDS (AA)... (2*)	Mo1499. . . . DEOXYCHOLIC ACID-INDUCED SENESCENT HEPATIC STELLATE CELLS... (2*) 	Mo1546. . . . TIME TO ONSET OF TEGASEROD EFFECT... (3*) (US WorldMeds provided funding for this realysis.)
Mo1400. . . . CALCIUM/ CALCINEURIN SIGNALING PATHWAY MEDIATES AUTOPHAGY... (2*)	Mo1500. . . . NRF2 ACTIVATION PROMOTES MUTANT K-RAS/P53 DRIVEN... (5*)	Mo1547. . . . IMPACT OF TRANSANAL IRRIGATION (TAI) DEVICE... (5*)
Mo1401. . . . FLAGELLIN INHIBITS THIAMIN UPTAKE BY PANCREATIC... (2*)	Mo1501. . . . THE RISK OF DEVELOPING PRIMARY HEPATOCELLULAR... (5*)	Mo1548. . . . EFFICACY, FEASIBILITY, AND SAFETY OF THE... (4*)
Mo1402. . . . PREVENTIVE AND THERAPEUTIC EFFECT OF TRAILPEG... (2*)	Mo1502. . . . THE ASSOCIATION OF HEPATOCELLULAR CARCINOMA AND... (5*)	Mo1549. . . . INFANT COLIC MIGHT PREDISPOSE TO BEHAVIORAL... (5*)
Mo1403. . . . DNA PROFILING OF MAIN PANCREATIC DUCT... (5*)	Mo1503. . . . COMPARISON OF SELF-EXPANDING METAL STENTS IN... (5*)	Mo1550. . . . INITIAL EXPERIENCE WITH ABDOMINAL MASSAGE DURING... (5*)
Mo1404. . . . CONCENTRATION CHANGES OF GEMCITABINE METABOLITES COMBINED... (5*)	Mo1504. . . . LONG NON-CODING RNA LINC00152 REGULATES CELL... (2*)	Mo1551. . . . LIFESTYLE, PSYCHOLOGICAL STRESS, AND INCIDENCE OF... (2*)
Mo1405. . . . MICRO-RNA ANALYSIS OF CYST FLUID FOR... (2*)	Mo1505. . . . MALIGNANT HILAR STRICTURES WITH BISMUTH IV... (5*)	Mo1552. . . . COMPLICATIONS OF ANAL SPHINCTER BOTULINUM TOXIN... (5*)
Mo1406. . . . THE CORRELATIONS OF ADIPONECTIN WITH SEVERITY... (5*)	Mo1506. . . . MISCLASSIFICATION OF KLATSKIN TUMORS: DID THE... (5*)	Mo1553. . . . COMPARISON OF ROME III AND ROME... (2*)
Mo1407. . . . PANCREATIC SENESCENT STROMA INFLUENCE ON PROGNOSIS... (5*)	Mo1507. . . . INCREASED SUSCEPTIBILITY TO BET INHIBITION IN... (2*)	Mo1554. . . . CHARACTERIZATION OF THE COLONIC RESPONSE TO... (5*)
Mo1433. . . . CHOLESTATIC JAUNDICE IN NEONATES: HOW COMMON... (5*) (The study requires no funding.)	Mo1508. . . . EXTRAHEPATIC MANIFESTATIONS OF NON-ALCOHOLIC FATTY LIVER... (5*)	Mo1555. . . . PROTON PUMP INHIBITORS REDUCE DUODENAL HYPERPERMEABILITY,... (5*)
Mo1434. . . . CHARACTERIZATION OF PEDIATRIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY... (5*)	Mo1509. . . . NONALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED... (5*)	Mo1556. . . . OPIOID USE DISORDER IS ASSOCIATED WITH... (5*)
Mo1491. . . . NOVEL PREOPERATIVE NOMOGRAMS PREDICT MICROVASCULAR INVASION... (5*)	Mo1510. . . . PREVALENCE AND RISK FACTORS FOR ADVANCED... (4*)	Mo1557. . . . NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)
Mo1492. . . . TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION IMPROVES GASTROINTESTINAL DISTURBANCES... (5*)	Mo1511. . . . ASSOCIATIONS BETWEEN WEIGHT LOSS METHOD, PATIENT... (4*)	Mo1558. . . . FUNCTIONAL DYSPESIA AND DUODENAL EOSINOPHILIA ARE... (4*)
Mo1493. . . . EUS-GUIDED BILIARY DRAINAGE IS NON-INFERIOR TO... (5*)	Mo1539. . . . ASSESSING THE RISK FOR ACUTE ISCHEMIC... (5*)	Mo1559. . . . GENERAL POPULATION PREVALENCE AND CLINICAL CHARACTERISTICS... (5*)
Mo1494. . . . THE CHANGING HISTOLOGICAL FACE OF GALLBLADDER... (5*)	Mo1540. . . . DETERMINANTS OF QUALITY OF LIFE IMPACT... (5*)	Mo1560. . . . APPLYING NUTRIENT DRINK TEST AS A... (4*)
Mo1495. . . . ASPARTATE-β-HYDROXYLASE REGULATES METABOLIC REPROGRAMMING IN HEPATOCELLULAR... (4*)	Mo1541. . . . PLECANATIDE IMPROVED PATIENT GLOBAL RATING OF... (3*) (Synergy Pharmaceuticals, Inc., New York, NY)	Mo1561. . . . PREVALENCE OF CYCLIC VOMITING SYNDROME IN... (5*)
Mo1496. . . . TRENDS IN CURE RATES AMONG MEDICARE... (5*)	Mo1542. . . . PRIMARY BILE ACIDS IN A SINGLE... (4*)	Mo1562. . . . EARLY-LIFE ADVERSITY INDUCES SEX-DEPENDENT GASTRIC HYPERSENSITIVITY... (4*)
Mo1497. . . . PREDICTIVE VALUES OF MUSCLE VOLUME AND... (5*)	Mo1543. . . . THE EFFECT OF LOW FODMAP DIET... (5*)	Mo1563. . . . REGIONAL GASTRIC RETENTION DURING GASTRIC EMPTYING... (5*)
	Mo1544. . . . ASSOCIATION OF CANNABIS AND HEALTH CARE... (5*)	Mo1564. . . . WHICH ANTI-NAUSEA THERAPIES DO PATIENTS BELIEVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1565. . . CONFOCAL LASER ENDOMICROSCOPY IN PATIENTS WITH...** (2*)|(Study supported by Michigan Institute for Clinical and Health Research (MICHR) grant number UL1TR000433)
- Mo1566. . . CHARACTERISTICS OF THE HOT-WATER BATHING PATTERN...** (4*)|
- Mo1567. . . IMPACT OF GENETIC VARIATION IN GLP-1...** (2*)
- Mo1568. . . CORRELATION BETWEEN SLEEP DISTURBANCE IN FUNCTIONAL...** (5*)
- Mo1569. . . EXOSOMAL HSA-MIR-933 IN GASTRIC JUICE AS...** (2*)|(Japan Society for the Promotion of Science(JSPS) KAKENHI Grant Number JP16K09252)
- Mo1570. . . A NOVEL COMBINED NONINVASIVE MULTIPLE GASTRIC...** (5*)
- Mo1571. . . COMPARISON OF GASTRIC SLOW WAVES AND...** (5*)
- Mo1572. . . DELAYED GASTRIC EMPTYING BY WIRELESS MOTILITY...** (3*)|(This study was supported by a grant from Medtronic.)
- Mo1573. . . 3D MRI IMAGING OF THE STOMACH...** (2*)
- Mo1574. . . GASTRIC ELECTRICAL NEUROSTIMULATION COMBINED WITH PYLOROPLASTY...** (5*)
- Mo1575. . . ASSESSMENT OF GASTRIC EMPTYING MOTILITY UTILIZING...** (5*)
- Mo1576. . . GASTRIC EMPTYING RESULTS FROM WIRELESS MOTILITY...** (5*)
- Mo1577. . . ADVANCED GASTRIC EMPTYING SCINTIGRAPHY TO EVALUATE...** (4*)
- Mo1578. . . SURGICAL INTERVENTIONS FOR REFRACTORY GASTROPARESIS: GASTRIC...** (5*)
- Mo1579. . . CLINICAL AND GASTRIC MOTILITY FEATURES IN...** (5*)
- Mo1580. . . EFFECT OF DIETARY INTERVENTION ON PATIENTS...** (4*)
- Mo1581. . . EVALUATION OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC...** (3*)|(The study was funded by Theravance Biopharma US, Inc., while medical writing assistance was provided by Colin Glen of Oxford PharmaGenesis, Oxford, UK and supported by Takeda Pharmaceutical Company Ltd.)
- Mo1582. . . TRANSCUTANEOUS VAGAL NERVE STIMULATION IMPROVES SYMPTOMS...** (4*)
- Mo1583. . . GHRELIN AND MOTILIN DERANGEMENTS DURING WIRELESS...** (7*)|
- Mo1584. . . EFFECTIVENESS OF LANREOTIDE IN THE TREATMENT...** (3*)|(This study was sponsored by Ipsen Pharmaceuticals.)
- Mo1585. . . ROLE OF SEX HORMONES AND THEIR...** (2*)
- Mo1586. . . OPIOID USE DISORDER IS ASSOCIATED WITH...** (5*)
- Mo1587. . . PRUCALOPRIDE VERSUS PLACEBO IN DIABETIC GASTROPARESIS...** (3*)|(Janssen Inc.)
- Mo1588. . . INCREASED SYMPTOM SEVERITY ASSOCIATED WITH THE...** (3*)|(Takeda Pharmaceuticals)
- Mo1589. . . GASTRIC RETENTION IN GASTROPARESIS: RELATIONSHIP OF...** (2*)
- Mo1590. . . BODY WEIGHT AND BODY WEIGHT CHANGES...** (2*)
- Mo1591. . . DOES OTHER END-ORGAN DAMAGE CORRELATE WITH...** (2*)
- Mo1592. . . MARIJUANA USE IN PATIENTS WITH SYMPTOMS...** (2*)
- Mo1593. . . DOCUMENTATION OF PYLORIC SMOOTH MUSCLE DYSFUNCTION...** (5*)
- Mo1594. . . MODELING DELAYED GASTRIC EMPTYING USING WNT1CRE-IDTR...** (2*)
- Mo1595. . . THE IMPACT OF RISK FACTORS ON...** (5*)
- Mo1596. . . A PILOT CHRONIC ANIMAL STUDY OF...** (2*)
- Mo1597. . . THE VIPUN BALLOON CATHETER REVEALS A...** (4*)
- Mo1598. . . THE DIAGNOSIS AND MANAGEMENT OF GASTROPARESIS:...** (5*)
- Mo1599. . . COMBINED GASTRIC ELECTRICAL STIMULATION PYLOROPLASTY IMPROVES...** (5*)
- Mo1600. . . ASSESSING PYLORUS DISTENSION WITH IMPEDANCE PLANIMETRY...** (5*)
- Mo1601. . . GASTROINTESTINAL SYMPTOMS IN CHILDREN DURING GASTRIC...** (5*)
- Mo1602. . . SCINTIGRAPHIC METHODOLOGY USING MID-ANTRUM REGIONS OF...** (5*)
- Mo1603. . . PREVALENCE AND INCIDENCE OF GASTROPARESIS IN...** (3*)|(This study was supported by Takeda Pharmaceuticals Intertiel Inc., All authors are employees of Takeda Pharmaceuticals Intertiel Inc.,)
- Mo1604. . . COMPARISON OF SYMPTOM AND QUALITY OF...** (3*)|(The parent investigation supporting this study was funded by Medtronic (grant MA501).)
- Mo1605. . . CLINICAL CHARACTERISTICS AND GUT PHYSIOLOGY IN...** (4*)
- Mo1606. . . AUTONOMIC AND ENTERIC FUNCTION PROFILING CAN...** (5*)
- Mo1607. . . BASELINE PREDICTIVE FACTORS FOR FORE AND...** (5*)
- Mo1608. . . ALTERED INTESTINAL PERMEABILITY AND EFFECT OF...** (5*)
- Mo1609. . . CAREGIVER BURDEN IN GASTROPARESIS: CORRELATION WITH...** (5*)
- Mo1610. . . CHARACTERIZING SYMPTOMS OF BRAIN FOGGINESS AND...** (5*)
- Mo1611. . . SYMPTOMS OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER...** (5*)
- Mo1612. . . SYMPTOM VARIABILITY THROUGHOUT THE DAY IN...** (5*)
- Mo1613. . . WIRELESS MOTILITY CAPSULE EVALUATION OF REGIONAL...** (5*)
- Mo1614. . . COMPARISON OF GASTRIC ACCOMMODATION MEASUREMENTS BY...** (5*)
- Mo1615. . . FAT-SOLUBLE VITAMINS, B12, AND IRON DEFICIENCY...** (3*)|(Progenity, Inc)
- Mo1616. . . CARDIAC SAFETY AND CLINICAL EFFICACY OF...** (5*)
- Mo1617. . . DIFFERENCES IN PYLORIC DISTENSIBILITY IN PATIENTS...** (5*)
- Mo1618. . . PER-ORAL ENDOSCOPIC PYLOROMYOTOMY FOR SEVERE REFRACTORY...** (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1619. . . . AN INTERNATIONAL SURVEY ON THE DIAGNOSIS... (5*)

Mo1620. . . . DISTENSION-INDUCED GASTRIC SLOW WAVE DYSRHYTHMIAS DEFINED... (2*)

Mo1622. . . . WHICH COMBO WORKS BEST? A COMPARISON... (5*)

Mo1623. . . . THE ROLE OF SOCIAL MEDIA ON... (5*)

Mo1624. . . . ARE PATIENTS WITH NON-COLORECTAL CANCER AT... (5*)

Mo1625. . . . ETHNIC DISPARITIES AND BODY MASS INDEX... (5*)

Mo1626. . . . EFFECT OF DYNAMIC POSITION CHANGES ON... (5*)

Mo1627. . . . COLON CANCER IN YOUNG AMERICANS... (5*)

Mo1628. . . . PROSPECTIVE PRE-COLONOSCOPY BOWEL PREPARATION STUDY COMPARING... (1*)

Mo1629. . . . EVALUATION OF THE DISSEMINATION AND IMPLEMENTATION... (2*)

Mo1630. . . . HISTOLOGY, TOTAL NUMBER OF POLYPS, AND... (5*)

Mo1631. . . . AGE AND GENDER DEPENDENT REDUCTIONS IN... (2*)

Mo1632. . . . INTERVAL COLORECTAL CANCER RATES IN VETERANS... (5*)

Mo1633. . . . SCREENING AND MANAGEMENT OF LYNCH SYNDROME... (5*)

Mo1634. . . . NO INCREASED RISK OF COLORECTAL ADENOMAS... (5*)

Mo1635. . . . REAL-LIFE EXPERIENCE WITH MORE THAN 20000... (5*)

Mo1636. . . . THE ADDITION OF OTHER FAECAL BIOMARKERS... (5*)

Mo1637. . . . SCREENING AND TREATING HELICOBACTER PYLORI INTEGRATED... (2*)

Mo1638. . . . ARE NEGATIVE FECAL IMMUNOCHEMICAL TEST HEMOGLOBIN... (3*)|(Fecal immunochemical tests were provided by Eiken Chemical Company.)

Mo1639. . . . USE OF FECAL IMMUNOCHEMICAL TESTS IN... (3*)|(Fecal immunochemical tests for this study were provided by Eiken Chemical Company.)

Mo1640. . . . DIFFERENT CUT-OFF LEVELS OF FECAL IMMUNOCHEMICAL... (5*)

Mo1641. . . . REPEAT FECAL OCCULT BLOOD TESTS FOR... (2*)

Mo1642. . . . PATIENTS ARE OFTEN UNAWARE OF ABNORMAL... (5*)

Mo1643. . . . CORRELATING QUANTITATIVE FECAL IMMUNOCHEMICAL TEST (FIT)... (5*)

Mo1644. . . . INAPPROPRIATE OUTPATIENT USE OF FECAL IMMUNOCHEMICAL... (5*)

Mo1645. . . . THE FECAL OCCULT BLOOD TEST POSITIVE... (5*)

Mo1646. . . . ASSOCIATION BETWEEN CONCENTRATIONS OF FECAL HEMOGLOBIN... (5*)

Mo1647. . . . FACTORS ASSOCIATED WITH COMPLETION OF MAILED... (2*)

Mo1648. . . . IMPROVING ACCESS TO COLONOSCOPY FOR UNINSURED... (1*)

Mo1708. . . . COMPARISON OF PRESENTING DIAGNOSES AND SYMPTOMS... (2*)

Mo1709. . . . RISK OF COLORECTAL CANCER INCIDENCE AND... (7*)

Mo1710. . . . PREVALENCE OF COLORECTAL NEOPLASIA AMONG PATIENTS... (4*)

Mo1711. . . . REDUCTION OF INCIDENT COLORECTAL CANCER AFTER... (2*)

Mo1712. . . . SURVEILLANCE OF HIGH-RISK POLYPS IN THE... (5*)

Mo1713. . . . SIGNIFICANCE OF FECAL HEMOGLOBIN CONCENTRATION FOR... (5*)

Mo1714. . . . EFFECTIVENESS OF PHONE PROMPT PRIOR TO... (2*)

Mo1715. . . . THE ISRAELI MULTI CENTER SWALLOW AND FORGET STUDY:... (3*)|(Check-Cap Ltd, Isfiya, Israel)

Mo1716. . . . INCIDENCE OF METACHRONOUS SESSILE SERRATED ADENOMAS... (5*)

Mo1717. . . . TRENDS IN EARLY-ONSET COLORECTAL CANCER INCIDENCE... (5*)

Mo1718. . . . RACIAL AND GEOGRAPHIC DISPARITIES IN PANCREATIC... (7*)

Mo1719. . . . ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION... (4*)

Mo1720. . . . INVESTIGATION OF RECOMMENDED ALCOHOL INTAKES AND... (5*)

Mo1721. . . . INCREASING INCIDENCE OF ADVANCED NON-CARDIA GASTRIC... (5*)

Mo1722. . . . ABDOMINAL OBESITY IS ASSOCIATED WITH ESOPHAGEAL... (5*)

Mo1723. . . . PREDICTORS OF STAGE III/IV COLORECTAL CANCER... (5*)

Mo1724. . . . METABOLIC SYNDROME IS ASSOCIATED WITH INCREASED... (2*)

Mo1725. . . . HELICOBACTER PYLORI INFECTION DOES NOT MODIFY... (2*)

Mo1726. . . . CHROMOENDOSCOPY LEADS TO A HIGHER SPIGELMAN-STAGE... (4*)

Mo1727. . . . GENETIC COUNSELING AND GERMLINE TESTING AMONG... (5*)

Mo1728. . . . GENETIC VARIANTS IN DPF3 ARE ASSOCIATED... (5*)

Mo1729. . . . FEASIBILITY OF UTILIZING PREMM SCORE FOR... (5*)

Mo1730. . . . BUTYRATE-TREATED COLON ORGANOIDS FROM FAP SUBJECTS... (4*)

Mo1731. . . . CANCER RISK IN PATIENTS AND FAMILIES... (4*)

Mo1732. . . . GENETIC RISK SCORE TO IDENTIFY INDIVIDUALS... (4*)

Mo1733. . . . PREVALENCE OF GERMLINE MUTATIONS IN PATIENTS... (5*)

Mo1734. . . . COMPARISON OF UNIVERSAL SCREENING YIELD IN... (5*)

Mo1735. . . . LOW RATES OF GENETIC COUNSELING AND... (5*)

Mo1736. . . . MOLECULAR CHARACTERISTICS OF THE DEPRESSED COLORECTAL... (5*)

Mo1737. . . . ALDH2 AND AUTOPHAGY-MEDIATED REDOX HOMEOSTASIS LIMIT... (2*)

Mo1738. . . . NOTCHLESS HOMOLOG1(NLE1), A STEPWISELY UPREGULATED GENE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1739. . . . MOLECULAR MARKERS, MLH1 AND MSI STATUS... (2*)	Bowel Disease Centre of Excellence Award".)	Mo1792. . . . SELF-REPORTED DIETARY BEHAVIORS FOR SYMPTOM MANAGEMENT... (4*)
Mo1740. . . . ALCOHOL AND COLON CANCER: DOES TIME... (2*)	Mo1775. . . . PREVALENCE OF FINANCIAL CONFLICTS OF INTEREST... (5*)	Mo1793. . . . DRIVERS OF HEALTHCARE COST FOR CHILDREN... (5*)
Mo1741. . . . INDUCTION OF WHOLE GENOME DOUBLING WITH... (2*)	Mo1776. . . . SUSTAINED IMPROVEMENTS IN FATIGUE AND QUALITY... (3*) (AMAG Pharmaceuticals, Inc.)	Mo1794. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND... (3*)
Mo1742. . . . PROXIMAL VERSUS DISTAL COLON ADENOCARCINOMA WITH... (5*)	Mo1777. . . . A PROSPECTIVE MULTI-CENTER STUDY ON THE... (4*)	Mo1795. . . . THREE YEAR OUTCOMES OF A COHORT... (5*)
Mo1743. . . . KNOCK-DOWN OF GRANULIN, A NOVEL STAT3-INTERACTING... (5*)	Mo1778. . . . FEMALE GENDER ASSOCIATED WITH LESS-SEVERE CROHN'S... (5*)	Mo1796. . . . VEDOLIZUMAB EXPERIENCE IN CHILDREN AND ADOLESCENTS... (5*)
Mo1744. . . . NLRP6 TARGETING SUPPRESSES COLONIC TUMORIGENESIS VIA... (2*)	Mo1779. . . . TRENDS IN EMERGENCY DEPARTMENT VISITS AND... (3*) (Sponsorship: Janssen Scientific Affairs, LLC)	Mo1797. . . . IMPACT OF PREMEDICATION AND OTHER VARIABLES... (5*)
Mo1745. . . . PATHOLOGICAL IMPACT OF TRANSANAL COLORECTAL TUBE... (5*)	Mo1780. . . . GENDER BIAS IN REFERRAL AND DIAGNOSIS... (2*)	Mo1798. . . . INFLAMMATORY MICROHETEROGENEITY IN UC: IMPLICATIONS FOR... (5*)
Mo1746. . . . 12-LIPOXYGENASE PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION THROUGH THE... (2*)	Mo1781. . . . ROLE OF G PROTEIN-COUPLED RECEPTOR 15... (4*)	Mo1799. . . . UTILITY OF A SIMPLE BLOOD TEST... (5*) (Testing of patient samples was provided by Prometheus Laboratories Inc.)
Mo1764. . . . SERUM N-GLYCOMIC BIOMARKERS PREDICT TREATMENT ESCALATION... (2*)	Mo1782. . . . THE ROLE OF CYCLOOXYGENASE IN COLITIS-ASSOCIATED... (2*)	Mo1800. . . . A SIMPLE SCORING TOOL PREDICTS EXPOSURE-RESPONSE... (3*) (Takeda Pharmaceuticals U.S.A., Inc.)
Mo1765. . . . REAL-LIFE EXPERIENCE WITH LONG-TERM MAINTENANCE OF... (5*)	Mo1783. . . . H. PYLORI-INDUCED PRDX2 PROTECTS AGAINST OXIDATIVE... (4*)	Mo1801. . . . INCORPORATING FECAL CALPROTECTIN IN CLINICAL PRACTICE... (5*)
Mo1766. . . . MULTIDISCIPLINARY TEAM CARE AT THE EMERGENCY... (5*)	Mo1784. . . . THE ROLE OF FOXM1 IN HELICOBACTER... (2*)	Mo1802. . . . TRANSMURAL HEALING ASSESSED USING MRI IS... (5*)
Mo1767. . . . PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS... (5*)	Mo1785. . . . CELLULAR SENESCENCE OF CD4+ T CELLS... (5*)	Mo1803. . . . THE MODIFIED HARVEY-BRADSHAW INDEX AND PARTIAL... (5*)
Mo1768. . . . ELEVATED RISK OF METACHRONOUS NEOPLASIA WITH... (5*)	Mo1786. . . . AGE- AND CANCER-ASSOCIATED OPLAH METHYLATION IS... (5*)	Mo1804. . . . THE ROLE OF FECAL CALPROTECTIN IN... (5*)
Mo1769. . . . OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES... (5*)	Mo1787. . . . THE FUNCTIONAL ROLE OF VEGFR-2 IN... (5*)	Mo1805. . . . INFLAMMATORY BOWEL DISEASE PATIENTS WITH ILEAL... (5*)
Mo1770. . . . ADHERENCE TO GUIDELINES REMAINS POOR AMONG... (5*)	Mo1788. . . . PREVALENCE AND RISK FACTORS OF FIRST-EVER... (5*)	Mo1806. . . . ENDOSCOPIC POUCH ACTIVITY IN ASYMPTOMATIC PATIENTS... (5*)
Mo1771. . . . THE FACTORS ASSOCIATED WITH THE LEVELS... (7*)	Mo1789. . . . INFLAMMATORY REACTION PATTERNS AND MOLECULAR GENETICS... (5*)	Mo1807. . . . MAGNETIC RESONANCE FINGERPRINTING (MRF) IS A... (2*) (Siemens Health)
Mo1772. . . . INCREASED HEALTHCARE UTILIZATION BY MEDICAID PATIENTS... (5*)	Mo1790. . . . MUCOSAL HEALING IS ACHIEVABLE WITH METHOTREXATE... (5*)	Mo1808. . . . RAID-MONITOR TEST IS UNAFFECTED BY GEOGRAPHICAL... (2*)
Mo1773. . . . COST DRIVERS AND TRENDS IN INFLAMMATORY... (6*) (Funding for this initiative is made possible through a grant from the Leo M. and Harry B. Helmsley Charitable Trust and United Health Group.)	Mo1791. . . . BIOLOGIC AND IMMUNOMODULATOR WITHDRAWAL IN PEDIATRIC... (2*) (This Tobacco Formula grant is under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)	Mo1809. . . . DIAGNOSTIC ACCURACY OF FECAL LACTOFERRIN AND... (4*) (Repha GmbH biologische Arzneimittel TechLab Inc)
Mo1774. . . . HEALTHCARE UTILISATION COSTS MAY BE REDUCED... (3*) (This work was supported by a peer reviewed grant from the Gastroenterological Society of Australia funded by Janssen: "Inflammatory		Mo1810. . . . FAECAL CALPROTECTIN CONCENTRATION IN INFLAMMATORY BOWEL... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1811. . . . RAPID POINT-OF-CARE ANTI-DRUG ANTIBODIES MEASUREMENT CORRELATES... (2*)|(1)

Mo1812. . . . CONSIDERATION OF SERUM IGA IN PATIENTS... (5*)

Mo1813. . . . BOTH FECAL IMMUNOCHEMICAL BLOOD TEST AND... (3*)

Mo1814. . . . A COMBINED SET OF FOUR SERUM... (5*)

Mo1815. . . . MODIFIED GLASGOW PROGNOSTIC SCORE IS USEFUL... (5*)

Mo1816. . . . PREDICTION OF ENDOSCOPIC ACTIVITY IN PATIENTS... (5*)

Mo1817. . . . RESPONDER DEFINITIONS FOR THE ULCERATIVE COLITIS... (3*)|(Genentech, Inc.)

Mo1818. . . . TARGETED LIPIDOMIC ANALYSIS OF THE PLASMA... (5*)

Mo1819. . . . PERFORMANCE OF NOVEL MYCOBACTERIAL DETECTION TEST... (5*)

Mo1820. . . . MONITORING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE:... (5*)

Mo1821. . . . THE UTILITY OF MONITR TEST AS... (5*)

Mo1822. . . . ELEVATED ECTODOMAIN OF TYPE 23 COLLAGEN... (5*)|(S. Sun, J.H. Mortensen, M.L. Olesen, M.A. Karsdal and T. Manon-Jensen are employed at Nordic Bioscience A/S which is a company involved in discovery and development of biochemical biomarkers. M.A. Karsdal and T. Manon-Jensen owns stocks at Nordic Bioscienc)

Mo1823. . . . ENDOSCOPIC PATTERNS AND LOCATION OF POST-OPERATIVE... (2*)

Mo1824. . . . HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES... (5*)|(Statistical alyses performed by Roberts Clinical Trials Inc.)

Mo1825. . . . FECAL CALPROTECTIN (FCAL) MONITORING IN ASYMPTOMATIC... (5*)

Mo1826. . . . HOLD THE MAYO, ARE ENDOSCOPISTS TAKING... (5*)

Mo1827. . . . CUMULATIVE HISTOLOGIC INFLAMMATION PREDICTS COLORECTAL NEOPLASIA... (5*)

Mo1828. . . . HISTOLOGIC DISEASE ACTIVITY AT SURGICAL RESECTION... (5*)

Mo1829. . . . DEGRADATION AND FORMATION OF TYPE III,... (5*)

Mo1830. . . . SEROLOGICAL BIOMARKERS OF TYPE VI COLLAGEN... (3*)|(Nordic Bioscience A/S)

Mo1831. . . . MMP-2 AND -8 DEGRADED AND CITRULLINATED-VIMENTIN... (2*)|(The assessment of VICM is done by and at the expense of Nordic Bioscience.)

Mo1832. . . . AN INVERSE CORRELATION OF SERUM FIBROBLAST... (4*)

Mo1833. . . . CAPSULE ENDOSCOPY IMPACT ON THERAPEUTIC DECISIONS... (5*)

Mo1834. . . . VALIDATION OF AN INTEGRAL DISEASE INDEX... (4*)

Mo1835. . . . THE DEVELOPMENT OF A NON-INVASIVE ULTRASONOGRAPHIC... (5*)

Mo1836. . . . CAN CROHN'S PATIENTS BE ACCURATELY PHENOTYPED... (2*)

Mo1837. . . . EFFECT OF UPADACITINIB ON EXTRA-INTESTINAL MANIFESTATIONS... (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the)

Mo1838. . . . CROHN'S DISEASE HAS AN INCREASED RISK... (5*)

Mo1839. . . . RISK FACTORS FOR ACUTE VENOUS THROMBOEMBOLISM... (5*)

Mo1840. . . . INCIDENCE OF ADVERSE PSYCHIATRIC EFFECTS OF... (2*)

Mo1841. . . . SAFETY AND EFFICACY OF ENDOSCOPIC DILATION... (5*)

Mo1842. . . . RELATIVE HAZARD OF CHRONIC KIDNEY DISEASE... (2*)

Mo1843. . . . A SIGNIFICANT DECLINE IN COLECTOMY RATES... (5*)

Mo1844. . . . LONG-TERM FATE OF THE EXCLUDED RECTUM... (5*)

Mo1845. . . . INCREASED RISK OF ADVANCED NEOPLASIA IN... (5*)

Mo1846. . . . ULCERATIVE COLITIS (UC) PATIENTS WITH PRIMARY... (4*)

Mo1847. . . . NUTRITIONAL INDICATORS AND POSTOPERATIVE OUTCOMES IN... (5*)

Mo1848. . . . EXTRAINTESTINAL MANIFESTATIONS AND THEIR IMPACT ON... (3*)|(Pfizer Inc)

Mo1849. . . . LONG-TERM OUTCOMES OF STEROID-RESPONSIVE AND NON-RESPONSIVE... (5*)

Mo1850. . . . PREOPERATIVE ANTI-TNFS ARE ASSOCIATED WITH A... (5*)

Mo1851. . . . THE TREATMENT OF PERIANAL FISTULAS BY... (5*)

Mo1852. . . . INVESTIGATION OF CORRELATION BETWEEN POUCH WALL... (5*)

Mo1853. . . . OPPORTUNISTIC INFECTIONS IN INFLAMMATORY BOWEL DISEASE:... (5*)

Mo1854. . . . WEEKEND DISCHARGES AND HOSPITAL READMISSIONS FOR... (5*)

Mo1855. . . . HOSPITALIZATION OUTCOMES FOR INFLAMMATORY BOWEL DISEASE... (5*)

Mo1856. . . . BIG DATA ANALYTICS IDENTIFIES ULCERATIVE COLITIS... (2*)

Mo1857. . . . 7ALPHA-HYDROXY-4-CHOLESTEN-3-ONE FOR DIAGNOSIS AND MANAGEMENT OF... (5*)

Mo1858. . . . OUTCOMES OF ACUTE PANCREATITIS IN INFLAMMATORY... (5*)

Mo1859. . . . DOES A POSITIVE CLOSTRIDIODES DIFFICILE RESULT... (6*)

Mo1860. . . . PREGNANT WOMEN WITH IBD HAVE WORSE... (5*)

Mo1861. . . . THE RISK OF ECTOPIC PREGNANCY IN... (5*)

Mo1862. . . . NO INCREASED RATES OF ADVERSE IBD-RELATED... (5*)

Mo1863. . . . EXTRAINTESTINAL MANIFESTATIONS AND QUALITY OF LIFE... (3*)|(The authors & AbbVie scientists designed the study, & alysed & interpreted the data. AbbVie funded the research & provided writing support. All authors contributed to the development of the content. The authors & AbbVie reviewed & approved the abstract; t)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1864. . . . INCREASING RATES OF INFECTIVE ENDOCARDITIS IN... (5*)|(There are no industry or commercial sources of funding.)

Mo1865. . . . PREDICTORS OF 30-DAY READMISSION ASSOCIATED WITH... (5*)

Mo1866. . . . PREDICTORS OF 30 DAYS READMISSIONS AFTER... (5*)

Mo1867. . . . THE IMPORTANCE OF MONITORING THE POSTPARTUM... (3*)|(UCB Sponsored)

Mo1868. . . . METHYLATION PATTERNS IN DYSPLASIA IN INFLAMMATORY... (7*)

Mo1869. . . . SCREENING, PREVALENCE AND INAPPROPRIATE IRON SUPPLEMENTATION... (5*)

Mo1870. . . . ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY... (4*)|(5)

Mo1871. . . . THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE... (5*)

Mo1872. . . . THE REGULATORY ROLE OF POLYCOMB REPRESSIVE... (2*)

Mo1873. . . . THE CONSTITUTIVE ANDROSTANE RECEPTOR (CAR) ACTS... (2*)

Mo1874. . . . INCREASED NCR+ ILC3 LEVELS AFTER BIOLOGICAL... (2*)

Mo1875. . . . IDENTIFICATION AND VALIDATION OF NOVEL CROHN'S... (2*)

Mo1876. . . . EXPRESSION OF CD69 ON PERIPHERAL LYMPHOCYTES... (4*)|(Unrestricted research grant from Janssen Cilag)

Mo1877. . . . TUMOR NECROSIS FACTOR α AND IL-17A... (4*)

Mo1878. . . . LYMPHOCYTE ACTIVATION GENE (LAG)-3 ON T... (3*)|(This project is funded by GlaxoSmithKline.)

Mo1879. . . . METHYLTRANSFERASE G9A AS AN EPIGENOMIC REGULATOR... (2*)

Mo1880. . . . ULCERATIVE COLITIS PATIENTS ARE CHARACTERIZED BY... (2*)

Mo1881. . . . MULTIOMICS ANALYSIS OF IBD ENDOSCOPIC BIOPSIES... (3*)|(Interfunding by Bristol Myers Squibb)

Mo1882. . . . IMMUNE CELL AND CHECKPOINT SIGNATURES IN... (3*)|(Study was performed in collaboration with Roche Pharma Research and Early Development,

Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. No specific funding was received)

Mo1883. . . . CLINICAL RESPONSE TO USTEKINUMAB IN CROHN'S... (5*)

Mo1884. . . . DIETARY WHEAT ALPHA-AMYLASE/TRYPsin INHIBITORS INDUCE SYSTEMIC... (2*)

Mo1885. . . . CHRONIC INFLAMMATION PROMOTES INTESTINAL MACROPHAGES TO... (4*)

Mo1886. . . . FLAGELLIN-ACTIVATED CD4 CELLS IN REMISSION CROHN... (2*)

Mo1887. . . . USTEKINUMAB ENDOSCOPIC RESPONSE AT WEEK 16... (3*)|(Truvion Healthcare (Preventis))

Mo1888. . . . IMPROVEMENT IN RADIOGRAPHIC SMALL BOWEL INFLAMMATION... (5*)

Mo1889. . . . YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE... (2*)

Mo1890. . . . USING THERAPEUTIC DRUG MONITORING TO PREDICT... (5*)

Mo1891. . . . POST-MARKETING SAFETY EXPERIENCE OF VEDOLIZUMAB IN... (3*)|(Medical writing assistance was provided by Alex Kisbey of Oxford PharmaGenesis, Oxford, UK and was supported by Takeda Pharmaceutical Company Ltd.)

Mo1892. . . . NON-MEDICAL REVERSE SWITCH BETWEEN THE ORIGINATOR... (4*)|(Fincial Support: This work was supported by NKFIH-OTKA (Hungarian Scientific Research Fund) Research Grant (Grant ID: K115345). This work was supported by the ÚNKP-18-3-I New tiol Excellence Program of the Ministry of Human Capacities, Hungary.)

Mo1893. . . . PERIPHERAL BLOOD EOSINOPHILIA FUNCTIONS AS A... (2*)

Mo1894. . . . EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT... (6*)

Mo1895. . . . EFFICACY OF INTRAVENOUS USTEKINUMAB RE-INDUCTION IN... (5*)

Mo1896. . . . VEDOLIZUMAB INDUCED ENDOSCOPIC REMISSION IN ANTI-TNF... (5*)

Mo1897. . . . BIOLOGICAL THERAPIES IN CHRONIC ANTIBIOTIC-REFRACTORY POUCHITIS... (5*)

Mo1898. . . . EVALUATION OF BODY MASS INDEX AND... (5*)

Mo1899. . . . PROGNOSTIC FACTORS FOR LONG-TERM ADALIMUMAB TREATMENT... (5*)

Mo1900. . . . TNF- α INHIBITORS AND RISK OF TYPE... (6*)

Mo1901. . . . ANTI-TNF DOSE AUGMENTATION INCIDENCE AND PERSISTENCE... (5*)

Mo1902. . . . MOOD AND ANXIETY DISORDERS AND PERSISTENCE... (6*)|(Crohn's and Colitis Cada, CIHR)

Mo1903. . . . THE RATES OF ANTI-TNF DOSE AUGMENTATION... (6*)|(Crohn's and Colitis Cada)

Mo1904. . . . CONCOMITANT STEROID THERAPY WITH ANTI-TNF THERAPY... (4*)

Mo1905. . . . A RETROSPECTIVE STUDY TO EXAMINE THE... (3*)|(AbbVie Pharmaceuticals S.A. (Greece))

Mo1906. . . . COMBINATION THERAPY OF VEDOLIZUMAB AND TOFACITINIB... (5*)

Mo1907. . . . EVALUATION OF USTEKINUMAB TREATMENT PATTERNS AMONG... (3*)|(Funded by Janssen Scientific Affairs, LLC.)

Mo1908. . . . NONBIOLOGIC DRUG USE BEFORE AND AFTER... (3*)|(Funded by Janssen Scientific Affairs, LLC, Horsham, PA, USA)

Mo1909. . . . EVALUATION OF HEALTH CARE UTILIZATION, HOSPITALIZATION/... (3*)|(Funded by Janssen Scientific Affairs, LLC.)

Mo1910. . . . LONG-TERM CLINICAL EFFICACY OF USTEKINUMAB IN... (5*)|(No industry or commercial sources to report)

Mo1911. . . . SERUM BILE ACIDS PROFILING IN IBD... (5*)

Mo1912. . . . VEDOLIZUMAB IN ELDERLY PATIENTS WITH INFLAMMATORY... (5*)

Mo1913. . . . TWO YEAR EXPERIENCE WITH VEDOLIZUMAB IN... (4*)

Mo1914. . . . USTEKINUMAB IS EFFECTIVE FOR THE TREATMENT... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1915. . . . LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR... (5*)	Mo1934. . . . UNEXPLAINED CHRONIC ABDOMINAL PAIN IN 50-YEAR-OLD... (5*)	Mo1957. . . . EFFECT OF LYOPHILIZED STERILE FECAL FILTRATE... (6*)
Mo1916. . . . EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR... (5*)	Mo1939. . . . PERIPARTUM CLOSTRIDIODES DIFFICILE INFECTION AND ITS... (5*)	Mo1958. . . . TOXIN A AND B COMBINED WITH... (5*)
Mo1917. . . . USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES... (5*)	Mo1940. . . . CLOSTRIDIUM DIFFICILE INFECTION MIMICS INTESTINAL ACUTE... (5*)	Mo1959. . . . A META-ANALYSIS OF THE SAFETY AND... (5*)
Mo1918. . . . CAN WE STOP ANTI-TUMOUR NECROSIS FACTOR... (5*)	Mo1941. . . . TREATMENT FOR REDUCING RECURRENCE OF C... (5*)	Mo1960. . . . CORTICOSTEROIDS AND ADVERSE OUTCOMES IN INFLAMMATORY... (5*)
Mo1919. . . . USTEKINUMAB EFFICIENCY AS A HIGHER-LINE THERAPY... (5*)	Mo1942. . . . CLOSTRIDIUM DIFFICILE OF THE ILEAL POUCH... (5*)	Mo1961. . . . INPATIENT MANAGEMENT OF SEVERE CLOSTRIDIUM INFECTION... (2*)
Mo1920. . . . RESULTS OF INTERIM ANALYSIS OF A... (5*)	Mo1943. . . . COLONOSCOPY-BASED FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY... (5*)	Mo1962. . . . MORBID OBESITY INCREASES 30-DAY READMISSION AND... (5*)
Mo1921. . . . TNF- α INHIBITORS HAVE SIMILAR EFFECTIVENESS IN... (5*)	Mo1944. . . . ADHERENCE TO THE TESTING GUIDELINES FOR... (5*)	Mo1963. . . . DOES ADDITION OF METRONIDAZOLE TO ORAL... (5*)
Mo1922. . . . SUPPLEMENTATION WITH BUTYRATE PRODUCING BACTERIA REDUCES... (4*)	Mo1945. . . . THE INFLUENCE OF PETS ON RISK... (1*)	Mo1964. . . . COMPARISON OF IN-VITRO PHOTODYNAMIC BACTERICIDAL EFFECT... (2*) (Small Grant Exploratory Research, Korea)
Mo1923. . . . LONG-TERM SAFETY OF FECAL MICROBIOTA TRANSPLANTATION... (5*)	Mo1946. . . . RECONSTITUTION OF PREBIOTIC-DRIVEN HOST-MICROBE SYNTROPHY IN... (4*)	Mo1965. . . . EVIDENCE FOR CELLULAR ENGRAFTMENT IN GI... (4*)
Mo1924. . . . CLOSTRIDIUM BUTYRICUM PROMOTES LIGANDS RELEASE FROM... (5*)	Mo1947. . . . TAXONOMIC AND FUNCTIONAL INTESTINAL DYSBIOSIS IN... (7*)	Mo1966. . . . INSTITUTIONAL EXPERIENCE WITH CAPSULE FECAL MICROBIOTA... (5*)
Mo1925. . . . TRANSGENERATIONAL IMPACTS OF ORAL PROBIOTICS ADMINISTRATION... (5*)	Mo1948. . . . GUT MICROBIOTA COMPOSITION AT DIAGNOSIS PREDICTS... (2*)	Mo1967. . . . DISPARITIES IN MANAGEMENT OF CLOSTRIDIODES DIFFICILE... (5*)
Mo1926. . . . A SINGLE CENTER EXPERIENCE: FECAL MICROBIOTA... (5*)	Mo1949. . . . DECREASED COMPLEXITY OF SERUM N-GLYCAN STRUCTURES... (4*)	Mo1968. . . . FECAL MICROBIOTA TRANSPLANTATION FOR TREATMENT OF... (5*)
Mo1927. . . . CITROBACTER RODENTIUM INDUCES CD4+ TISSUE RESIDENT... (4*)	Mo1950. . . . POSITIVE ENZYME IMMUNOASSAY (EIA) TOXIN TESTING... (4*)	Mo1969. . . . GASTROSTOMY TUBE PLACEMENT (GTP) AND ITS... (5*)
Mo1928. . . . TOLL-LIKE RECEPTOR2-MEDIATED ACCELERATION OF INTESTINAL MUCOSAL... (2*)	Mo1951. . . . FECAL MICROBIOTA TRANSPLANT DECREASES MORTALITY IN... (5*)	Mo1970. . . . EFFICACY OF COLONOSCOPY, NASOGASTRIC TUBE, ENEMA,... (5*)
Mo1929. . . . CANDIDA ALBICANS SC5314 INHIBITS NLRP3/NLRP6 INFLAMMASOME... (2*)	Mo1952. . . . EFFICACY OF ORAL VANCOMYCIN PROPHYLAXIS FOR... (5*)	Mo1971. . . . IN VITRO AND IN VIVO VIRULENCE... (2*) (Nil)
Mo1930. . . . HARNESSING ANTI-INFLAMMATORY GUT BIOACTIVES TO MODULATE... (4*)	Mo1953. . . . GROWTH INHIBITION OF CLOSTRIDIODES DIFFICILE BY... (4*)	Mo1972. . . . AN ANALYSIS OF LONG-TERM EFFICACY AND... (5*)
Mo1931. . . . URINE METABOLOMIC SIGNATURES DIFFERENTIATE PREGNANCY FROM... (5*)	Mo1954. . . . FECAL MICROBIOTA TRANSPLANTATION IS SAFE AND... (5*)	Mo1973. . . . PREDICTORS OF TREATMENT FAILURE IN FECAL... (5*)
Mo1932. . . . MECHANISTIC INSIGHT INTO BACTERIAL HTPG-HOST INTERACTIONS... (2*)	Mo1955. . . . VE303, A LIVE BIOTHERAPEUTIC PRODUCT FOR... (3*) (Vedanta Biosciences Inc.)	Mo1974. . . . CLOSTRIDIUM DIFFICILE INFECTION (CDI) IS ASSOCIATED WITH... (5*)
Mo1933. . . . ASSOCIATION BETWEEN PRENATAL ANTIBIOTICS EXPOSURE AND... (5*)	Mo1956. . . . CONSTIPATION IS A COMPLICATION OF ORAL... (5*)	Mo1975. . . . INPATIENT COSTS ASSOCIATED WITH C. DIFFICILE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1977. . . . THE EFFECT OF ANTI-INFLAMMATORY PROPERTIES OF... (5*)	Mo1996. . . . ASSESSING SEVERITY AND HEALTHCARE RESOURCE UTILIZATION... (3*) (Takeda Pharmaceuticals Intertiol Co.)	Mo2017. . . . ANTIMICROBIAL PEPTIDE ELAFIN REVERSES OBESITY, INSULIN... (2*)
Mo1978. . . . OUTCOMES OF FECAL MICROBIOTA TRANSPLANTATION FOR... (5*)	Mo1997. . . . ACUTE PANCREATITIS WITH CELIAC DISEASE: HAS... (5*)	Mo2018. . . . HEPATOCYTE-SPECIFIC OVEREXPRESSION OF FADS1 ATTENUATED DIETARY... (2*)
Mo1979. . . . HOSPITAL - ONSET CLOSTRIDIUM DIFFICILE INFECTION... (5*)	Mo1998. . . . CELIAC AUTOIMMUNITY AND PREGNANCY OUTCOMES... (5*)	Mo2019. . . . DEFINING CLINICALLY SIGNIFICANT WEIGHT REGAIN AFTER... (5*)
Mo1980. . . . VOLUME OF FECAL FILTRATE FOR FECAL... (5*)	Mo1999. . . . PREVALENCE OF CELIAC DISEASE (CD) IN... (5*)	Mo2020. . . . CHARACTERISTICS OF A CASH-PAY GI-BASED MEDICAL... (5*)
Mo1981. . . . ETIOLOGIES, TRENDS AND SHORT-TERM OUTCOMES OF... (5*)	Mo2000. . . . INCIDENCE OF CELIAC DISEASE IS INCREASING... (6*)	Mo2021. . . . NUMBER OF FOLLOW-UP VISITS IS INDEPENDENTLY... (5*)
Mo1982. . . . GENDER DIFFERENCES IN FECAL BACTERIOME AND... (4*)	Mo2001. . . . EPIDEMIOLOGY OF PATIENTS ADMITTED FOR CELIAC... (5*)	Mo2022. . . . WEIGHT LOSS ADVICE FOR FATTY LIVER... (5*)
Mo1983. . . . THE UTILITY OF IGA BASED SEROLOGIC... (5*)	Mo2002. . . . CELIAC DISEASE: ENHANCING EDUCATIONAL SUPPORT FOR... (5*)	Mo2023. . . . ASSOCIATION BETWEEN OBESITY AND RISK OF... (5*)
Mo1984. . . . SYMPTOM PROFILES, GLUTEN FREE DIET ADHERENCE,... (5*)	Mo2003. . . . COMPARISON OF QUALITY OF CELIAC DISEASE... (5*)	Mo2024. . . . OBESITY PROLONGS HOSPITALIZATION IN CHRONIC PANCREATITIS... (5*)
Mo1985. . . . MINIMALLY-INVASIVE MONITORING OF INTESTINAL VILLOUS HEALTH... (3*)	Mo2004. . . . HOW ARE CELIAC DISEASE PATIENTS FOLLOWED... (5*)	Mo2025. . . . COLORECTAL CANCER SCREENING RATES ARE LOWER... (4*)
Mo1986. . . . LATIGLUTENASE IMPROVES QUALITY OF LIFE IN... (3*) (Immunogenics LLC (dba ImmunogenX))	Mo2005. . . . ASSESSMENT OF PARENTAL GLUTEN-FREE DIET KNOWLEDGE... (6*)	Mo2026. . . . EFFECTIVENESS OF ANTI-OBESITY MEDICATIONS IN "REAL... (2*)
Mo1987. . . . RESPONDER ANALYSIS FOR LATIGLUTENASE REDUCTION IN... (3*)	Mo2006. . . . AN EDUCATIONAL APP TO SUPPORT THE... (6*)	Mo2027. . . . HIGH STRESS LEVEL IS ASSOCIATED WITH... (5*)
Mo1988. . . . USE OF CLADRIBINE FOR ULCERATIVE JEJUNITIS... (5*)	Mo2007. . . . COMPARISON OF CELIAC DISEASE PATIENT SATISFACTION... (5*)	Mo2028. . . . A STRUCTURED, COMPREHENSIVE LIFESTYLE INTERVENTION PROGRAM... (5*)
Mo1989. . . . ASSESSMENT OF NOVEL CANDIDATE BIOMARKERS OF... (4*)	Mo2008. . . . BLENDERIZED DIETS ARE ASSOCIATED WITH IMPROVED... (5*)	Mo2029. . . . OCTREOTIDE AMELIORATES OBESITY-INDUCED PANCREATIC STEATOSIS VIA... (5*)
Mo1990. . . . ADHERENCE TO THE GLUTEN-FREE DIET AND... (3*) (Takeda Pharmaceutical Company)	Mo2009. . . . ASSOCIATION BETWEEN COLORECTAL ADENOMA AND NONALCOHOLIC... (2*)	Mo2030. . . . COST-EFFECTIVENESS OF EARLY INITIATION AND/OR MORE... (4*)
Mo1991. . . . CO-LOCALISATION OF IGA AND IGG ANTI-TISSUE... (4*)	Mo2010. . . . THE IMPACT OF ADJUSTABLE INTRAGASTRIC BALLOON... (2*)	Mo2031. . . . A FUNCTIONAL SCREENING APPROACH FOR ANIT-OBESITY... (4*)
Mo1992. . . . SOLVING THE STAIN DILEMMA: COMPUTATIONAL IMAGE... (4*)	Mo2011. . . . SMALL INTESTINAL MICROBIAL SHIFTS TOWARDS BILE-TOLERANT-ASSOCIATED-MICROBIOTA... (2*) (NIDDK r01 21769 NIDDK r01 29867)	Mo2032. . . . INTESTINAL ELECTRICAL STIMULATION ALTERS HYPOTHALAMIC EXPRESSIONS... (2*)
Mo1993. . . . HEALTHCARE UTILIZATION AND COMORBIDITIES AMONG PEOPLE... (5*)	Mo2012. . . . HIGH-FAT DIET REDUCES BROWN ADIPOSE TISSUE... (2*)	Mo2041. . . . ARTIFICIAL INTELLIGENCE AUGMENTS REAL-TIME HISTOLOGY OF... (2*)
Mo1994. . . . IS THE INCREASE IN CELIAC DISEASE... (5*)	Mo2013. . . . HEPATIC AGO2 IS INDISPENSABLE FOR NASH... (2*)	Mo2042. . . . CHROMOENDOSCOPY REDUCES THE SUBSEQUENT RISK OF... (4*)
Mo1995. . . . THE POSITIVE AND NEGATIVE RIPPLE-EFFECT OF... (4*)	Mo2014. . . . COMPARATIVE EFFECTS OF BAR502, A DUAL... (5*)	Mo2043. . . . IMAGE ENHANCED ENDOSCOPY DOES NOT IMPROVE... (5*)
	Mo2015. . . . THE ROLE OF SMALL INTESTINAL BACTERIA... (5*)	Mo2044. . . . 0.02 VITAMIN C SOLUTION SPRAY FOR... (2*)
	Mo2016. . . . THE TGF- β /SMAD3 ADAPTOR SPTBN1 AND ALDH2... (2*)	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo2045. . . . MACHINE-LEARNING-BASED AUTOMATIC DIAGNOSTIC SYSTEM USING LINKED... (5*)	Tu1006. . . . DEVELOPMENT OF AN EVIDENCE-BASED STRATEGY INCORPORATING... (4*)	Tu1029. . . . IMPACT OF SPECIFIC TEACHING STRATEGIES ON... (5*)
Mo2046. . . . AUTOMATED REAL TIME ENDOSCOPIC SCORING BASED... (5*)	Tu1007. . . . PATIENT-INITIATED ELECTRONIC MESSAGING WITH PHYSICIANS IS... (5*)	Tu1030. . . . A LOOK AT HOW ENDOCUFF AFFECTS... (5*)
Mo2047. . . . AUTOMATED DETECTION OF ABDOMINAL FREE FLUID... (5*)	Tu1008. . . . PROXIMAL NEOPLASIA YIELD AMONG SUBJECTS REFERRED... (2*)	Tu1031. . . . BEST PRACTICES IN TEACHING ENDOSCOPY: A... (5*)
Mo2048. . . . UNSUPERVISED MACHINE LEARNING BASED AUTOMATIC DEMARCATION... (5*)	Tu1009. . . . TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL, NON-INVASIVE,... (2*)	Tu1032. . . . DOES MENTORSHIP IMPACT TRAINEE PARTICIPATION IN... (5*)
Mo2049. . . . AUGMENTING GASTROINTESTINAL HEALTH: A DEEP LEARNING... (5*)	Tu1010. . . . VALIDATION OF A STOOL-DERIVED EUKARYOTIC RNA... (3*) (Geneoscopy)	Tu1033. . . . A SNAPSHOT OF WOMEN IN GASTROENTEROLOGY... (5*)
Mo2050. . . . NOVEL COMPUTER-ASSISTED DETECTION SYSTEM OF COLORECTAL... (3*)	Tu1011. . . . CHARACTERISTICS OF INDIVIDUALS UNDERGOING FIT FOR... (5*)	Tu1034. . . . PROXIMAL SERRATED POLYP DETECTION RATE IS... (5*)
Mo2051. . . . AUTOMATED COMPUTER DETECTION OF COLONOSCOPY COMPLETION... (5*)	Tu1012. . . . LOW RATES OF METACHRONOUS ADVANCED NEOPLASIA... (4*)	Tu1035. . . . IMPACT OF PATIENT EDUCATION ON SWITCH... (1*)
Mo2052. . . . APPLICATION OF MACHINE LEARNING AND ARTIFICIAL... (7*)	Tu1013. . . . ARE OUT-OF-POCKET COSTS UNDER MEDICARE A... (1*)	Tu1036. . . . ENSURING JUDICIOUS PPI USE THROUGH AN... (5*)
Mo2053. . . . PRE-PROCEDURAL ASSESSMENT OF THE FASTING STATE... (5*) (The eNose Company, Zutphen, NL, provided Aeonose device for study but no funding.)	Tu1014. . . . ABERRANT CRYPT FOCI PREDICT RISK OF... (5*)	Tu1037. . . . ADDRESSING THE GENDER DIVIDE: FEMALE GASTROENTEROLOGISTS... (5*)
Mo2054. . . . A SEMI-SUPERVISED BLEEDING DETECTION METHOD IN... (3*)	Tu1015. . . . MULTI-TARGET STOOL DNA TESTING: YIELD AS... (4*)	Tu1038. . . . SOCIAL INFLUENCES ON CAREER CHOICES IN... (4*)
Mo2055. . . . A NATURAL LANGUAGE BASED TOOL IMPROVES... (5*)	Tu1016. . . . COLORECTAL CANCER SCREENING: HOLES AND HOPE... (5*)	Tu1039. . . . WHY NOT BE A LEADER? CHARACTERISTICS... (5*)
Mo2056. . . . PERORAL ENDOSCOPIC MYOTOMY: EFFECTS OF THE... (5*)	Tu1017. . . . PREVALENCE OF COLONIC POLYPS IN END-STAGE... (5*)	Tu1040. . . . EXPERIENCED ENDOSCOPY TEACHERS USE TEACHING STRATEGIES... (5*)
Mo2057. . . . INITIAL NORTH AMERICAN EXPERIENCE WITH ENDOSCOPIC... (4*)	Tu1018. . . . SHOULD SCREENING FOR COLORECTAL CANCER START... (5*)	Tu1041. . . . ELECTRONIC CASE-BASED GI BLEEDING MODULE IMPROVES... (5*)
Tu1000. . . . CHRONIC LIVER DISEASE IS ASSOCIATED WITH... (5*)	Tu1019. . . . INCREASING PREVALENCE OF SESSILE SERRATED POLYPS... (5*)	Tu1042. . . . INNOVATIVE INSTRUCTIONAL STRATEGIES FOR INCORPORATING THE... (5*)
Tu1001. . . . PERFORMANCE OF THE VETERAN'S CHOICE PROGRAM... (5*)	Tu1020. . . . UNDERUTILISATION OF RESOURCES FOR COLORECTAL CANCER... (5*)	Tu1043. . . . GASTROENTEROLOGY FELLOWS HAVE SIMILAR POLYP, ADENOMA... (5*)
Tu1002. . . . WEEKEND ADMISSIONS FOR ACUTE CHOLANGITIS: IMPORTANCE... (5*)	Tu1021. . . . DISTANCE OF TRAVEL TO THE SITE... (5*)	Tu1044. . . . WORK-LIFE CONFLICT AND ITS HEALTH EFFECTS... (4*)
Tu1003. . . . CHARACTERIZING LOW-VALUE PPI USE AMONG OLDER... (4*)	Tu1022. . . . QUALITY OF BOWEL PREPARATION AMONG PATIENTS... (5*)	Tu1045. . . . TEACHING THE "FOUR-POSITION METHOD" MAKES BEGINNER... (5*)
Tu1004. . . . FRAGMENTED CARE IS PREVALENT AMONG PATIENTS... (5*)	Tu1023. . . . ADDITIONAL INTESTINAL MUCOSAL BIOPSY SAMPLING FOR... (5*)	Tu1046. . . . KNOWLEDGE AND PRESCRIBING PATTERNS OF INTERNAL... (5*)
Tu1005. . . . ANESTHESIA ROLE IN HOSPITALIZATION FOR PNEUMONIA... (3*) (Medivators)	Tu1027. . . . ESOPHAGEAL MANOMETRY COMPETENCY PROGRAM IMPROVES PERFORMANCE... (5*)	Tu1047. . . . FOOD FOR THOUGHT: GASTROENTEROLOGY FELLOW AND... (5*)
	Tu1028. . . . FACTORS CONTRIBUTING TO ENTRUSTMENT DECISIONS IN... (7*)	Tu1144. . . . CELLULAR SIGNALING CASCADES FOR ACTIVATION OF... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1145. . . . INDUCTION OF LIVER
AUTOPHAGY AMELIORATES IMPAIRED...
(3*)|(Tsumura & Co.)
- Tu1146. . . . SCHLAFEN 3 KNOCKOUT MICE
DISPLAY GENDER-SPECIFIC... (5*)
- Tu1147. . . . NPT2B, A TYPE II SODIUM-
PHOSPHATE COTRANSPORTER,... (2*)
- Tu1148. . . . MICROFLUIDIC ORGANOTYPIC
SYSTEM FOR THE ANALYSIS... (4*)
- Tu1149. . . . IDENTIFYING FUNCTIONAL
PATHWAY ASSOCIATIONS BETWEEN
GENE... (2*)
- Tu1150. . . . INSULIN PROMOTES THE
INVASION AND MIGRATION... (2*)
- Tu1151. . . . HUMAN MYOFIBROBLASTS
SUPPORT PROLIFERATION OF INTESTINAL...
(5*)
- Tu1152. . . . CORDYCEPIN INDUCES G2/M
PHASE ARREST AND... (2*)
- Tu1153. . . . REGULATION OF KETOGENESIS
BY WNT/ β -CATENIN/PPAR γ SIGNALING...
(2*)
- Tu1154. . . . TROP2 UPREGULATION IN
MOUSE PRE-NEOPLASTIC STOMACH... (2*)
- Tu1155. . . . EXPRESSION OF GCRG213,
LINE-1 ENDONUCLEASE VARIANT,... (2*)
- Tu1156. . . . EVALUATION OF SERUM TFF3
LEVELS IN... (5*)
- Tu1157. . . . ANALYSIS OF GASTRIC POLYPS
FROM WESTERN... (5*)|(NIL)
- Tu1158. . . . GENOME-WIDE ANALYSIS FOR
GASTRIC ADENOCARCINOMA-SPECIFIC
H.PYLORI... (2*)
- Tu1159. . . . BLOOD MQTL EFFECTS ARE
CONSISTENT DURING... (6*)
- Tu1160. . . . GENE EXPRESSION SIGNATURE
OF THE "POINT... (4*)
- Tu1161. . . . A PROTOCOL FOR LIVE-FACS
FROM CRYOPRESERVED... (2*)
- Tu1162. . . . USING TRANSCRIPTOMICS TO
SUBCLASSIFY ULCERATIVE COLITIS... (6*)
- Tu1163. . . . HISTONE DESACETYLASE 2
FAVORS AIEC INVASION... (4*)
- Tu1164. . . . SHARED GENETIC MUTATIONS
ARE FOUND IN... (2*)
- Tu1169. . . . SEX MODERATES THE
RELATION BETWEEN NAUSEA... (2*)
- Tu1170. . . . HOSPITAL ADMISSIONS AND
TREATMENT COST OF... (5*)
- Tu1171. . . . IS THE CONCLUSIVE EVIDENCE
FOR GERD... (5*)
- Tu1172. . . . INCOMPLETE RESPONSE OF
SYMPTOMS OF GASTROESOPHAGEAL...
(2*)
- Tu1173. . . . ESOPHAGEAL MUCOSAL
INTEGRITY IS UNCHANGED IN... (5*)
- Tu1174. . . . RECLASSIFICATION OF
PATIENTS WITH GASTROESOPHAGEAL
REFLUX... (5*)
- Tu1175. . . . EVALUATION OF MINIMAL
CHANGE LESION USING... (5*)
- Tu1176. . . . SHORTER (48-HOUR) BRAVO
PH MONITORING MAY... (5*)
- Tu1177. . . . ESOPHAGEAL BASELINE
IMPEDANCE FROM HIGH RESOLUTION...
(5*)
- Tu1178. . . . ASSOCIATION BETWEEN
GASTROESOPHAGEAL JUNCTION
MORPHOLOGY AND... (5*)
- Tu1179. . . . A DISTINCT PATTERN OF
RUMINATION SYNDROME... (4*)
- Tu1180. . . . HIGH RESOLUTION
MANOMETRY (HRM) EVALUATION OF...
(5*)
- Tu1181. . . . PROSPECTIVE STUDY OF A
COHORT OF... (1*)
- Tu1182. . . . HIGH RESOLUTION
ESOPHAGEAL MANOMETRY RESULTS
AFFECT... (5*)
- Tu1183. . . . MEASUREMENT OF
ESOPHAGEAL BASELINE IMPEDANCE: A...
(1*)
- Tu1184. . . . MUCOSAL IMPEDANCE
PREDICTS ABILITY TO DISCONTINUE... (2*)
- Tu1185. . . . PROLONGED (96 H) WIRELESS
AMBULATORY ESOPHAGEAL... (5*)
- Tu1186. . . . E-CADHERIN AND EPIDERMAL
GROWTH FACTOR (EGF)... (4*)
- Tu1187. . . . SYMPTOM RECOGNITION
DURING AMBULATORY PH-IMPEDANCE
MONITORING:... (5*)
- Tu1188. . . . REFLUX PATTERN AND ROLE
OF IMPEDANCE-PH... (5*)
- Tu1189. . . . A BRIEF MANOMETRIC INDEX
FOR COMPREHENSIVE... (5*)
- Tu1190. . . . POSTREFLUX SWALLOW-
INDUCED PERISTALTIC WAVE INDEX
INDEPENDENTLY... (5*)
- Tu1191. . . . BASELINE IMPEDANCE ON
HIGH-RESOLUTION ESOPHAGEAL
IMPEDANCE-MANOMETRY... (5*)
- Tu1192. . . . CLINICAL UTILITY OF
ADVANCED IMPEDANCE METRICS... (5*)
- Tu1193. . . . IMPACT OF CHRONIC OPIATES
ON ESOPHAGEAL... (5*)
- Tu1194. . . . ESOPHAGOGASTRIC JUNCTION
DISTENSIBILITY IS NEARLY ALWAYS... (2*)
- Tu1195. . . . 3D-PRESSURE TOPOGRAPHY
OF THE ESOPHAGOGASTRIC JUNCTION...
(2*)
- Tu1196. . . . IMPAIRED SWALLOW-
INDUCED AXIAL ESOPHAGEAL
SHORTENING/ LES... (2*)
- Tu1197. . . . ENDOSCOPIC
INTRASPHERIC INJECTION OF BOTOX
IN... (2*)
- Tu1198. . . . INEFFECTIVE ESOPHAGEAL
MOTILITY IS ASSOCIATED WITH... (5*)
- Tu1199. . . . ENDOSCOPIC MANAGEMENT
OF ESOPHAGEAL SOFT FOOD... (5*)
- Tu1200. . . . UTILIZING FUNCTIONAL
LUMINAL IMAGING PROBE (FLIP)... (2*)
- Tu1201. . . . CODEINE INDUCES MAJOR
MOTILITY DISORDERS IN... (5*)
- Tu1202. . . . KEY PARAMETERS OF
ESOPHAGOGASTRIC JUNCTION (EGJ)... (5*)
- Tu1203. . . . PHARMACOLOGIC
INTERROGATION OF PATIENTS WITH
ESOPHAGEAL... (4*)
- Tu1204. . . . MUSCLE LAYER FIBROSIS DO
NOT REDUCE... (5*)
- Tu1205. . . . EOSINOPHILS EXPRESSING
TGF-B1 IN THE MUSCLE... (5*)
- Tu1206. . . . DYSPHAGIA IS A COMMON
CONSEQUENCE OF... (5*)
- Tu1207. . . . THE CHICAGO CLASSIFICATION
FREQUENTLY IDENTIFIES MANOMETRIC...
(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1208. . . . NORMAL PARAMETERS OF DISTENSION-INDUCED CONTRACTILITY ASSESSED... (2*)	Tu1229. . . . IMPAIRED ESOPHAGOGASTRIC JUNCTION RECESSIVE RELAXATION PLAYS... (5*)	Tu1248. . . . THE EFFICACY OF FLUOXETINE FOR TREATMENT... (5*)
Tu1209. . . . CLINICAL, MANOMETRIC AND PSYCHOLOGICAL PROFILE OF... (5*)	Tu1230. . . . CLINICAL OUTCOME AFTER SINGLE HYDRAULIC ESOPHAGOGASTRIC... (1*)	Tu1249. . . . AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)... (5*)
Tu1210. . . . ESOPHAGEAL PATHOLOGY IS THE LIKELY ETIOLOGY... (5*)	Tu1231. . . . DIFFERENCES IN TRANSABDOMINAL ULTRASONOGRAPHIC PARAMETERS AMONG... (4*)	Tu1250. . . . TOTAL DAILY OPIOID DOSE IS ASSOCIATED... (2*)
Tu1211. . . . ESOPHAGOGASTRIC JUNCTION MEASURES FOLLOWING PER ORAL... (2*)	Tu1232. . . . DISTAL ESOPHAGEAL DYSMOTILITY AND BOLUS CLEARANCE... (5*)	Tu1251. . . . EFFECT OF ACUTE ESOPHAGEAL ACID EXPOSURE... (2*)
Tu1212. . . . HIGH PREVALENCE OF DYSPHAGIA AND ASSOCIATED... (2*)	Tu1233. . . . RAPID DRINKING CHALLENGE MAY HELP DISTINGUISH... (2*)	Tu1252. . . . TOPOGRAPHICAL PLOTS OF ESOPHAGEAL DISTENSION AND... (2*)
Tu1213. . . . ACUTE ADMINISTRATION OF CODEINE HAS NO... (5*)	Tu1234. . . . CROSS-SECTIONAL IMAGING IN PATIENTS WITH ESOPHAGOGASTRIC... (4*)	Tu1253. . . . VASCULAR PRESSURE BANDS ON HIGH RESOLUTION... (5*)
Tu1214. . . . FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY (FLIP)... (5*)	Tu1235. . . . CLINICAL UTILITY OF HIGH-RESOLUTION ESOPHAGEAL MANOMETRY... (5*)	Tu1254. . . . ASSOCIATION BETWEEN MEDICATION USE AND GERD... (5*)
Tu1215. . . . COMPARISON OF SAFETY OF TREATMENT OPTIONS... (5*)	Tu1236. . . . PATHOPHYSIOLOGICAL MECHANISMS ASSOCIATED WITH SUPRAGAESTRIC BELCHING... (5*)	Tu1255. . . . THE EFFICACY OF TOPICAL LIDOCAINE IN... (5*)
Tu1216. . . . RAPID SEQUENCE CT SCAN IMAGING TO... (2*)	Tu1237. . . . ESOPHAGEAL ACID SENSITIVITY IN PATIENTS WITH... (4*)	Tu1256. . . . DEEP LEARNING FOR ESOPHAGEAL MANOMETRY -... (5*)
Tu1217. . . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS... (5*)	Tu1238. . . . THE TRANSITION ZONE AND DYSPHAGIA: A... (2*)	Tu1257. . . . ESOPHAGEAL HISTOPATHOLOGIC PATTERNS IN PATIENTS UNDERGOING... (5*)
Tu1218. . . . ABERRANT STRIATED MUSCLE CONTRACTILITY IN SYMPTOMATIC... (2*)	Tu1239. . . . ESOPHAGEAL HYPERVIGILANCE AND VISCERAL ANXIETY ARE... (2*)	Tu1258. . . . MAST CELL INFILTRATION ASSOCIATED WITH LOSS... (2*) (declared.)
Tu1219. . . . MONTE CARLO SIMULATION CONFIRMS AGE-RELATED GROUP... (2*)	Tu1240. . . . ASSESSMENT OF ESOPHAGAL BOLUS TRANSIT AND... (5*)	Tu1259. . . . YIELD OF ENDOSCOPIC ULTRASOUND AND COMPUTED... (5*)
Tu1220. . . . ACID EXPOSURE AND DYSMOTILITY IN SYMPTOMATIC... (5*)	Tu1241. . . . EFFECTS OF STRENGTH TRAINING ON DEGLUTITIVE... (2*)	Tu1260. . . . UPRIGHT AND SUPINE INTEGRATED RESIDUAL PRESSURE... (5*)
Tu1221. . . . LOW CLINICAL RELEVANCE OF CERVICAL INLET... (5*)	Tu1242. . . . DEGLUTITIVE STRIATED MUSCLE ENSEMBLE CONTRACTILITY INDICES:... (2*)	Tu1261. . . . PHARYNGEAL PRESSURIZATION SEEN ON PHARYNGEAL SCREENING... (5*)
Tu1222. . . . ESOPHAGEAL DYSMOTILITY OF ASIAN PEOPLE WITH... (5*)	Tu1243. . . . SUSTAINED ESOPHAGEAL CONTRACTIONS ON FUNCTION LUMINAL... (5*)	Tu1262. . . . THE EFFECT OF AGING ON ESOPHAGO-UES... (2*)
Tu1223. . . . EFFECTIVENESS OF N-ACETYLCYSTEINE ON THE TREATMENT... (5*)	Tu1244. . . . SWALLOWING AGAINST LARYNGEAL RESTRICTION (SALR) EXERCISE... (2*)	Tu1263. . . . VARIATION OF BASAL UES PRESSURE WITHIN... (2*)
Tu1224. . . . DEPRESSION OF HYDROGEN SULFIDE SYNTHESIS ENZYMES... (5*)	Tu1245. . . . INITIAL GAINS BY SWALLOWING AGAINST LARYNGEAL... (2*)	Tu1264. . . . INTER-OBSERVER AGREEMENT FOR ANALYSIS OF FUNCTIONAL... (5*)
Tu1225. . . . HYPERCONTRACTILE MOTILITY DISORDERS OF THE ESOPHAGUS:... (5*)	Tu1246. . . . HIGH RESIDUAL UPPER ESOPHAGEAL SPHINCTER PRESSURE... (5*)	Tu1265. . . . COMPARING REAL-TIME VS POST-PROCESSING DATA IN... (5*)
Tu1226. . . . FACTORS ASSOCIATED WITH SPASTIC ESOPHAGEAL DISORDERS... (5*)	Tu1247. . . . ASSOCIATION OF NON-DYSPHAGIA SYMPTOMS AND UPPER... (5*)	Tu1266. . . . PROSPECTIVE EVALUATION OF THE CLINICAL RESPONSE... (5*)
Tu1227. . . . EFFICACY OF PER-ORAL ENDOSCOPIC MYOTOMY FOR... (5*)		Tu1267. . . . RELATIONSHIP BETWEEN UPPER ESOPHAGEAL PRESSURES AND... (5*)
Tu1228. . . . ACHALASIA QUALITY OF LIFE SCORE AND... (5*)		

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1268. . . INCOMPLETE ESOPHAGEAL BOLUS CLEARANCE IS ASSOCIATED... (5*)
- Tu1269. . . INCOMPLETE BOLUS CLEARANCE CONTRIBUTES TO SEVERITY... (5*)
- Tu1270. . . CONTROL OF ESOPHAGEAL SECONDARY PERISTALSIS BY... (4*)
- Tu1271. . . APPLICATION OF A NOVEL LEG ELEVATION... (4*)
- Tu1272. . . IMPACT OF GABA-B AGONIST BACLOFEN ON... (4*)
- Tu1273. . . ELEVATION OF BASAL EGJ PRESSURE IS... (5*)
- Tu1274. . . IMPACT OF PATIENT POSITION ON ESOPHAGEAL... (5*)
- Tu1275. . . HEMATOLOGICAL INDICES IN ACHALASIA PATIENTS AND... (4*)
- Tu1276. . . DIAGNOSTIC ACCURACY OF AN ESOPHAGEAL SWEEP... (5*)
- Tu1277. . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION: DETERMINATION OF... (4*)
- Tu1278. . . UTILITY OF ESOPHAGEAL DUAL PH SENSORS-IMPEDANCE... (1*)
- Tu1279. . . CORRELATION OF NOVEL INFLAMMATORY-NUTRITIONAL BIOMARKERS WITH... (5*)
- Tu1280. . . PERFORMING MORE THAN TEN SWALLOWS DURING... (5*)
- Tu1281. . . UPPER ESOPHAGEAL SPHINCTER IS HYPOTENSIVE IN... (5*)
- Tu1282. . . CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF... (5*)
- Tu1283. . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION ASSOCIATED WITH... (5*)
- Tu1284. . . SWALLOW-TO-SWALLOW VARIATION IN ESOPHAGEAL MOTOR PATTERNS... (5*)
- Tu1285. . . MANOMETRIC CHARACTERISTICS OF UPPER ESOPHAGEAL SPHINCTER... (2*)
- Tu1286. . . DURATION OF SYMPTOMS AND MANOMETRIC PARAMETERS... (5*)
- Tu1287. . . ESOPHAGEAL MOTILITY AND ANTI-REFLUX BARRIER FUNCTION... (5*)
- Tu1288. . . THE PREVALENCE OF DISACCHARIDASE DEFICIENCY IN... (5*)
- Tu1289. . . PILL ESOPHAGRAM CAN IDENTIFY PEDIATRIC PATIENTS... (5*)
- Tu1290. . . RELATIONSHIPS BETWEEN CLINICAL CHARACTERISTICS, TREATMENT, AND... (5*)
- Tu1291. . . VARIATIONS IN PRACTICE PATTERNS IN THE... (2*)
- Tu1292. . . ABNORMAL 24-HOUR PH-IMPEDANCE TESTING IS NOT... (4*)
- Tu1305. . . ASSOCIATION OF PHENOTYPES OF LOW MUCOSAL... (5*)
- Tu1306. . . PREVALENCE OF CANNABINOID USE DISORDER HAS... (5*)
- Tu1307. . . PHYSICAL ACTIVITY AND ITS IMPACT ON... (5*)
- Tu1308. . . POOR SLEEP QUALITY AND DYSPESIA:ITS NOT... (5*)
- Tu1309. . . EFFECT OF RIKKUNSHITO ON GASTROINTESTINAL MOTILITY... (3*)|(TSUMURA & CO. (Japan) provided study medication for this trial.)
- Tu1310. . . EFFICACY AND SAFETY OF SOYO-SAN FOR... (2*)|(This study was supported by grants from the Korea Evaluation Institute of Industrial Technology (No.10060251, The project of 'Development of the diagnostic device for functional dyspepsia based on Korean-Western medicine fusion abdomil diagnosis'.)
- Tu1311. . . ENDOSCOPIC GASTRIC FUNCTION TEST: THE RELATIONSHIP... (4*)
- Tu1312. . . CAMOSTAT MESILATE, PANCRELIPASE AND RABEPRAZOLE COMBINATION... (1*)
- Tu1313. . . EATING AND PSYCHIATRIC DISORDERS ARE INDEPENDENT... (5*)
- Tu1314. . . CLASSIFYING FUNCTIONAL DYSPESIA USING A NOVEL... (5*)
- Tu1315. . . ACYLATED GHRELIN LEVELS WERE ASSOCIATED WITH... (1*)
- Tu1316. . . DOES MEASUREMENT OF SYMPTOMS DURING A... (5*)
- Tu1318. . . TOOSENDANIN EXERTS ANTITUMOR ACTIVITY IN GASTRIC... (2*)
- Tu1319. . . PREDICTIVE FACTORS OF LYMPH NODE METASTASIS... (5*)
- Tu1320. . . PROGNOSIS OF GASTRIC DYSPLASIA AFTER COMPLETE... (5*)
- Tu1321. . . STRATIFICATION OF CT SURVEILLANCE BASED ON... (5*)
- Tu1323. . . IMPLICATION OF MOLECULAR SUBTYPE OF GASTRIC... (1*)
- Tu1324. . . IMPACT OF AGE ON STAGE-SPECIFIC MORTALITY... (2*)
- Tu1325. . . COMPARISON OF GASTRIC CANCER PATIENTS BEFORE... (5*)
- Tu1326. . . HIGH PREVALENCE OF DISTANT METASTASIS AND... (4*)
- Tu1327. . . RISK FACTORS OF EARLY AND ADVANCED... (1*)
- Tu1328. . . OUTCOMES OF GI POLYPS RESECTED USING... (5*)
- Tu1329. . . OUTCOMES IN PATIENTS UNDERGOING GASTRECTOMY FOR... (5*)
- Tu1330. . . FACTORS ASSOCIATED WITH DEGREE OF DUODENAL... (4*)
- Tu1331. . . EMERGENCY PRESENTATIONS FOR GASTROSTOMY COMPLICATIONS IN... (5*)
- Tu1415. . . MANAGEMENT OF ACUTE PANCREATITIS IN CHILDREN... (5*)
- Tu1416. . . PROLONGED HYPERAMYLASEMIA IN PATIENTS WITH ACUTE... (5*)
- Tu1417. . . ACUTE PANCREATITIS IN PATIENTS WITH CYSTIC... (5*)
- Tu1418. . . THE EPIDEMIOLOGY OF ACUTE PANCREATITIS IN... (5*)
- Tu1419. . . SAFETY AND EFFICACY OF AN ED... (5*)
- Tu1420. . . SAME ADMISSION CHOLECYSTECTOMY FOR MODERATE TO... (5*)
- Tu1421. . . MORE ABOUT NPO IN ACUTE PANCREATITIS... (5*)
- Tu1422. . . DEVELOPMENT AND VALIDATION OF RISK PREDICTION... (2*)
- Tu1423. . . ROLE OF INFLAMMATORY MARKERS IN STEP-UP... (5*)
- Tu1424. . . MARKED SERUM LIPASE ELEVATIONS ARE ASSOCIATED... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1425. . . . ARE OPIATE NAIVE PATIENTS WITH ACUTE... (5*)	Tu1445. . . . COMPARISON OF ONSITE, GLUCOMETER-MEASURED, CYST FLUID... (5*)	Tu1535. . . . SEX, RACE AND INSURANCE DISPARITIES IN... (5*)
Tu1426. . . . ADMITTING ACUTE PANCREATITIS PATIENTS WHO REQUIRE... (5*)	Tu1446. . . . CLINICOPATHOLOGICAL FEATURES OF PANCREATIC DUCTAL ADENOCARCINOMA... (5*)	Tu1536. . . . ASSESSING THE SURVIVAL OUTCOME RELATIONSHIP BETWEEN... (5*)
Tu1427. . . . ACUTE PANCREATITIS AND BMI: MORTALITY RATES... (5*)	Tu1447. . . . EFFICACY OF LUMEN-APPPOSING METAL STENT INSERTION... (5*)	Tu1537. . . . DEMOGRAPHICS FOR DO-NOT RESUSCITATE STATUS AND... (5*)
Tu1428. . . . GASTROINTESTINAL FISTULISATION IN WALLED OFF PANCREATIC... (5*)	Tu1448. . . . ALCOHOL-INDUCED EXPERIMENTAL PANCREATITIS: THERAPEUTIC BENEFITS BY... (2*)	Tu1538. . . . ETIOLOGY OF CIRRHOSIS CHANGING TRENDS OVER... (5*)
Tu1429. . . . LEFT VENTRICULAR ASSIST DEVICE (LVAD), HEART... (5*)	Tu1449. . . . PIRFENIDONE AMELIORATES WELL-ESTABLISHED CHRONIC PANCREATITIS IN... (2*)	Tu1539. . . . PREVALENCE OF LIVER DISEASE IN PATIENTS... (5*)
Tu1430. . . . THE PREVALENCE OF VITAMIN D DEFICIENCY,... (5*)	Tu1450. . . . COMBINATION OF HEPARANASE INHIBITORS AND ASPIRIN... (5*)	Tu1540. . . . HEPATOBILIARY-SPECIFIC DELETION OF POLYMERIC IMMUNOGLOBULIN RECEPTOR... (6*)
Tu1431. . . . FACTORS PREDICTING FAILURE OF PERCUTANEOUS DRAINAGE... (5*) (Nil)	Tu1451. . . . CLINICAL CHARACTERISTICS AND OUTCOMES OF IMMUNE... (5*)	Tu1541. . . . VALIDATION OF NON-INVASIVE BIOMARKERS OF LIVER... (2*)
Tu1432. . . . COMPARISON OF OUTCOME IN ACUTE PANCREATITIS... (5*)	Tu1452. . . . EPITHELIAL PROLIFERATION OF THE INTRAPANCREATIC DUCTS... (4*)	Tu1542. . . . THE EFFECT OF LOW-ENERGY EXTRACORPOREAL SHOCK... (5*)
Tu1433. . . . RISK FACTORS AND INCIDENCE FOR 30-DAY... (5*)	Tu1453. . . . TEDUGLUTIDE AMERIORATES EXTRA-PANCREATIC INFLAMMATION BY REDUCTION... (2*) (Shire Pharmaceuticals)	Tu1543. . . . REVERSAL OF IMMUNE EXHAUSTION FOLLOWING SVR... (3*) (The Bristol-Myers Squibb Virology Fellows Research Program for 2015-2017, (EA).)
Tu1434. . . . TRENDS IN EARLY VS LATE MORTALITY... (5*)	Tu1454. . . . USEFULNESS OF TRANSABDOMINAL SHEAR WAVE ELASTOGRAPHY... (5*)	Tu1544. . . . ACCURACY OF NON-INVASIVE TESTS TO DETECT... (5*)
Tu1435. . . . MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS... (4*)	Tu1455. . . . CARBOXYL ESTER LIPASE DOES NOT MEDIATE... (2*)	Tu1545. . . . SHEAR WAVE ELASTOGRAPHY USE FOR SCREENING... (5*)
Tu1436. . . . OBESITY BUT NOT NAFLD IS A... (5*)	Tu1456. . . . MORPHINE TREATMENT IN ACUTE PANCREATITIS AFFECTS... (2*)	Tu1546. . . . GPBAR1 IS A MODULATOR OF LIVER... (5*)
Tu1437. . . . DEPLETION OF GRAM-POSITIVE BACTERIA IN THE... (2*)	Tu1457. . . . ELEVATED BODY MASS INDEX INCREASES RISK... (5*)	Tu1547. . . . GAUCHER DISEASE PRESENTING AS NEONATAL CHOLESTASIS... (5*)
Tu1438. . . . ACCURACY OF ENDOSCOPIC ULTRASOUND TO ASSESS... (5*)	Tu1458. . . . IMPACT OF PATIENT'S WEIGHT ON PERFORMING... (5*)	Tu1548. . . . STATIN-ASSOCIATED AUTOIMMUNE MYOPATHY: AN UNUSUAL CAUSE... (5*)
Tu1439. . . . GROWTH FACTOR RECEPTOR SIGNALING IN MEN1... (4*)	Tu1459. . . . A PAIN IN THE GUT: A... (5*)	Tu1549. . . . SKYROCKETING LIVER ENZYMES: A REMARKABLE CASE... (5*)
Tu1440. . . . PREOPERATIVE C-REACTIVE PROTEIN/ALBUMIN RATIO PREDICTS CANCERIZATION... (5*)	Tu1473. . . . THERAPEUTIC EFFICACY OF CHEMORADIOTHERAPY WITH MIRIPLATIN... (2*)	Tu1550. . . . INFLAMMATION, ARTERIAL STIFFNESS AND DIRECTLY-ACTING ANTIVIRALS... (4*)
Tu1441. . . . ANALYSIS OF PANCREAS CYST GROWTH RATES... (7*)	Tu1474. . . . UTILITY OF ENDOSCOPIC ULTRASOUND IN THE... (5*)	Tu1551. . . . HEPATITIS C PATIENTS WITH ADVANCED AGE,... (5*)
Tu1442. . . . ASSOCIATION OF DIABETES MELLITUS FOR LONG... (5*)	Tu1475. . . . SYSTEMIC INFLAMMATORY RESPONSE MARKERS AS PROGNOSTIC... (5*)	Tu1552. . . . PREVALENCE OF HEPATITIS E VIRUS INFECTION... (4*) (5)
Tu1443. . . . PERFORMANCE CHARACTERISTICS OF DNA ANALYSIS IN... (5*)	Tu1476. . . . AFATINIB COMBINED WITH GEMCITABINE/CISPLATIN IN CHEMOTHERAPY... (3*) (Boehringer Ingelheim)	Tu1553. . . . HEPATITIS B VIRUS PATIENTS WITH MEDICAID... (3*) (Research funding: Gilead Sciences)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1554. . . . HEPATITIS B REACTIVATION IN INDIVIDUALS WITH... (5*)
- Tu1555. . . . RISKY ALCOHOL CONSUMPTION IS COMMON AMONG... (5*)
- Tu1593. . . . VIRULENCE PHENOTYPES OF ATYPICAL ENTEROPATHOGENIC ESCHERICHIA... (5*)
- Tu1594. . . . TETHERED CAPSULE OCT IMAGING OF THE... (6*)|
- Tu1595. . . . INFLAMMATORY POTENTIAL OF DIET, CIRCULATING INFLAMMATORY... (2*)
- Tu1596. . . . MULTIPLEX GASTROINTESTINAL PATHOGEN PCR TESTING IN... (5*)
- Tu1597. . . . THE ROLE OF ANTIBIOTICS IN ACUTE... (5*)
- Tu1598. . . . EXAMINING THE UTILITY OF GASTROINTESTINAL PATHOGEN... (5*)
- Tu1599. . . . AQUAPORIN-5 EXPRESSION IS REDUCED IN LYMPHOCYTIC... (4*)
- Tu1600. . . . AIR OR CARBON DIOXIDE INSUFFLATION IN... (5*)
- Tu1601. . . . DIARRHEA IN TUBE-FED HOSPITALIZED PATIENTS: FEEDING... (4*)
- Tu1602. . . . MEASUREMENT OF STRESS AND ANXIETY AND... (7*)
- Tu1603. . . . GASTROINTESTINAL COMPLICATIONS IN PATIENTS WITH LOCAL... (5*)
- Tu1604. . . . EFFICACY AND SAFETY OF ANAL SPHINCTER... (5*)
- Tu1605. . . . CHRONIC INTESTINAL PSEUDO-OBSTRUCTION IN CHILDREN: EPIDEMIOLOGY... (5*)
- Tu1606. . . . PREVALENCE OF CHILD ABUSE IN CHILDREN... (5*)
- Tu1607. . . . SOMATIC AND PSYCHOSOCIAL FACTORS ASSOCIATED WITH... (2*)
- Tu1608. . . . LONG-TERM FOLLOW-UP OF GUT-DIRECTED HYPNOTHERAPY SELF-EXERCISES... (5*)
- Tu1609. . . . HOW OFTEN DO GASTROENTEROLOGIST'S SCREEN FOR... (5*)
- Tu1610. . . . RESILIENCE IN IRRITABLE BOWEL SYNDROME IS... (2*)
- Tu1611. . . . PSYCHOLOGICAL FLEXIBILITY AS AN IMPORTANT FEATURE... (2*)
- Tu1612. . . . CENTRALIZED SENSITIVITY PHENOTYPE AS A PREDICTOR... (2*)
- Tu1613. . . . GLOBAL IBS SYMPTOM IMPROVEMENT IN COGNITIVE-BEHAVIORAL... (2*)
- Tu1614. . . . VIRTUAL REALITY MINDFULNESS THERAPY REDUCES PAIN... (4*)
- Tu1615. . . . IS IT ARFID, A GASTROINTESTINAL DISORDER... (5*)
- Tu1616. . . . INTEGRATED INFLAMMATORY BOWEL DISEASE- BEHAVIORAL MEDICINE... (5*)
- Tu1617. . . . PREDICTING SUCCESSFUL OUTCOMES OF ANORECTAL BIOFEEDBACK... (5*)
- Tu1618. . . . PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS (FGIDS)... (2*)
- Tu1619. . . . SELF-PERCEIVED STRESS IS ASSOCIATED WITH CHEST... (5*)
- Tu1620. . . . WHAT IS COGNITIVE IN/FLEXIBILITY IN IRRITABLE... (4*)
- Tu1621. . . . ATTENTIONAL BIAS IN PEDIATRIC INFLAMMATORY BOWEL... (4*)
- Tu1623. . . . EPIDEMIOLOGY OF CYCLIC VOMITING SYNDROME: ANALYSIS... (3*)|(Takeda Pharmaceuticals)
- Tu1624. . . . SEASONAL VARIATIONS IN THE INCIDENCE AND... (5*)
- Tu1625. . . . INCIDENCE AND RISK FACTORS OF DIVERTICULITIS... (5*)
- Tu1626. . . . NATIONAL TRENDS, OUTCOMES AND PREDICTORS OF... (5*)
- Tu1627. . . . BUDD CHIARI SYNDROME: A STUDY FROM... (5*)
- Tu1628. . . . SHOULD ORIGINAL RESEARCH BE SHARED ON... (5*)
- Tu1629. . . . INCREASING BODY MASS INDEX, MALE GENDER,... (5*)
- Tu1630. . . . HEPATOCELLULAR CARCIOMA INCIDENCE IS DECREASING AMONG... (5*)
- Tu1631. . . . CHARACTERIZATION OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE... (4*)
- Tu1632. . . . ASSOCIATION BETWEEN BOWEL MOVEMENTS AND DIVERTICULITIS... (2*)|(R01 DK101495, K24 DK 098311 and UM1 CA186107 from the tIol Institutes of Health)
- Tu1633. . . . HIGH PROPORTION OF DIFFUSE TYPE GASTRIC... (5*)
- Tu1634. . . . THE PREVALENCE OF CARCINOID TUMORS OF... (5*)
- Tu1635. . . . EPIDEMIOLOGY AND MANAGEMENT OF ACHALASIA IN... (5*)
- Tu1636. . . . THE USE OF WEB FORUMS DATA... (3*)|(Da Nutricia Research)
- Tu1637. . . . CARDIAC RISK OF PROKINETICS: A POPULATION-BASED,... (5*)
- Tu1638. . . . CHANGING TRENDS IN US HOSPITALIZATIONS WITH... (5*)
- Tu1639. . . . QUANTIFYING RISK FACTORS FOR ISCHEMIC COLITIS:... (5*)
- Tu1640. . . . A LEFT-TO-RIGHT SHIFT REEVALUATION OF COLORECTAL... (5*)
- Tu1641. . . . ANALYSIS OF UC COLECTOMY RATES IN... (5*)
- Tu1642. . . . VALIDATION OF THE BRISTOL STOOL CHART... (2*)
- Tu1643. . . . RISING INCIDENCE OF SMALL INTESTINAL CANCER... (5*)
- Tu1644. . . . GASTRIC CANCER SCREENING AT 2 U.S.... (5*)
- Tu1645. . . . KILLING TWO BIRDS WITH ONE STONE:... (5*)
- Tu1646. . . . VARIATION IN RURAL COLORECTAL CANCER SCREENING... (6*)
- Tu1647. . . . STATE-LEVEL HEALTH INSURANCE STATUS IS ASSOCIATED... (5*)
- Tu1648. . . . LOW YIELD OF ENDOSCOPIC SURVEILLANCE FOR... (5*)
- Tu1649. . . . GALLBLADDER POLYP IS ASSOCIATED WITH PROXIMAL... (5*)
- Tu1650. . . . ACCURACY OF ELECTRONIC HEALTH RECORD BILLING... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1651. . . TELEPHONE COUNSELING INTERVENTION IMPROVES UPTAKE OF... (4*)	Tu1671. . . SMALL BOWEL NEOPLASIA DETECTION IN LYNCH... (5*)	study was conducted with unrestricted funding from Celgene Corporation.)
Tu1652. . . COLORECTAL CANCER SCREENING AND PATIENT NAVIGATION:... (2*)	Tu1672. . . PREVALENCE OF GENE MUTATIONS IN PATIENTS... (4*)	Tu1708. . . EARLY CHILDHOOD INFLAMMATORY BOWEL DISEASE IS... (2*)
Tu1653. . . ACCURACY OF INITIAL RECOMMENDED COLONOSCOPY SURVEILLANCE... (2*)	Tu1673. . . SINGLE-GENE VS. MULTI-GENE PANEL TESTING IN... (5*)	Tu1710. . . USTEKINUMAB TO TREAT PEDIATRIC PATIENTS WITH... (2*)
Tu1654. . . THE EFFECT OF GENDER AND RACE... (5*)	Tu1691. . . PLATINUM BASED THERAPY IN PATIENTS WITH... (5*)	Tu1711. . . EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS... (3*) (Eli Lilly and Company)
Tu1655. . . THE LONG TERM IMPACT OF ROUX-EN-Y... (5*)	Tu1692. . . CLINICAL CHARACTERISTICS OF TAXANE-BASED CHEMOTHERAPY-INDUCED COLITIS... (5*)	Tu1712. . . REDUCTION IN INFLAMMATORY BIOMARKERS IN A... (3*) (Eli Lilly and Company)
Tu1656. . . GASTRIC CANCER AND GEOGRAPHICAL/ETHNIC SHIFTS IN... (5*)	Tu1693. . . POTENTIATION OF CALCIUM-ACTIVATED CHLORIDE SECRETION AND... (4*)	Tu1713. . . EFFICACY AND SAFETY OF 2 OR... (3*) (Takeda)
Tu1657. . . REGIONAL AND RACIAL DISPARITIES IN GASTRIC... (4*)	Tu1694. . . CLINICAL FEATURES OF RITUXIMAB-INDUCED GASTROINTESTINAL TOXICITIES... (5*)	Tu1714. . . IMPACT OF UPADACITINIB ON THE GENERAL... (3*) (AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl)
Tu1658. . . MECKEL'S DIVERTICULUM- A NIDUS FOR ILEAL... (4*)	Tu1695. . . ANTI-ANGIOGENESIS CANCER THERAPY-RELATED GASTROINTESTINAL INJURY CAN... (5*)	Tu1715. . . A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB... (3*)
Tu1659. . . ENDOMETRIAL POLYPS ARE MORE LIKELY TO... (2*)	Tu1696. . . NEUTROPENIC COLITIS - CLINICAL FEATURES, TREATMENT... (5*)	Tu1716. . . HIGHLY BIOAVAILABLE CURCUMIN (THERACURMIN®) FOR CROHN'S... (5*)
Tu1660. . . INCREASING INPATIENT ADMISSIONS, COSTS, AND MORTALITY... (5*)	Tu1697. . . COMPARISON OF RISK FACTORS BETWEEN INTESTINAL... (5*)	Tu1717. . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE... (3*) (Pfizer Inc)
Tu1661. . . PREVALENCE, IN-HOSPITAL OUTCOMES AND RESOURCE UTILIZATION... (5*)	Tu1698. . . FLUOROPYRIMIDINE-INDUCED INTESTINAL MUCOSAL INJURY IS ASSOCIATED... (1*)	Tu1718. . . IMMUNOGENICITY OF USTEKINUMAB IN PATIENTS WITH... (3*) (This study was funded by Janssen Research & Development, LLC)
Tu1662. . . THE EPIDEMIOLOGY OF GASTRIC CANCER IN... (5*)	Tu1699. . . BIFIDOBACTERIUM ANIMALIS SUBSPECIES LACTIS ENGINEERED TO... (5*)	Tu1719. . . CLINICAL REMISSION BY LEGACY VERSUS FDA... (3*) (This study was funded by Janssen Research & Development, LLC)
Tu1663. . . ANATOMICAL DISTRIBUTION OF GASTRIC CANCER IN... (5*)	Tu1700. . . ANTI-INFLAMMATORY AND ANTI-OXIDATIVE EFFECTS OF 17-β... (5*)	Tu1720. . . EFFICACY OF TOFACITINIB MAINTENANCE THERAPY FOR... (3*) (Pfizer Inc)
Tu1664. . . DOES THE GEOGRAPHIC DISTRIBUTION OF THE... (5*)	Tu1701. . . EFFECTS OF 17β-ESTRADIOL ON COLORECTAL CANCER... (5*)	Tu1721. . . MAINTENANCE OF EFFICACY FOLLOWING TOFACITINIB DOSE... (3*) (Pfizer Inc)
Tu1665. . . TRISOMY 21 DOES NOT INCREASE THE... (5*)	Tu1702. . . ELEVATED O-GLCNACYLATION INCREASES FOXM1 PROTEIN VIA... (4*)	Tu1722. . . DARVADSTROCEL TREATMENT OUTCOMES IN CROHN'S DISEASE... (3*) (Takeda Pharmaceutical Company)
Tu1666. . . ANALYSIS OF THE ASSOCIATION BETWEEN POVERTY... (5*)	Tu1703. . . CYSTATHIONINE-GAMMA-LYASE EXPRESSING BONE MARROW-DERIVED CELLS INHIBIT... (2*)	Tu1723. . . IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH... (3*) (This study was funded by Janssen Research & Development, LLC)
Tu1667. . . RACIAL/ETHNIC DISPARITIES IN GASTRIC CANCER INCIDENCE,... (5*)	Tu1704. . . THE PREVELANCE OF PRIMARY MALIGNANT NEOPLASM... (5*)	
Tu1668. . . WHAT IS THE PREVALENCE OF SERRATED... (2*)	Tu1705. . . COLONOSCOPY IS INDICATED AFTER AN EPISODE... (5*)	
Tu1669. . . CHROMOENDOSCOPY LEADS TO A HIGHER INSIGHT-STAGE... (4*)	Tu1706. . . EARLY ENDOSCOPIC EVALUATION ASSOCIATED WITH SHORTER... (5*)	
Tu1670. . . EXOGENOUS AND ENDOGENOUS ASSOCIATED FACTORS TO... (5*)	Tu1707. . . PATIENT REPORTED MEASURES OF HEALTH STATUS... (3*) (This	

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1724. . . . ASSOCIATION OF USTEKINUMAB SERUM CONCENTRATIONS AND... (3*)|(Janssen Research & Development, LLC funded this study.)

Tu1725. . . . CHARACTERIZATION OF PATIENTS WITH DELAYED RESPONSE... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1726. . . . THE IMPACT OF EARLY DISEASE CONTROL... (3*)|(Takeda)

Tu1727. . . . RAPIDITY OF SYMPTOMATIC AND INFLAMMATORY BIOMARKER... (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the)

Tu1728. . . . LONG-TERM EFFICACY AND PHARMACODYNAMICS OF THE... (3*)|(The OPERA II study was funded by Pfizer. These alyses were funded by Pfizer and Shire. Medical writing support was provided by Emma Saxon PhD of PharmaGenesis London and funded by Shire.)

Tu1729. . . . LONG-TERM EFFICACY OF TOFACITINIB IN PATIENTS... (3*)|(Pfizer Inc)

Tu1730. . . . IMPROVEMENT IN PATIENT-REPORTED INFLAMMATORY BOWEL DISEASE... (3*)|(Pfizer Inc)

Tu1731. . . . EARLY HISTOLOGIC IMPROVEMENT DEMONSTRATED WITH ORAL... (3*)|(This study is sponsored by Celgene Corporation.)

Tu1732. . . . CHANGES IN SIMPLIFIED ENDOSCOPIC SCORE FOR... (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl)

Tu1733. . . . CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD... (3*)|(This study is sponsored by Celgene Corporation.)

Tu1734. . . . EFFECT OF VEDOLIZUMAB ON SURGICAL RATES... (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)

Tu1735. . . . EFFECTS OF USTEKINUMAB INDUCTION THERAPY ON... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1736. . . . MOLECULAR RESPONSE TO USTEKINUMAB IN MODERATE-TO-SEVERE... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1737. . . . EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL... (3*)|(The TURANDOT II study was funded by Pfizer and Shire. These alyses were funded by Shire. Medical writing support was provided by PharmaGenesis London and funded by Shire.)

Tu1738. . . . BIOMARKER AND PHARMACOKINETIC DATA FROM THE... (3*)|(The TURANDOT II study was funded by Pfizer and Shire. These alyses were funded by Shire. Medical writing support was provided by PharmaGenesis London and funded by Shire.)

Tu1739. . . . EFFICACY AND SAFETY OF USTEKINUMAB THROUGH... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1740. . . . SUSTAINED REMISSION IN PATIENTS WITH MODERATE... (3*)|(The study was funded by Janssen Research & Development, LLC)

Tu1741. . . . A NOVEL ORAL FORMULATION OF BUDESONIDE... (3*)|(Dr. Falk Pharma GmbH)

Tu1742. . . . LONG-TERM IMMUNOGENICITY OF INTRAVENOUS VEDOLIZUMAB IN... (3*)|(Takeda)

Tu1743. . . . IV IRON TREATMENT OF IRON DEFICIENCY... (3*)|(AMAG Pharmaceuticals, Inc.)

Tu1744. . . . TARGETED RELEASE ORAL CYCLOSPORINE (ST-0529) AS... (3*)

Tu1745. . . . CORRELATION OF FECAL CALPROTECTIN AND C-REACTIVE... (3*)|(Are Pharmaceuticals, Inc.)

Tu1746. . . . A PHASE 3 STUDY OF VEDOLIZUMAB... (3*)|(Takeda Pharmaceutical Company, Ltd.)

Tu1747. . . . EFFECT OF TELEMEDICINE FOR INFLAMMATORY BOWEL... (2*)|(This research was supported by the Agency for Healthcare Research and Quality (1R01HS018975-01A1) and the University of Maryland General Clinical Research Centers Program. Zaid Bilgrami was supported by the Program for Research Initiated by Students and)

Tu1748. . . . ORAL CURCUMIN IS NOT MORE EFFECTIVE... (2*)

Tu1749. . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF INTRAVENOUSLY... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1750. . . . NOVEL RIFAMYCIN SV MULTI-MATRIX FORMULATION FOR... (3*)|(Clinical study was funded by Dr. Falk Pharma GmbH.)

Tu1751. . . . THE EFFECT OF REMOTE ISCHEMIC CONDITIONING... (3*)|(Novo Nordisk Foundation)

Tu1752. . . . ANALYSIS OF HEMATOLOGICAL CHANGES IN TOFACITINIB-TREATED... (3*)|(Pfizer Inc)

Tu1753. . . . ANALYSIS OF THE IMPACT OF BODY... (3*)|(Pfizer Inc)

Tu1754. . . . SAFETY AND TOLERABILITY OF BT-11, A... (3*)|(Study was funded by Landos Biopharma, Inc.)

Tu1755. . . . EFFICACY OF COMBINATION THERAPY OF FECAL... (2*)

Tu1756. . . . THE TREATMENT NAIVE RECTAL TRANSCRIPTOME IDENTIFIES... (2*)

Tu1757. . . . FUNCTIONAL REGULATORY ANNOTATION OF FINE-MAPPED IBD... (2*)

Tu1758. . . . INFLAMMATORY BOWEL DISEASE TRANSCRIPTOMES REVEAL REDUCED... (4*)

Tu1759. . . . NEW METHYLATION BIOMARKER PANEL OF INFLAMMATORY... (5*)

Tu1760. . . . ALTERATIONS IN EXPRESSION QUANTITATIVE TRAIT LOCI... (2*)

Tu1761. . . . POLYGENIC RISK SCORES ARE ASSOCIATED WITH... (2*)

Tu1762. . . . GENETIC BACKGROUND OF THIOPURINE-INDUCED PANCREATITIS IN... (2*)

Tu1763. . . . SYSTEMIC AND TISSUE MODULATION OF IL-23... (3*)|(Boehringer Ingelheim and AbbVie funded the study and research. AbbVie provided medical writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the abstract. The authors maintained control ov)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1764. . . . INHIBITION OF MYELOID DIFFERENTIATION 1 SPECIFICALLY... (2*)**
- Tu1765. . . . HISTONE 3 LYSINE 27 ACETYLATION PROFILING... (2*)**
- Tu1766. . . . DYSREGULATED LNCRNAs IN INFLAMMATORY BOWEL DISEASE... (2*)**
- Tu1767. . . . MULTI-ALLELES POLYMORPHISMS PREDICT PRIMARY NON-RESPONSE TO... (5*)**
- Tu1768. . . . IDENTIFYING MOLECULAR FEATURES CONTRIBUTING TO DISEASE... (4*)**
- Tu1769. . . . DNA METHYLATION SIGNATURES IN CROHN'S DISEASE-RELATED... (2*)**
- Tu1770. . . . TLR7 AGONIST INDUCED DERMATITIS EXACERBATED COLITIS... (2*)**|(This work is supported by the Yakult bio science foundation. Author was the employee of Takeda pharm. Co-author was the employee of Miyarisan, Tabe mitsubishi, Ezaki pharm.)
- Tu1771. . . . PRENATAL MATERNAL STRESS INDUCES GUT DYSBIOSIS... (5*)**
- Tu1772. . . . 'INDIGO NATURALIS' AMELIORATES ULCERATIVE COLITIS VIA... (5*)**
- Tu1773. . . . CHARACTERISTICS AND PATHOGENIC ROLE OF ADHERENT-INVASIVE... (2*)**
- Tu1774. . . . MICROBIOME FUNCTIONALGENOMICS REVEALS NOVEL BACTERIAL STRAINS... (3*)**|(Biomica Ltd. Rehovot, Israel, www.biomicamed.com)
- Tu1775. . . . THE NOD2 ASSOCIATION WITH CD-ASSOCIATED SEROLOGICAL... (2*)**
- Tu1776. . . . CLOSTRIDIUM DIFFICILE DIAGNOSIS BY TOXIN ENZYME... (5*)**
- Tu1777. . . . THE GUT MICROBIOME MODULATES COLORECTAL TUMORIGENESIS... (2*)**|
- Tu1778. . . . THE GUT MICROBIAL PROFILE OF PRECLINICAL... (4*)**
- Tu1779. . . . CINNAMON EXTRACT AMELIORATES EXPERIMENTAL COLITIS VIA... (4*)**
- Tu1780. . . . DIETARY WHEAT AMYLASE TRYPSIN INHIBITORS MODIFY... (2*)**
- Tu1781. . . . SEASONAL VARIATION OF FECAL MICROBIOTA IN... (1*)**
- Tu1782. . . . COMPOSITIONAL CHANGES IN THE GUT MICROBIOTA... (2*)**
- Tu1783. . . . IN VITRO EFFECTS OF XYLO-OLIGOSACCHARIDE ON... (2*)**
- Tu1784. . . . ABNORMALITIES IN THE FECAL MICROBIOME OF... (4*)**
- Tu1785. . . . EB8018 IS ABLE TO DECREASE TNF α ... (3*)**|(ENTEROME S.A.)
- Tu1786|BSQS5. . . . CHARACTERIZATION OF THE FISTULA-ASSOCIATED MICROBIOME IN... (4*)**|(The Tobacco Formula grant is under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)
- Tu1787. . . . POTENTIAL PROTECTIVE EFFECT OF PD-1 INHIBITOR... (5*)**
- Tu1788. . . . COMPLETE ENGRAFTMENT OF THE HUMAN GUT... (2*)**
- Tu1789. . . . TREATMENT RESPONSE TO USTEKINUMAB AND VEDOLIZUMAB... (5*)**
- Tu1790. . . . BACTERIA DERIVED TRYPTAMINE PRODUCTION ALTERS HOST... (2*)**
- Tu1791. . . . INSIGHTS INTO ALTERATION OF GUT MICROBIOTA... (4*)**
- Tu1792. . . . GUT MICROBIOME DIVERSITY IN ACUTE SEVERE... (2*)**
- Tu1793. . . . EUKARYOTIC MICROBIAL DYSBIOSIS IN TREATMENT-NAÏVE PATIENTS... (6*)**|(This work was supported by the Leo M. and Harry B. Helmsley Charitable Trust)
- Tu1794. . . . ADHERENT-INVASIVE ESCHERICHIA COLI COLONIZATION PROMOTES INTESTINAL... (2*)**
- Tu1795. . . . CHANGES IN SMALL INTESTINAL MICROBIOME DURING... (4*)**
- Tu1796. . . . MANAGEMENT OF INFLAMMATORY BOWEL DISEASE PATIENTS... (2*)**|(Promoting Access and Care through Centers of Excellence (PACE) Network, Crohn's and Colitis Cada.)
- Tu1797. . . . HERPES ZOSTER VIRUS IN INFLAMMATORY BOWEL... (5*)**
- Tu1798. . . . LOW MOLECULAR WEIGHT HEPARIN (LMWH) COMPARED... (5*)**
- Tu1799. . . . A NATIONAL, RETROSPECTIVE, OBSERVATIONAL STUDY ON... (3*)**|(Ferring Pharmaceuticals)
- Tu1800. . . . A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY... (3*)**|(This study is supported by Ferring Pharmaceuticals.)
- Tu1801. . . . PRESCRIBING PATTERNS AND LONG-TERM CONTINUATION RATES... (5*)**
- Tu1802. . . . PERCEIVED QUALITY OF CARE IS ASSOCIATED... (1*)**|(The study was supported by the McGill CAS Research Support Program, the Kimberly Sue McCall Award in IBD Research and the Nesbitt-McMaster Award and the WI230654 Pfizer unrestricted research grant.)
- Tu1803. . . . IDENTIFICATION OF PATIENTS WITH INFLAMMATORY BOWEL... (6*)**
- Tu1804. . . . EFFECTIVENESS OF A REMOTE PATIENT MONITORING... (3*)**|(Abbvie Cada)
- Tu1805. . . . REGIONAL IBD SURVEILLANCE ENDOSCOPY NORTH WEST... (6*)**
- Tu1806. . . . KNOWLEDGE AND ATTITUDES TOWARDS PREGNANCY IN... (5*)**
- Tu1807. . . . THE COMPARISON OF DISEASE-RELATED KNOWLEDGE OF... (5*)**
- Tu1808. . . . SIGNIFICANT REDUCTION OF ADMISSION TIME AT... (5*)**
- Tu1809. . . . INFREQUENT COUNSELING BY PHYSICIANS ON IBD... (5*)**
- Tu1810. . . . FRAGILITY INDEX OF RANDOMIZED CONTROLLED TRIALS... (5*)**
- Tu1811. . . . THE CONCERT INITIATIVE: IMPROVING COMMUNITY CARE... (3*)**|(Financial support for this study is being provided by AbbVie; AbbVie participated in the design of the study and approval of the abstract; all authors contributed to the development of the abstract and maintained control over the fil content.)
- Tu1812. . . . USE OF ADVANCED PRACTICE NURSING TO... (5*)**
- Tu1813. . . . WHAT ARE THE MOST CHALLENGING ASPECTS... (5*)**
- Tu1814. . . . INFLAMMATORY BOWEL DISEASE, THE EMERGENCY DEPARTMENT,... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1815. . . . CONCENTRATION OF INFLIXIMAB IN THE NON-INFLAMED... (2*)|(This study was partly supported by AMED (Japan Agency for Medical Research and Development) (J160705148).)

Tu1816. . . . COMBINATION OF BIOMARKERS REFLECTING TYPE IV... (5*)

Tu1817. . . . INCREASING SUBCUTANEOUS FAT AND WEIGHT ARE... (2*)

Tu1818. . . . ULTRA-PROACTIVE THERAPEUTIC DRUG MONITORING INCORPORATING INFLIXIMAB... (5*)|(Mundipharma)

Tu1819. . . . SERUM MARKER PANEL FOR DETECTION OF... (3*)|(Kepler Diagnostics, Inc. purchased all alyzed ELISA kits)

Tu1820. . . . PROACTIVE INFLIXIMAB DRUG MONITORING IS SUPERIOR... (5*)

Tu1821. . . . PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF RADIOLOGICAL... (5*)

Tu1822. . . . IFX SERUM LEVELS AT TROUGH DO... (5*)

Tu1823. . . . THERAPEUTIC DRUG MONITORING-BASED OPTIMIZATION SHOULD BE... (5*)

Tu1824. . . . TROUGH LEVELS OF INFLIXIMAB BETTER CORRELATE... (5*)

Tu1825. . . . USTEKINUMAB THERAPEUTIC DRUG MONITORING IN CROHN'S... (5*)

Tu1826. . . . EVALUATION OF PREDICTORS OF DURABLE CLINICAL... (5*)

Tu1827. . . . MAINTENANCE LEVELS OF VEDOLIZUMAB DO NOT... (4*)|(Prometheus Laboratories)

Tu1828. . . . ENHANCING UTILIZATION OF THERAPEUTIC DRUG MONITORING... (2*)|

Tu1829. . . . COMPARISON OF SERUM CONCENTRATIONS OF USTEKINUMAB... (5*)

Tu1830. . . . INFLIXIMAB AND ADALIMUMAB CONCENTRATIONS MAY VARY... (3*)|(This study was funded by Inform Diagnostics.)

Tu1831. . . . USE OF DRUG-TOLERANT ASSAYS IN INFLAMMATORY... (3*)|(Prometheus Laboratories (who performed the drug/antibody assays))

Tu1832. . . . ASSOCIATION OF VEDOLIZUMAB LEVELS WITH CLINICAL... (5*)

Tu1833. . . . WEEK 2 ADALIMUMAB LEVEL PREDICTS SHORT-TERM... (5*)

Tu1834. . . . A PROTOCOL FOR SAFE REINTRODUCTION OF... (5*)

Tu1835. . . . ASSOCIATION BETWEEN VEDOLIZUMAB TROUGH CONCENTRATION AND... (5*)

Tu1836. . . . INFLIXIMAB TROUGH LEVELS ARE NOT PREDICTIVE... (2*)

Tu1837. . . . DEVELOPING A NOVEL MEDICATION ADHERENCE INDEX... (5*)

Tu1838. . . . DOES SWITCHING BETWEEN 5-AMINOSALICYLATES AFFECT THIOPURINE... (5*)

Tu1839. . . . IMPACT OF USTEKINUMAB TDM ON CLINICAL... (3*)

Tu1840. . . . LOW DRUG LEVELS DURING INFLIXIMAB MAINTENANCE... (5*)

Tu1841. . . . COMPARATIVE ANALYSIS OF BLOOD AND MUCOSAL... (4*)

Tu1842. . . . NOVEL POPULATION SUBSETS OF TCRBHI TH17,... (5*)

Tu1843. . . . ACETYLCHOLINE SECRETING T-CELLS CONTRIBUTE TO INNATE... (3*)|(Galvani Bioelectronics unrestricted research grant)

Tu1844. . . . DETERMINING PREDICTORS OF GASTROINTESTINAL DISEASE IN... (5*)

Tu1845. . . . IDENTIFICATION OF A UNIQUE POPULATION OF... (4*)|(This work was supported by the Gatorade Trust through funds distributed by the University of Florida, Department of Medicine.)

Tu1846. . . . HIGHER TNF α AND MIP-1 β EXPRESSION IN... (4*)

Tu1847. . . . UREASE-POSITIVE PROTEOBACTERIA IN CROHN'S DISEASE IDENTIFIED... (6*)

Tu1848. . . . ESCHERICHIA COLI SIDEROPHORE PRODUCTION INDUCES INTESTINAL... (2*)

Tu1849. . . . ROSEBURIA INTESTINALIS FLAGELLIN ALLEVIATES EXPERIMENTAL COLITIS... (2*)

Tu1850. . . . ADHERENT-INVASIVE ESCHERICHIA COLI IN INFLAMMATORY BOWEL... (2*)

Tu1851. . . . STUDY ON THE INFLAMMATORY MECHANISMS OF... (2*)

Tu1852. . . . METFORMIN AMELIORATED INFLAMMATORY BOWEL DISEASE BY... (2*)

Tu1853. . . . FAECALIBACTERIUM PRAUSNITZII PRODUCES BUTYRATE TO DECREASE... (2*)

Tu1854. . . . ASSOCIATION BETWEEN QPCR ASSAYS TARGETING FIMS/FIMH... (3*)|(Enterome was the sponsor of the study)

Tu1855. . . . MICROBIOTA EXPOSURE IN EARLY LIFE IMPACTS... (2*)

Tu1856. . . . THE SIDEROPHORE YERSINIABACTIN POTENTIATES INFLAMMATORY BOWEL... (4*)

Tu1857. . . . NEONATAL SUPPLEMENTATION WITH A LACTOBACILLUS RHAMNOSUS... (2*)

Tu1858. . . . SEGMENTED FILAMENTOUS BACTERIA INDUCE ALTERNATIVE TH17... (2*)

Tu1859. . . . ALTERING DIETARY FERMENTABLE CARBOHYDRATE (FODMAP) CONTENT... (2*)

Tu1860. . . . THE OCCURRENCE OF UPPER GASTROINTESTINAL DISEASE... (5*)

Tu1861. . . . UNIDENTIFIED COCCOID BACTERIA (UCB) ARE ASSOCIATED... (5*)

Tu1862. . . . HISTAMINE IS IMPORTANT FOR MACROPHAGES ACTIVITIES... (2*)

Tu1863. . . . DIFFERENCES AMONG LUMINAL AND MUCOSAL MICROBIOTA... (4*)

Tu1867. . . . LNCRNAs TARGETED BY ENTERIC BACTERIAL INFECTION... (2*)

Tu1868. . . . THERAPEUTIC FECAL MICROBIOTA TRANSPLANTATION CONTROLS INTESTINAL... (6*)

Tu1869. . . . CHARACTERIZATION OF CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA... (6*)

Tu1870. . . . ENDOBARRIER[®] IMPLANTATION IS ASSOCIATED WITH MARKED... (2*)|(NIDDK rO1 21769 NIDDK rO1 29867)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1871. . . THE ASSOCIATION BETWEEN ANTIBIOTICS EXPOSURE DURING... (4*)	Tu1888. . . THE UTILITY OF MULTIPLEX GI PCR... (5*)	Tu1907. . . LIVER FIBROSIS STAGE AT BASELINE PREDICTS... (2*)
Tu1872. . . THE HUMAN INTESTINAL PROTEOME IN CHILDREN... (7*)	Tu1889. . . THE PROTECTIVE ANTIMICROBIAL ACTIVITY OF VSL#3... (5*)	Tu1908. . . EFFICACY OF PHARMACOTHERAPY IN THE TREATMENT... (5*)
Tu1873. . . BOWEL CLEANSING MAY AFFECT DIAGNOSTIC YIELD... (5*)	Tu1890. . . GASTRIC MICROBIOTA IN HELICOBACTER PYLORI-NEGATIVE AND... (2*) 	Tu1909. . . ROUX-EN-Y GASTRIC BYPASS IMPROVES ESOPHAGEAL SYMPTOMS... (5*)
Tu1874. . . DETECTION OF ENTERIC INFECTIONS IN THE... (5*)	Tu1891. . . AUTOMATED MOLECULAR DETECTION OF HELICOBACTER PYLORI... (3*) (This study was funded by AutoGenomics inc.)	Tu1910. . . ESOPHAGITIS AFTER BARIATRIC SURGERY: LARGE CROSS-SECTIONAL... (4*)
Tu1875. . . CHRONIC ANTIBIOTIC USE AND SUBSEQUENT DEVELOPMENT... (2*)	Tu1892. . . COMPARISON OF HIGH AND LOW MOLECULAR... (2*) (Small Grant Exploratory Research, korea)	Tu1911. . . BARIATRIC SURGERY IS ASSOCIATED WITH REDUCED... (5*)
Tu1876. . . FECAL MICROBIOTA TRANSPLANTATION FOR IMMUNE CHECKPOINT... (4*)	Tu1893. . . SPANISH SPECIALYST CARE SURVEY ON THE... (3*) (Laboratorios Casen Recordati, Spain.)	Tu1912. . . WEIGHT LOSS AND METABOLIC IMPROVEMENTS ONE... (2*) (GI Dymics provided training for the clinical staff.)
Tu1877. . . FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR IRRITABLE... (5*)	Tu1894. . . COLONIC MUCOSAL MICROBIOME IS ASSOCIATED WITH... (4*)	Tu1913. . . 'TO DELAY OR NOT TO DELAY:... (5*)
Tu1878. . . FECAL MICROBIOTA TRANSPLANTATION (FMT) IN IRRITABLE... (5*)	Tu1895. . . COLONIC MUCOSAL MICROBIOME CORRELATES WITH DIETARY... (2*)	Tu1914. . . BODY COMPOSITION AS FOLLOW UP OF... (5*)
Tu1879. . . RAPID AND DURABLE ENGRAFTMENT OF DONOR... (4*) (the funding source from Gut Microbiome Research Center provided by the Faculty of Medicine, The Chinese University of Hong Kong)	Tu1896. . . ASTAXANTHIN ATTENUATED INTESTINAL HYPERMOTILITY INDUCED BY... (2*)	Tu1915. . . FEASIBILITY OF SERUM LIPIDOMICS AND FECAL... (2*)
Tu1880. . . DURABLE FREEDOM FROM CLOSTRIDIUM DIFFICILE INFECTION... (3*) (This alysis was funded by Rebiotix Inc., Roseville, MN, USA.)	Tu1897. . . ENTERIC METHANE OR HYDROGEN PRODUCTION IN... (2*)	Tu1916. . . ASSESSMENT OF NOVEL PLICATION TECHNIQUE IN... (5*)
Tu1881. . . ECONOMIC EVALUATION OF A FECAL MICROBIOTA... (4*)	Tu1898. . . A COMPARISON OF PATIENTS WITH UNEXPLAINED... (2*)	Tu1917. . . IMPACTS OF LIRAGLUTIDE USE IN WEIGHT... (5*)
Tu1882. . . FECAL VIRUS-LIKE PARTICLES REDUCE BACTERIAL DENSITY... (6*)	Tu1899. . . MICROBIAL FECALIZATION OF THE SMALL INTESTINE... (2*) (NIDDK r01 21769 NIDDK r01 29867)	Tu1918. . . SEVERE NUTRITIONAL COMPLICATIONS AFTER BARIATRIC SURGERY... (4*)
Tu1883. . . SELECTIVE MICROBIOTA TRANSPLANTATION INDUCES RADIATION PROCTITIS... (1*) 	Tu1900. . . DOSE RESPONSE FOR ARGON PLASMA COAGULATION... (5*)	Tu1919. . . COMPLIANCE WITH EARLY POST-OPERATIVE FOLLOW-UP REDUCES... (4*)
Tu1884. . . PRE-TREAT WITH FAECALIBACTERIUM PRAUSNITZII PREVENT THE... (2*)	Tu1901. . . LOW FREQUENCY VAGAL NERVE STIMULATION USING... (2*)	Tu1920. . . CHANGES IN QUALITY OF LIFE, BODY... (5*)
Tu1885. . . PROTECTIVE EFFECT OF SMT (SELECTIVE MICROBIOTA... (2*)	Tu1902. . . PROSPECTIVE STUDY INVESTIGATING CHANGES IN GASTRIC... (2*)	Tu2026. . . MIR-23B-3P PROMOTES CARCINOGENICITY THROUGH PETN/PI3K/AKT PATHWAY... (2*)
Tu1886. . . COMMENSAL DERIVED BIOPRODUCTS CONTRIBUTE TO MODULATE... (2*)	Tu1903. . . A COMPARISON OF GASTRIC PLICATION ALONE... (5*)	Tu2027. . . GREATER LINE-1 HYPOMETHYLATION IN TUBULAR ADENOMAS... (4*)
Tu1887. . . PATIENTS WITH APPENDECTOMY HAVE SIGNIFICANTLY LESS... (4*)	Tu1904. . . BARIATRIC SURGERY IS ASSOCIATED WITH INCREASED... (5*)	Tu2028. . . IDENTIFICATION OF 5-FLUOROURACIL (5-FU) RESISTANCE-RELATED MICRORNA... (4*) (5)
	Tu1905. . . CHANGES IN METABOLIC AND INFLAMMATORY BIOMARKERS... (5*)	Tu2029. . . ESOPHAGEAL ADENOCARCINOMA WITH INTESTINAL METAPLASIA PHENOTYPE... (5*)
	Tu1906. . . 30 DAY READMISSION AFTER ROUX-EN Y... (5*)	Tu2030. . . NOVEL CIRCULAR RNA NF1 ACTS AS... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
 (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu2031. . . . ITGBL1 PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION VIA THE... (4*)

Tu2032. . . . ADDITION OF PRESERVATIVE BUFFER IMPROVES DNA... (4*) (Exact Sciences The Champions for Hope Foundation Florida Pancreatic Cancer Coalition)

Tu2033. . . . QUANTITATION OF METHYLATION LOAD OF TUMOR... (2*)

Tu2034. . . . FACTORS ASSOCIATED WITH PATHOLOGICAL COMPLETE RESPONSE... (4*)

Tu2035. . . . NEUROTENSIN PROMOTES EPITHELIAL-MESENCHYMAL TRANSFORMATION VIA ERK... (2*)

Tu2036. . . . A PATIENT SELF-MADE ONE STEP QUICK... (5*)

Tu2037. . . . NOVEL GENOMIC ANALYSIS OF CENTRAL AMERICA... (2*)

Tu2038. . . . LAPAROSCOPY-ASSISTED VERSUS ENTEROSCOPY-ASSISTED ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY... (5*)

Tu2039. . . . GASTRIC PERORAL ENDOSCOPIC PYLOROMYOTOMY (G-POEM) FOR... (5*)

Tu2040. . . . PROSPECTIVE ASSESSMENT OF THE USE OF... (5*)

Tu2041. . . . THE OUTCOME OF ENDOSCOPIC MUCOSAL RESECTION... (5*)

Tu2042. . . . INVESTIGATION OF POLYETHYLENE GLYCOL RECOVERY RATE... (5*)

Tu2043. . . . EFFICACY AND SAFETY OF PERCUTANEOUS RENDEZ-VOUS... (5*)

Tu2044. . . . SMALL BOWEL PREPARATION PRIOR TO VIDEO... (5*)

Tu2045. . . . EFFICACY AND SAFETY OF NOVEL, DISPOSABLE... (5*)

Tu2046. . . . CHOLEDOCHOSCOPE WITH STENT PLACEMENT FOR TREATMENT... (5*)

Tu2047. . . . A TRANSNASAL IMAGING TUBE FOR UNSEDATED... (4*)

Tu2051. . . . CANDIDATE AND EXPLORATORY GENETIC ASSOCIATION STUDY... (2*)

Tu2052. . . . POTENTIAL NOVEL SEROLOGICAL MICRO-RNA MARKERS OF... (4*)

Tu2053. . . . INFLAMMATORY BOWEL DISEASE IN CYSTIC FIBROSIS... (5*)

Tu2054. . . . ACUTE PANCREATITIS IN PATIENTS WITH DOWN... (4*) (5)

Tu2055. . . . CHARACTERIZATION OF GASTROINTESTINAL SYMPTOMS IN FABRY... (3*) (Sanofi Genzyme)

Tu2056. . . . THE IMPACT OF METABOLIC SYNDROME (MS)... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)